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I. INTRODUCTION 
 
The importance of natural products for medicine is undisputed. Since the earliest time 
mankind has been using extracts from natural sources like plants, animals and fungi for 
treatment of different diseases without knowing their relation between chemical structures 
and biological activity. During the development of modern natural sciences it was disco-
vered that many of the earlier used natural extracts contain in fact biological active 
compounds which can be used as drugs or therapeutics and applied for medical treatment. 
Quite often natural products serve as biochemical tools or they led to the discovery of a 
hitherto unknown biochemical pathway or molecular target. Nevertheless, in the context of 
the human genome project speculations arose that there might be not enough natural 
products to probe the functions of all genes via selective interaction of natural products 
with the corresponding proteins.[1] On the other hand natural products offer structurally 
interesting platforms that might be used to produce natural product-like molecules. This 
way the chances of discovering novel modes of biological activity might be higher.[2,3] 
 
The search for bioactive natural compounds from marine organisms is still a relatively new 
field because of the difficulties involved in collecting samples and the fact that there is 
virtually no ethnobotanical data to draw on. However the biodiversity of the marine 
environment exceeds by far that of its terrestrial counterpart, thus the oceans represent a 
huge resource for new biologically active compounds. Many of these molecules possess 
unique structural features which are enormous and specific enough to protect the 
organisms in a very hostile environment. New drug discoveries indicate that marine 
organisms have a vast potential for new pharmaceuticals and will become a much more 
profound source than any other group of terrestrial organisms. 
 
In the present work two topics concerning natural product synthesis are being discussed. 
The first topic represents a novel convergent synthetic way to a biologically active 
cyclodepsipeptide, Cryptophycin-3, whereas the second represents the synthesis of an 
epoxide containing protein-reactive natural compound, Epoxomicin. 
 
Depsipeptides or depsides, i.e. heterodic peptides, which contain not only an amide bond 
but also other types of bonds (usually an ester, i.e. a depside bond or a disulphide bridge) 
as part of their backbone, are another group of peptide derivatives with interesting biologi-
I. INTRODUCTION 
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cal properties. Although their occurrence and pharmacological values are incomparable 
with those of peptides, they still represent an interesting target for drug research and devel-
opment. 
 
Cyclodepsipeptides are cyclic depsipeptides containing at least one hydroxy acid. In 
addition cyclodepsipeptides often also contain unusual amino acids, such as extended, N-
methylated, hydroxylated, or halogenated ones. The hydroxy acids are frequently derived 
from the polyketide pathway, so many cyclodepsipeptides are macrocyclic hybrid peptide/ 
polyketide-like molecules. Compounds of this type have quite recently been accessed by a 
chemoenzymatic route.[4]  Thanks to their modular natures and the presence of peptide 
subunits, cyclodepsipeptides are ideal lead compounds for the generation of libraries of 
natural product-like compounds or compound collections of interest in the context of 
chemical genetics and target discovery.[5,6,7] One can also argue that an organism, by 
producing cyclodepsipeptides, has a flexible tool available for responding to a possible 
hostile environment by simple combination of post-translationally modified amino acids 
and one larger building block from another biosynthetic pathway. A quite prominent 
family of cyclodepsipeptides are the Cryptophycins. 
 
The first representative of these cyclic depsipeptides, Cryptophycin-1 (1) (Figure 1), was 
isolated in 1990 from a marine blue-green algae.[8] Some later, the isolation and structure 
of Cryptophycin-24 (3), also known as arenastatin A, was described.[9] Initially  
Cryptophycin-1 was  classified as an antifungal agent, but it was later discovered to have 
powerful antitumor activity caused by disruption of microtubule assembly.[10] It blocks the 
cell cycle at the G2/M phase apparently through inhibition of tubulin polymerization into 
microtubules.[11,12] Its extreme potency has led to additional studies investigating other 
possible modes of action.[12,13,14] Of particular interest was the fact that Cryptophycin 
showed activity against some multiple drug resistance (MDR) cell lines. Because of their 
interesting biological activities and challenging molecular structures, the total synthesis of 
Cryptophycin-3 (5) and its an analogue has been reported. 
 
I. INTRODUCTION 
 3 
O O
H
N
O
N OO
O
H
R3
OMe
R1 R2
O
R1 R2 R3
O O
H
N
O
N OO
O
H
R3
OMe
R1 R2
R1 R2 R3
Me H ClCryptophycin 3 (5)
Cryptophycin 4 (6) Me H H
Cryptophycin 1   (1)
Cryptophycin 2   (2)
Cryptophycin 24 (3)
Cryptophycin 52 (4)
Me H Cl
Me H
H H H
Me
H
Me Cl  
 
Figure 1: Important structures of Cryptophycins 
 
The sequencing of the human genome has transformed the way in which scientists think 
about biology. However there is a vast gulf between the wealth of genome sequence 
information and our knowledge of genome function. Researchers are now confronting the 
task of understanding  the cellular and molecular functions of thousands of predicted gene 
products. The genome gives rise to the proteome, and the combinatorial interactions among 
proteins make living organisms so complex at the molecular level. To understand these 
interactions the development of new technologies and concepts to expedite global analysis 
of protein function is required.[15] A growing number of research laboratories are exploring 
biology with chemistry-based strategies that are capable of yielding insight into the role of 
individual proteins in complex biological systems. The field of chemical synthesis often 
plays a major role in this process, perhaps most visible through simplification in 
identifying protein targets of bioactive natural products.[16] 
 
Nature engages protein targets with reactive small molecules in many ways, and the 
number of natural products that covalently modifies proteins is likely to be very large. A 
provocative subset of biologically active natural products is endowed with electrophilic 
functional groups that covalently modify nucleophilic residues in specific protein targets. 
Lipstatin[17] and fumagillin[18] embody the chemistry of the carbonyl group and the epoxide 
respectively and they are prominent examples of protein-reactive natural products (Figure 
2). These  protein reactive natural products are highly attractive as molecular probes for 
protein activity profiling experiments because they provide information about enzyme 
active sites in complex proteomes.[19] 
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Figure 2: The structures of Lipstatin and Fumagillin 
 
Numerous biologically active natural products that mediate their activities via inhibition of 
specific intracellular protein targets have been isolated. The second part of this work 
represents the synthesis of Epoxomicin (7) (Figure 3), a peptidyl epoxide natural product 
that acts as a covalent inhibitor of the proteasome.[20] 
 
Epoxomicin was isolated based on its potent in vivo antitumor activity against solid tumors 
derived from B16 melanoma.[21] Epoxomicin belongs to a small family of linear peptides, 
of which all share two structural features: a threonine or serine residue and an α,β-epoxy-
ketone derived from leucine or γ,δ-dehydroleucine. 
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Figure 3: The structure of Epoxomicin (7) 
 
These α,β-epoxyketone containing peptides exert their biological activities via adduct 
formation with intracellular target proteins since the reduction of this reactive epoxide 
results in loss of biological activity.[22]  
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II. THE FAMILY OF CRYPTOPHYCINS 
 
1. Biological activity of Cryptophycins 
 
The Cryptophycins are potent tumor-selective cytotoxins, isolated from blue-green algae 
Nostoc sp. ATCC 53789 and Nostoc sp.SV 224.[8] When Cryptophycin-1 was first isolated 
by Schwartz and co-workers, they chose the name Cryptophycin because of the 
compound’s highly potent fungicidal activity against filamentous fungi and yeast of the 
genus Cryptococcus. Because of the narrow range of anti-fungal activity of Cryptophycin-
1 (1) and its low therapeutic index,[23] the development of Cryptophycin-1 as an anti-fungal 
compound was not pursued. Cryptophycin-1 was later isolated by Moore and co-workers, 
who screened over 1000 extracts of blue-green algae in search of compounds that exhibited 
antitumor activity.[8b] Cryptophycin-1, the most abundant cytotoxin of the 
Cryptophycins,[24] has potent activity in the pM range in the multi-drug-resistant (MDR) 
cell lines SKVLB1 and MCF-7/ADR, [25] thereby surpassing vinblastine, paclitaxel, and 
colchicine in the ability to retain cytotoxic activity in MDR cell lines. 
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Figure 4: Important biologically active Cryptophycins 
 
A structurally simpler Cryptophycin, Cryptophycin-24 (arenastatin A 3), was isolated from 
an Okinawan marine sponge, Dysidea arenaria.[26] Although Cryptophycin-24 lacks the 
chlorine substituent on the aryl ring of the C10 side chain and the methyl group at C6, it is 
extremely potent against KB cells (Figure 4).[27] Unfortunately, Cryptophycin-24 has a 
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half-life of approximately 10 min in mouse serum due to ester hydrolysis.[28] Therefore 
Cryptophycin-52 (4), the C6 gemdimethyl analogue of Cryptophycin-1, was prepared to 
decrease the rate of ester hydrolysis in vivo.[29,30]  This synthetic analogue is the first Cryp-
tophycin to undergo clinical trials for the treatment of cancer.[31] Out of around 450 ana-
logues, Cryptophycin-52 has emerged as a promising clinical candidate, advancing even to 
phase 2 clinical studies. Table 1 shows IC50 values for some representative Cryptophy-
cines. [32]   
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Figure 5: Structure of some other important Cryptophycin analogues 
 
The Cryptophycins are microtubule-destabilizing agents that elicit cytotoxic effects by bin-
ding noncovalently to a site at, or overlapping, the Vinca site on tubulin at the rhizoxin/ 
maytansine site.[25,27,33-35] Cryptophycin-1 also induces the phosphorylation of Bcl-2[36] and 
activates the apoptosis process.[12,37] Similar to other known antimitotic agents,[38] Crypto-
phycin-1 slows microtubule dynamics at low concentrations[10,13] while at subnanomolar 
concentrations it causes a complete loss of microtubule within cells. Through its action on 
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microtubules and possibly other yet to be discovered targets, Cryptophycin induces potent 
cytotoxicity by activating the apoptotic pathway.[12,37]  
 
Table 1: [a] Data from references: (compounds 1,2,3,5,10)[8h], (compounds 4,8)[30], (com-
pound 6)[8b], (compound 9)[29] 
 KB = human nasopharyngeal carcinoma cell line 
 CCRF-CEM = human leukemia cell line 
Compound IC50 [nM][a] Cell type 
1 0.0092 KB 
2 0.057 KB 
3 0.198 KB 
4 0.022 CCRF-CEM 
5 3.23 KB 
6 2.15 KB 
8 0.021 CCRF-CEM 
9 0.054 CCRF-CEM 
10 6.0 KB 
 
One of the strong features of Cryptophycin is that it lacks cross resistance with paclitaxel, 
doxorubicin,[39] and other families of drugs such as DNA alkylators, topoisomerase II 
inhibitors, and antimetabolites[40] which are generally used in combination protocols for the 
treatment of cancer. Cryptophycin-1 has also been found to exhibit excellent 
antiproliferative activity in vivo against five solid tumors of murine origin (i.e. colon 
adenocarcinomas 38 and 51, taxol-sensitive and taxol-resistant mammary adenocarcinoma 
M16, and pancreatic ductal adenocarcinoma) that were subcutaneously transplanted into 
mice.[8b,41] In vitro, Cryptophycin-1 was shown to be highly toxic to the human 
nasopharyngeal carcinoma and the human colorectal adenocarcinoma cell lines.[8b] 
 
2. Structure-activity relationships of Cryptophycins 
 
Structure-activity relationship (SAR) studies of the C10 side chain of Cryptophycin-1 
demonstrated that introduction of a second chloro substituent at the C5′ position of the C10 
side chain decreased activity by a factor of 120, while absence of the C3′-Cl decreased 
activity by a factor of 10.[25] A factor of 30 decrease inactivity was observed when the C4′-
O-methyl group was absent.[41] These data suggested that the 3′-C1 and 4′-MeO are 
required for optimal activity. More recently, it was revealed that the cytotoxicity of 
Cryptophycin can be more dramatically affected by altering the C10 side chain. 
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Patel and co-workers prepared analogues of Cryptophycin-52 (4) that were tested in the 
human leukemia CCRF-CEM tumor cell line.[31] Substitutions for the benzyl moiety and 
alternative substitution patterns on the aromatic ring were also made. Substitution of the 
C10 aryl ring with a naphthyl ring, altering the tether length between the macrocycle and 
the aryl ring, removing the aromatic ring, or replacing it with a cyclohexyl group, led to 
analogues with varying degrees of reduced activity. Variations in the substitution pattern of 
the benzyl ring of the Cryptophycin-52 analogues revealed that the 3′-Cl substituent 
provides an increased in vitro activity, whereas compounds lacking the 3′-Cl substituent 
were active only in the 4 to 120 nM range with the exception of the analogue containing an 
unsubstituted benzyl ring at C10 which was active and had an ED50 value of 183 pM. The 
compound with the most activity was the 3′-C1, 4′-NMe2 analogue 9, which had an IC50 
value 2.5 times that of Cryptophycin-52  (Figure 5).[31] 
 
The structure activity studies also showed that variations in the fragment A epoxide are 
well tolerated, revealing even compounds that are active against murine Panc-03 tumors at 
much lower doses.[31] The chlorohydrin 8 is one example. Compounds, such as 5 or 6, that 
lack the epoxide ring still are quite active which shows that there is no covalent bond upon 
binding to the tubulin. The triamide 10 is characterized by poor solubility and low bio-
availability but still shows reasonable activity.  
 
The SAR determined from isolated analogues of Cryptophycin-1 and synthesized 
Cryptophycin analogues of Cryptophycin-52 suggested that any analogue synthesized 
should retain the following on the C10 side chain for optimal activity: (1) the R 
stereochemistry at C10, (2) a benzyl moiety, and (3) a chloro substitution at the 3′ (meta) 
position. Therefore we have chosen to synthesize Cryptophycin-3 (5) and its an 
analouge(11)(Figure 6), they both contain the side at C10 with benzyl moiety and R 
stereochemistry.  
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Figure 6: Structure of Cryptophycin-3 (5) and analouge 11 
 
While the in-vitro and in-vivo studies with Cryptophycin-52 were very promising, the 
clinical studies revealed significant neurological toxicity and only weak or no therapeutic 
response. Nevertheless, from a chemical point of view the ω-hydroxy acid of Cryptophycin 
should be an interesting building block allowing to restrict the conformation of tri- and 
tetrapeptides that are inserted in between the hydroxyl and carboxyl function.  
 
3. Previous total and formal syntheses of Cryptophycins  
 
3.1 The first Tius synthesis 
 
The Tius group was first to publish the relative and absolute stereochemistry for the 
crytophycins in 1994.[24] In 1995 they synthesized and corrected the structures of 
Cryptophycin-1 and -3. For the purposes of retrosynthetic analysis, Cryptophycin-1 was 
disconnected into four units (Scheme 1). Unit A 12a is a polyketide-derived molecular 
fragment, unit B 13a is an O-methyl-D-chlorotyrosine derivative, whereas units C 14a and 
D 15a correspond to (R)-3-amino-2-methyl-propanoic acid and (S)-2-hydroxy-4-
methylvaleric (L-leucic) acid derivative. The macrocyclisation occurs by amide bond 
formation  between unit B and unit C. 
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Scheme 1: Retrosynthetic analysis by Tius group 
 
Scheme 2 summarizes the first successful approch to unit A, 12a. In this synthesis 
compound 16 was prepared from commercially available dihydrocinnamaldehyde and tri-
methyl-phosphonoacetate in the presence of tetramethylguanidine. Reduction with 
DIBAL-H and Sharpless asymmetric epoxydation using L-(+)-diethyl tartrate of 16 led to 
epoxy alcohol 17. Regio- and stereo-specific epoxide ring opening with trimethyl 
aluminium resulted in the desired diol which was protected as acetonide 18. Benzylic 
bromination with NBS led to an unstable bromide which was immediately 
dehydrobrominated with DBU and became styrene 19. But in a large scale reaction 19 was 
eroded by the formation of diastereomeric tetrahydrofuryl alcohol. Hydrolysis of the 
acetonide group in 19 with  aqueous methanolic HCl led to diol on which the  primary OH 
was selectively protected as tosylate by Ley’s procedure[42] and secondary OH was 
protected as TBS ether and led to 20. Displacement of tosylate by cyanide was followed by 
the reduction with DIBAL-H generating thecorresponding aldehyde, which on Horner-
Emmons homologation with trimethylphosphonoacetate led to 12a. 
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Scheme 2: The synthetic pathway to unit A 12a 
 
Scheme 3 shows the assembly of unit A and unit B. Before coupling, the methyl ester of 
12a was hydrolysed to acid 21 with lithium hydroxide and the protected unit B 13a was 
prepared from commercially available D-tyrosine in five steps. Chlorination[43] with 
sulfuryl  chloride was followed by protection of amine with BOC. Then methylation of the 
phenol took place with dimethyl sulfate in presence of potassium carbonate. Hydrolysis of 
the methyl ester with aqueous NaOH gave back to acid which on reesterrification with 
2,2,2-trichloroethanol in presence of DCC and pyridine gave the Troc ester. Cleavage of 
BOC with trifluoroacetic acid was leading to the trifluoroacetate salt of 13a. Mixing a 
solution of 21 in anhydrous DMF with pentafluorophenyl diphenylphosphonate (FDPP), 
the trifluoroacetate salt of 13a and DIEA at room temperature led to the amide which after 
cleavage of the silyl ether protecting group  with HF produced 22 in good yield. 
 
12a
LiOH CO2H
OTBS +
Cl
OCH3
H2N
OO
CCl3
1. FDPP, DIEA, 73%
2. MeCN/HF, 90%
OH
O
HN Cl
OMeOO
21 13a
22
CCl3
95%
 
 
Scheme 3: Coupling of unit A and unit B 
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The Tius synthesis follows a highly convergent strategy to join unit C 14a and unit D 15a, 
(Scheme 4). The β-amino acid 14a was prepared from commercially available (S)-(+)-3-
hydroxy-2-methylpropanoate 23, which was converted to the amide with ammonia and on 
reduction with borane led to amine 24. Protection of the amino group as Boc derivative, 
followed by oxidation of the primary alcohol with ruthenium tetroxide, led to carboxylic 
acid 14a. Commercially available L-leucic acid was converted to allyl ester 15 under 
phase-transfer conditions by stirring with allyl bromide and  tetra-n-butylammonium 
chloride. The coupling of 14a with 15a was accomplished with DCC and DMAP to 
produce a dipeptide analogue which on deprotection with morpholine and catalytic 
Pd(PPh3)4[44] led to 25. 
 
HO OMe
O
1. NH3, 50%
2. BH3, 77%
HO NH2
1. (Boc)2O, 100%
2. RuCl3, 74%
23 24
HO NHBoc
O
+
O O
OH
1. DMAP/DCC,
2. morpholine,
  Pd(PPh3)4
14a 15a
O
O
NHBoc
O OH
25
92%
100%
 
 
Scheme 4: Coupling of unit C and unit D 
 
The ester linkage between 22 and 25 was installed through the use of DCC/DMAP to 
produce a seco compound (Scheme 5), which the sequential removal of Troc and Boc 
protecting groups occured on by treatment with zinc and acetic acid, followed by neat 
trifluoro-acetic acid and providing 26. Macrolactamization of 26 with FDPP in presence of 
DIEA in DMF gave Cryptophycin-3 (5) in 64% yield. Epoxidation with m-CPBA led to a 
ca. 2/1 mixture of Cryptophycin-1 (1) and the corresponding (7S,8S)-trans-epoxide 27. 
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Scheme 5: Coupling of unit C + D and unit A + B 
 
3.2 The Leahy-Gardinier synthesis 
 
The first synthesis to address the stereochemical problem posed by the epoxide was 
conducted by Leahy and Gardinier.[45] A diol was used as a convenient synthetic equivalent 
of the epoxide. For the synthesis of unit A (Scheme 6) two asymmetric fragments, (R)-
mandelaldehyde derivative 28 and the boron enolate derived from Evans chiral imide 29[46] 
were coupled and led to a single product 30. Trimethylaluminium-mediated transamidation 
produced the corresponding Weinreb amide, which on treatment with allylmagnesium 
bromide provided allyl ketone 31. Exposure of 31 to acetaldehyde and samarium iodide 
reduced the C5 carbonyl group to alcohol and at the same time converted C7 hydroxyl to 
corresponding acetate.[47]  Protection of the C5 OH as p-methoxybenzyl (PMB) ether was 
followed by reductive cleavage of the acetete with DIBAL-H and protection as a TIPS 
derivative of C7 to give 32. The conversion of 32 to 33 was accomplished by oxidative 
cleavage of the terminal alkene to the aldehyde, followed by Horner–Emmons 
homologation using Masamune-Roush conditions and oxidative cleavage of the PMB 
protecting group with DDQ. 
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Leahy and Gardinier followed a rather different strategy for the assembly of units B, C, 
and D (Scheme 7). Protected aminoalcohol 34 was prepared from the reduction of  known 
amide.[48] 
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N O
Bn
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TIPSO
O
1. Me3Al, MeONHMe
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57
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2. PMBOC(NH)CCl3
OPMB
TIPSO
TIPSO
3. DIBAL-H
4. TIPSOTf
1. OsO4
2. Horner-Emmons
3. DDQ OH
TIPSO
TIPSO
CO2
tBu
28 29 30
31
32 33
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Scheme 6: Leahy-Gardiner’s synthesis of unit A 
 
The amine 34 was then coupled with acid unit B 13b in presence of  HOBT and EDC. 
Deprotection of TBS with TBAF and oxidation of primary the alcohol function with 
ruthenium tetroxide resulted in unit B + C compound 35. After deprotection coupling of 35 
with the benzyl ester of  L-leucic acid, unit D 15b took place with DCC. A final cleavage 
of benzyl ester with Raney nickel led to unit B + C + D compound 36 in good yield. 
The coupling  of unit A 33 with unit B+C+D fragment, 36 under Yamaguchi conditions 
produced 37 (Scheme 8).[49] Cleavage of Boc and tert-butyl ester protecting groups took 
place in a single operation, by exposure of 37 to HCl without disturbing the silyl ether 
protecting groups. Macrolactamization was carried out with O-benzotriazole-1-yl-
N,N,N`,N`-bis-(pentamethylene)uronium hexafluorophosphate[50] in good yield and finally 
after deprotection of  the silyl protecting groups the cyclic compound 38 was obtained. 
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Scheme 7: Leahy- Gardiner’s assembly of tripeptide 
 
For the formation of epoxide the Leahy and Gardinier developed a very ingenious 
modification of the Sharpless method. 4-Azido-1,1,1-trimethoxybutane, prepared from 
commercially available 4-chlorobutyronitrile in two steps, was allowed to react with diol 
38 in presence of trimethylchlorosilane according to Sharpless’ conditions and led to 39. 
Exposure of 39 to triphenylphosphine and water generated to the C7-C8 chlorohydrin 
which on reaction with potassium carbonate led to Cryptophycin-1 (1) in overall good 
yield. 
 
3.3 The Tius-Li synthesis 
 
In this synthesis (R) Mandelic acid is an attractive starting material as a sole source of 
asymmetry  for unit A (Scheme 9). [51] (R)-Methyl mandelate (40) was converted to the O-
ethoxyethyl derivative and then reduction of the ester group with DIBAL gave protected 
mandelaldehyde 41, which was combined with diene 42 by a hetero Diels-Alder 
reaction.[52]  Exposure of the crude Diels-Alder 43 product to trifluoroacetic acid, followed 
by workup, gave a 10/1 mixture of 44 and 45. Stirring a solution of this product mixture 
over KF/alumina[53] epimerized 44 to 45 as a 1/4 mixture. 
.  
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Scheme 8: Leahy-Gardiner’s final steps of synthesis of Cyrptophycin-1 
 
Reduction of the 1/4 mixture with L-selectride gave alcohol 46 as a single isomer. 
Reaction of 46 with boron trifluoride etherate and 1,3-propanedithiol converted the mixed 
acetal todithioketal. ubsequent proctection of the syn C7-C8 diol as acetonide gave 47. 
Treatment of this dithioketal with iodomethane and calcium carbonate led to the β-
hydroxyaldehyde, which on Horner-Emmons reaction with allyldiethylphosphonoacetate 
led to unit A 48. The allyl ester in 48 was cleaved in presence of catalytic palladium(0) and 
morpholine (Scheme 10 )[44] and coupling with unit B compound 13 took place with EDCl 
and triethylamine to produce 49. Esterification of the C5 hydroxyl group with unit C + D 
compound 25 occurred in the presence of DCC and DMAP and led to seco compound 50. 
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Scheme 9: The Tius-Li synthesis of 48 
 
Simultaneous removal of the Boc and acetonide protecting groups in 50 took place with 
trifluoroacetic acid. The macrolactamization,[50] developed by Eli Lilly Co. was a simple 
treatment of the seco compound in toluene with 2-hydroxypyridine producing 38, the same 
intermediate from Leahy’s synthesis. Treatment of 38 with trimethyl orthoformate and 
PPTS, followed by addition of acetyl bromide led to a sensitive bromohydrin formate, 
which on exposure to potassium bicarbonate gave Cryptophycin-1 (1) in overall good 
yield. 
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Scheme 10: Tius-Li’s final steps of synthesis of Cryptophycin-1 
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3.4. The synthesis of unit A 
 
Since the subunit A is the most challening from a synthetic point of view, the following 
section summarizes various synthesis of this hydroxy acid. These synthesis illustrate 
various ways to establish the anti-OH / Me vicinal stereochemical pattern. 
 
3.4.1 The Sih chemoenzymatic synthesis 
 
The Sih synthesis of unit A relies upon an enzymatic hydrolysis of a racemic ester 
(Scheme 11).[54] (E)-Methyl styryl acetate 51 was first treated with LDA, followed by 
dimethyl sulfate to produce a racemic ester which on exposure to Candida rugosa lipase in 
phosphate buffer led to carboxylic acid (S)-52 in 45% and methyl ester (R)-53 in 48% 
yield. After separation of the methyl ester (R)-53 from the carboxylic acid the ester was 
reduced with DIBAL-H to aldehyde 54. The introduction of the remaining carbons of unit 
A was accomplished by means of a Reformatsky reaction with tert-butyl 4-
bromocrotonate. In this reaction the undesired syn-γ-adduct 55 was isolated in 22%, along 
with the desired anti-γ-adduct 12b in 18% yield. The undesired major product 55 was 
converted to desired anti-product through a Mitsunobu inversion. Exposure of 55 to 2,4-
dinitrobenzoic acid, diethylazodicarboxylate (DEAD) and triphenylphosphine led to 
nitrobenzoate 57 with correct C5 stereochemistry along with triene 56. The nitrobenzoate 
57 was hydrolysed to 12b with methanolic potassium carbonate. The overall yield of 55 
from 12c was 13% yield. Although Sih’s synthesis of unit A provides an illustration of the 
synthetic utility of an enzyme-mediated kinetic resolution, the yield is inferior to that of the 
first Tius synthesis. 
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Scheme 11: The Sih chemoenzymatic synthesis of unit A 
 
3.4.2 The Lilly chemoenzymatic synthesis  
 
Commercially available (R)-carvone 58 was bioreduced with Trigonopsis variables 
(ATCC 10679) using glucose as a carbon source to produce saturated alcohol (de>98%, as 
judged by GC)[55], which on protection of the secondary hydroxyl group as the TBS 
derivative led to 59 (Scheme 12). After ozonolysis, Criegee rearrangement and hydrolytic 
cleavage of intermediate acetate 59 alcohol 60 was produced.[56]  Oxidation of 60 took 
place in a two phase system in presence of catalytic TEMPO, to cyclohexanone which on 
Baeyer-Villiger oxidation with 30% aqueous hydrogen peroxide and sufficient 
trifluoroacetic acid led to 61. The electron-with-drawing effect of the β-silyloxy substituent 
was expected to favor the rearrangement to lactone 61.[57] The conversion of 61 to unit A 
12a followed a conventional strategy. Reduction of lactone 61 to lactol with DIBAL-H was 
succeeded by a Horner-Emmons reaction and then oxidation of the primary hydroxyl group 
gave the aldehyde. After that addition of phenylmagnesium bromide produced 
diastereomeric benzylic alcohol 62. 
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Scheme 12: The Lilly’s chemoenzymatic synthesis 
 
The elimination of water from 62 was done with 3 equivalents of methanesulfonic 
anhydride and 9 equivalents of triethylamine in presence of catalytic DMAP leding to 
styrene 12a and tetrahydrofuran 63 in a 4/1 ratio. This chemoenzymatic synthesis of unit A 
is interesting because it relies upon a non-obvious strategy. 
 
3.4.3 Synthesis via [2,3]-Wittig rearrangement 
 
Nakai and Mikami[58] synthesized unit A via an anionic [2,3]-Wittig rearrangement as a 
key step. As shown in Scheme 13 they started commercially available (E)-3-penten-2-ol 
(64).[59] On reaction with propargyl bromide and strong base under phase transfer condition 
compound 64 was converted to the corresponding allyl propargyl ether. The subsequent 
anionic [2,3]-Wittig rearrangement with n-butyllithium gave a 9/1 mixture of di-
astereomers and the protection of the C5 alcohol of the major product led to 65 as TBS 
ether. Selective hydroboration of the terminal alkyne in the presence of 1,2-disubstituted 
alkene with disamylborane, followed by oxidation of the intermediate vinylborane led to 
aldehyde which on Horner-Emmons homologation gave the α,β-unsaturated ester 66. On 
ozonolysis[60] of 66 followed by reductive workup, Wittig reaction with benzylidene 
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triphenylphosphorane and finally deprotection of the TBS protectinting group with HF 
gave unit A compound 12c in an good overall yield. 
 
OH 1. Propargyl
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2. n-BuLi
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H
CO2CH3
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64 65
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Scheme 13: Synthesis via a Wittig rearrangement 
 
3.4.4 Asymmetric crotylboration 
 
Michael Martinelli and co-workers in Eli Lilly Company have described a very brief 
synthesis of unit A[61-63]  based on an asymmetric crotylboration reaction.[64] After mono 
protection of 1,3-diol 67 (Scheme 14) the free hydroxyl group was oxidized with sodium 
hypochlorite in presence of TEMPO and led to aldehyde 68.[65] The enantiometrically pure 
Brown asymmetric crotylboron reagent[61-63] was added to 68, followed by oxidation with 
hydrogen peroxide providing homoallylic alcohol 69 in ≥ 99% ee and de. After 
quantitative removal of the silyl protecting group with fluoride the compound 69 was again 
oxidized to an aldehyde. A methyl ester homologue was made by phosphonate, then the 
ester group hydrolysed with base produced carboxylic acid 70. The Eli Lilly group 
introduced the phenyl ring of Cryptophycin by means of a Heck reaction with iodobenzene 
at the end of the synthetic sequence that led to Cryptophycin-52 (4). 
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Scheme 14: Synthesis by asymmetric crotylboration reaction 
 
White [66,67] and co-workers applied a similar strategy for the synthesis of unit A 
(Scheme15). After preparing compound 69 they protected the free hydroxyl group with 
TBS and cleaved the terminal alkene group by ozonolysis, which led to aldehyde 71. The 
styryl group was introduced through a Horner-Emmons reaction[68] and showed E isomer 
as the exclusive reaction product on which the selective removal of  the primary siliyl 
group took place with HF-pyridine complex leading to alcohol 72. The Dess-Martin 
periodinane oxidized the alcohol to aldehyde, which was converted to 12d and protected 
unit A 12b by  homologation with (tert-butoxycarbonylmethylene)triphenylphosphorane[69] 
in an good overall yield. 
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Scheme 15: Synthesis of 12d from intermediate 69 
 
On addition to the enantioselective crotylboration approach, White has also disclosed a 
related strategy based on a diastereoselective allylstannation of a chiral, non-racemic 
aldehyde.[66] In this synthesis they introduced the styryl part by Takai reaction [70] followed 
by Stile coupling with phenyltrimethylstannane to produce protected unit A 12d.[71] 
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3.4.5 Noyori hydrogenation − Frater alkylation 
 
Georg and co-workers[72] have later made clever use of the Noyori asymmetric 
hydrogenation to control the absolute stereochemistry at C5 of unit A (Scheme16).[73] 
Methyl-5-benzyloxy-3-oxopentanone 73 was hydrogenated in presence of (S)-
BINAP/RuBr2 to the  (R) alcohol with 97% ee, which on exposure to LDA in THF, 
followed by a solution of iodomethane in HMPA led to anti-product 74.[74]  
Hydrogenolytic cleavage of the benzyl ether protecting group, followed by protection of 
the primary alcohol group as TBS ether derivative gave ester 75. The reduction of the ester 
group with DIBAL-H led to the primary alcohol which on oxidation with TPAP/NMO[75] 
produced aldehyde 71, the same intermediate that White used, and from this point on, 
Georg’s and White’s synthesis were parallel. 
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Scheme 16: Synthetic pathway by Noyori hydrogenation − Frater alkylation 
 
3.4.6 (S)-(−)-2-Acetoxysuccinic anhydride as starting material 
 
This is a very unconventional synthetic pathway for unit A, described by Lavalee and co-
workers (Scheme 17).[76] Regioselective ring opening at C1 of (S)-2-acetoxysuccinic 
anhydride 76 with lithium phenylacetylide was followed by non-stereoselective reduction 
by sodium borohydride which on base-mediated hydrolysis led to 1/1 mixture 
diastereomeric diols. Exposure of this mixture to tosic acid led to diastereomeric lactones 
77 and 78. In the compound 77 the hydroxyl group was protected as  ether was followed by 
quantative reduction with LiAlH4 to produce diol 79. Sequencial pivaloylation of  the 
primary hydroxyl group, followed by acetylation of secondary hydroxyl group in situ, led  
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to fully protected triol 80. After selective hydrolysis of the THP protecting group with 
aqueous acetic acid, this allylic acetate was exposed to lithium dimethyl cuprate and gave 
81. The conversion of 81 to unit A compound 12c took place in five steps. Protection of C5 
alcohol by THP, the cleavage of pivaloate by LiAlH4, Swern oxidation of the primary 
alcohol, exposure to (tert-butoxycarbonylmethylene)triphenyl phosphorane and finally 
hydrolytic cleavage of THP group led to 12b in a good yield. 
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Scheme17: Synthetic pathway of unit A from acetoxysuccinic anhydride 
 
The compound 78 was semihydrogenated over Lindar’s catalyst and led to alkene 82. On 
methyl cuprate addition to 82, protection of the C5 hydroxyl group as THP ether and 
reduction of the carboxylic acid to primary alcohol with LiAlH4 led to 83. Compound 83 
was converted to 12b through the same last three steps (Swern oxidation; Wittig 
homologation; hydrolysis) as has been described for the conversion of 12b from 81. 
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3.4.7 Vinyl epoxide reduction 
 
Like the original Tius publication, Furuyama and Shimizu made use of the Sharpless 
asymmetric epoxidation for control of the absolute stereochemistry of unit A.[77] The para-
methoxybenzyl derivative 84 of 3-hydroxypropanal (Scheme 18) was treated with [1-
(ethoxycarbonyl)ethyl]triphenylphosphorans, followed by reduction of the ester function 
with DIBAL-H  to the primary alcohol which was converted to the non-racemic epoxide 85 
under Sharpless condition, using (+)-diethyl tartrate the chiral inducer. After Swern  
oxidation, the epoxyaldehyde was exposed to benzylidenetriphenylphosphorane and 
warming to room temperature led to Z-styryl compound 86. After that the key step in the 
sequence was the palladium mediated reduction-isomerisation  which set the relative and 
absolute stereochemistry at C5 and C6 (unit A). The isomerization process was initiated by 
the epoxide ring opening with formation of a π-allyl palladium species (Figure 7). The 
conversion took place by reaction with catalytic Pd(0), tri-n-butyl-phosphine and triethyl 
ammonium formate. 
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Scheme 18: Synthetic pathway by vinyl epoxide reduction 
 
Interconversion between this π-allyl intermediate and a σ-boned palladium species was 
reversible. Relief of non-bonding interactions between phenyl and methyl groups favored 
one of the two rotamers of the σ- bound intermediate. Conversion to another π-allyl spe-
cies, followed by reductive elimination of palladium, completed the catalytic cycle which 
after deprotection of  PMB group led to 87. Protection of both hydroxyl groups as TBS 
ether and selective hydrolysis of primary TBS with acetic acid gave 72 (Scheme 15) which 
on Swern oxidation and Horner-Emmons homologation leading to 12a, the unit A com-
pound of the first Tius synthesis. 
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Figure 7: The proposed mechanism for the reduction-isomerisation step 
 
3.4.8 Synthesis via Mitsunobu reaction. 
 
In this synthesis, the unit A was prepared by syn-aldol methodology followed by 
Mitsunobu reaction (Scheme 19).[78] The Evans aldol reaction was done between the 
auxiliary 88 and the protected aldehyde 89. After reductive removal of the chiral auxiliary 
the primary hydroxyl group of 90 was protected by silylation to allow the inversion of the 
secondary hydroxyl group by Mitsunobu reaction.[79] Basic ester hydrolysis delivered an 
alcohol, which was protected giving 91. Extension of the carbon chain on the other 
terminus was done by oxidative removal of the p-methoxy benzyl group, followed by 
Swern oxidation and Horner-Wadsworth-Emmons reaction  to give compound 92. 
Construction of the styrene part was done by selective removal of the primary silyl 
protecting group, Swern oxidation and Wittig reaction between the obtained aldehyde and 
benzyl phosphonate providing the target compound 12d. 
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Scheme 19: Synthesis by Mitsunobu reaction 
 
II. THE FAMILY OF CRYPTOPHYCINS 
 27 
3.5. Syntheses of some important Cryptophycin analogues 
 
3.5.1. Synthesis of stable Cryptophycin-52 (4) 
 
In comparison with Cryptophycin-1 (1), Cryptophycin-52 (4) contains an additional methyl 
group in unit C, which increases the steric hindrance and diminishes the rate of hydrolytic 
cleavage of the unit C-unit D ester linkage. Synthesis of Cryptophycin-52 was done by 
several groups and one of them was the group of A. K. Ghosh.[80]  They synthesised by 
assembly of three fragments (Scheme 20), phenyl hexenal 93, D-tyrosine phosphonate 94, 
and protected β-amino acid derivative of 95. In the fragment 93 both of the stereogenic 
centres at C3 and C4 were derived from optically active 4-phenylbutyrolactone, synthe-
sised enantioselectively by Corey-Bakshi-Shibata reduction.[81] A Horner-Emmons olefi-
nation between aldehyde 93, and phosphonate 94 generated the key tyrosine octadienamide 
subunit, which on esterification with acid of 95 offered the corresponding protected acyclic 
precursor for Cryptophycin-52. Removal of the appropriate protecting groups followed by 
cycloamidation of the resulting amino acid constructed the 16-membered macrocyclic ring. 
They generated the sensitive epoxide at the final step of the synthesis with m-CPBA as a 
2/1 mixture of two diastereomers. 
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Scheme 20: Retrosynthetic analysis of Cryptophycin-52 
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3.5.2 1-Aza-Cryptophycin-1, an unstable Cryptophycin 
 
An alternative strategy for stabilizing the Cryptophycins against hydrolytic cleavage is by 
replacement of labile ester  links for amide links between unit A and unit D. In this context 
the Tius group discussed the synthesis and aspects of the reactivity of 1-aza-Cryptophycin-
1.[82] The synthesis of aza analogue of unit A (Scheme 21) controls the epoxide 
stereochemistry by using (R)-methyl mandelate 96 as a source of asymmetry. Conversion 
of methyl ester 96 to Weinreb amide was done in presence of trimethylaluminium, and the 
hydroxyl group was protected as TBS ether, followed by the reaction with ethylmagnesium 
bromide which led to ethyl ketone 97. Condensation of di-n-butylboryl enolate[83,84,]  
derived from 97 with 3,3-dihydroxypropanol, [85,86]   followed by oxidative work up, led 
exclusively to syn diol 98. Acid hydrolysis of the acetal function to the aldehyde and 
Horner-Emmons reaction under Masamune-Roush conditions gave allyl ester 99. 
Conversion of alcohol to tosylate was followed by Luche reduction of the keto group and 
led to alcohol 100 with 20/1 stereoselectivity.[87] Exposure of 100 to 
tetramethylguanidinium azide and reduction of azide with triphenylphosphine led to 
primary amine 101, an analogue of unit A. 
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Scheme 21: Synthesis of analogue of unit A of 1-Aza Cryptophycin-1 
 
The condensation of 101 with fragment 25 (unit C + D) was mediated by FDPP, which on 
palladium catalyst cleavage of the allyl ester produced carboxylic acid 102 (Scheme 22). 
The carboxylate group of 102 was condensed by the ame conditions with protected unit B 
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13a to give the seco compound. Exposure of this compound to TFA, followed by evapora-
tion to dryness and reaction with 2-hydroxypyridine led to cyclic syn-diol compound 103. 
The conversion of syn-diol in 103 to epoxide was accomplished through orthoformate, 
which was treated with acetyl bromide and then with potassium bicarbonate. leading to an 
approximately equimolar mixture of  desired epoxide 104 and 105.  
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Scheme 22: Synthesis of 1-aza-Cryptophycin-1 
 
3.5.3. Synthesis of Cryptophycin-24 (3) 
 
3.5.3.1 Synthesis via N-Acyl-β-lactam macrolactonization 
 
The simplest of the macrolides, Cryptophycin-24 (3) which lacks a chiral centre at C6 and 
a chlorine substituent in the tyrosine moiety, was synthesized by George and co-
workers.[88,89] In this synthesis a efficient and concise approach, involving a cyanide-
initiated acyl-β-lactam ring opening followed by cyclization was applied successfully. The 
retrosynthetic analysis for Cryptophycin-24 reveals that the molecule 106 be assembled 
from three basic building blocks, octadienoate esters 12b, L-leucic derivative 15c and N-
acylazetidinones 107 (Scheme 23). The introduction of the 3′-phenyl group of Cryptophy-
II. THE FAMILY OF CRYPTOPHYCINS 
 30 
cin-24 could be accomplished by a Heck reaction, at the early stage in the synthesis, or 
later in the synthetic scheme. This approach made the synthesis flexible for incorporation 
of various aryl substituents at the C3′ position. 
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Scheme 23: Retrosynthetic pathway to Cryptophycin-24 (3) 
 
3.5.3.2 Synthesis via RCM approach 
 
Georg and co-workers later also synthesized Cryptophycin-24 (3) from diene 108 using 
RCM conditions.[90] The intermediate diene 108 was prepared by assembly of epoxy 
alcohol 109[15,16] and acid 110 (Scheme 24).  
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Scheme 24: RCM approach for synthesis of Cryptophycin-24 (3) 
 
In the final step the macrocyclization was done by metathesis reaction of diene 108 with 
the Grubbs 1 catalyst[91] with exclusive formation of the E-isomer to provide 
Cryptophycin-24 in good yield and the synthesis has been achieved in the presence of the 
chemically reactive styrene epoxide moiety. 
 
There are some other reports of total and formal synthesis[92-94] but they are not discussed 
here because of their low selectivity  and moreover they are more or less similar to other 
pathways of synthesis. 
 
4. Key reactions and mechanisms 
 
4.1. Aldol reaction 
 
The aldol reaction is one of the most important methods of forming carbon-carbon bonds. 
The addition of an enolate to an aldehyde leads to the formation of at least one chiral 
center. In the case of α-substituted enolates it has been possible to control the product 
stereochemistry to a large extent, while the aldol reaction of α-unsubstituted chiral enolates 
was for many years a “problem child” for synthetic chemists because of its insufficient 
stereoselectivity. Progress in this area has only been made in the last few years using either 
new chiral auxiliaries or alternatives to the aldol reaction.[95] 
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Aldol reaction, a classical method for the construction of carbon chains with oxygen func-
tionality in 1,3-positions,[96] has undergone remarkable changes in the last twenty years. 
The impulse for this development was given by the increasingly ambitious synthetic goals, 
which were provided in particular by the macrolide and polyether antibiotics with their 
many functional groups. New and particularly stereoselective variants of the aldol reaction 
have proved to provide the key to success. 
 
4.1.1 Syn selective Crimmins aldol 
 
An important application of chiral oxazolidinethiones and thiazolidinethiones is the 
asymmetric aldol condensation of their corresponding N-acyl derivatives with suitable 
aldehyde partners. The use of N-acyloxazolidinethiones and thiazolidinethiones in 
asymmetric aldol additions complements very well other existing methodologies such as 
the dialkylboron enolates of N-acyloxazolidinones pioneered by Evans,[97] and the tin(II) 
enolates of N-acyl sultams developed by Oppolzer.[98]  
Since the first report of the use of chiral N-acyloxazolidinethiones in asymmetric aldol-
type reactions by Nagao in 1985,[99] the number of examples of their application in the total 
synthesis of natural products has grown exponentially. More recently, Crimmins and 
coworkers published a detailed account of their work in asymmetric aldol additions 
employing titanium(IV) enolates of N-acyloxazolidinethiones and N-acylthiazolidinethi-
ones.[100] Crimmins addressed the importance of the dialkylboron enolates of N-acyloxazo-
lidinones as the most commonly used enolates for the preparation of the Evans syn 
products. 
The reaction with boron enolates proceeds via the non-chelated transition state i to deliver 
the well-known Evans syn products 113 (Scheme 25). However, the use of titanium(IV) 
enolates of N-acyloxazolidinethiones and N-acylthiazolidinethiones allows the reaction to 
proceed via the chelated transition state ii to deliver the non-Evans syn products 114. 
Furthermore, Crimmins reported the potential of titanium(IV) enolates of both N-
acyloxazoli-dinethiones 111 and N-acylthiazolidinethiones 112 for the preparation of both 
Evans and non-Evans syn aldol products by variation of the reaction conditions. 
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Scheme 25: Non-chelated (i) and chelated (ii) transition states in the asymmetric aldol 
addition of titanium(IV) enolates of N-acyloxazolidinethiones and thiazolidinethiones. 
 
Crimmins found that the diastereoselectivity of the titanium(IV) enolates of N-acyloxazo-
lidinethiones and N-acylthiazolidinethiones to deliver the Evans 113 or non-Evans syn 
products 114 is dependent on the nature and amount of the base used to generate the eno-
lates.[100] The Evans syn products were obtained, via the non-chelated transition state i, 
when the titanium enolates were formed in the presence of two equivalents of a base such 
as (–)-sparteine. It was suggested that the second equivalent of amine coordinates to the 
metal center preventing further coordination of the imide or thioimide carbonyl to the 
metal center. Non-Evans syn products were obtained when only one equivalent of amine 
was used to generate the enolates. In this case the imide carbonyl or the thiocarbonyl 
coordinated to the metal center to produce the highly ordered chelated transition state ii. 
Coordination of the imide carbonyl or thiocarbonyl to the metal center led to reversal of 
the π-facial orientation of the enolate in the transition state.[100]  
 
4.2 Wittig reaction 
 
It is a reaction between a carbonyl compound (aldehyde or ketone only) and a species 
known as  phosphonium ylide to form an alkene. Unlike with other elimination reactions, 
the Wittig elimination step occurs only from an intermediate not from isolated starting ma-
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terials. This intermediate is made in situ in the reaction and decomposes spontaneously. 
The Wittig reaction is therefore a connective alkene-forming reaction. It is much more 
widely used than the Julia or Peterson reaction, because the Wittig reaction only needs one 
step. 
An ylide is a species with positive and negative charges on adjacent atoms, and a 
phosphonium ylide carries its positive charge on phosphorous. They are made from 
phosphonium salts by deprotonation them with a strong base (Scheme 26). 
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Scheme 26: Synthesis of ylide 
 
The stereochemistry of the Wittig reaction can be affected by solvent, cation, temperature, 
and type of aldehyde. Z-stereoselectivity is maximized by polar aprotic solvent, exclusion 
of lithium salts, and low reaction temperature.[101] It is assumed that, the reaction occurs 
through a [2+2] cycloaddition of the ylide with the aldehyde, which can result in a cis- or 
trans-configuration of the oxaphosphetane (Scheme 27). Because of the four participating 
electrons, the thermal cycloaddition has to occur via a MÖBIUS transition state or a [π2 s + 
π2a] approach, respectively.[102] The two double bonds approach each other in a 
perpendicular fashion with the R groups as far as possible apart from each other. 
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Scheme 27: Mechanism of Wittig reaction 
 
Therefore, the transition state leading to the cis-oxaphosphetane is favoured. The collapse 
of the four membered oxaphosphetane is stereoselective and the cis-oxaphosphetane 
exclusively forms a cis-olefin and trans-oxaphosphetane only trans-olefin. The formation 
of the 1,2-substituted oxaphosphetane is kinetically controlled, but when stabilized ylide 
are used the thermodynamic stability of the oxaphosphetane is increased and therefore, the 
selectivity of the cis-oxaphosphetane is decreased. Consequently in this case the E-alkene 
can be favored. 
 
4.3 Coupling reactions 
 
A key step in the peptide production process is the fomation of the peptide bond. This 
requires the activation of a carboxylic acid which is generally done by a so-called coupling 
reagent (Figure 8). The peptide coupling reagent field has clearly evolved in the last 
decades from carbodiimides to onium (phosphonium and uronium) salts. 
 
II. THE FAMILY OF CRYPTOPHYCINS 
 36 
Carbodiimides
N C N
DIC
N N C N
Cl
N C N
EDAC DCC
XXTU - Uronium Salts
X NY
N
O
PF6
- / BF4
-
HBTU : X=Y=H
TBTU : X=Y=H
HCTU : X=H, Y=Cl
HATU : X=N, Y=H
Z= BF4
-
Z= PF6
-
Z= PF6
-
Z= PF6
-
X
N
N
O
N
P
N
N NPF6
-
PyBOP: X=Y=H
PyAOP: X=N, Y=H
Z= PF6
-
Z= PF6
-
Phosphonium salts
Coupling additives
N
N
N
OH
N
N
N
OH
Cl
HOBt Cl-HOBt
N
C N
N
 
 
Figure 8: Coupling additives and coupling reagents 
 
4.3.1. Coupling by carbodiimides 
 
The area of industrial coupling reagents began in 1955 with the introduction of dicyclo-
hexylcarbodiimide (DCC), which at that time was already known and well studied as a 
reagent for formation of amide bonds. The mechanism of the carbodiimide activation is 
complex and depending on the solvent, starts by a proton transfer, followed by addition of 
carboxylate to form the O-acylisourea 115 (Scheme 28). This is the most reactive species 
which can attack the amino component to give the corresponding amide. However, the O-
acylisourea 115 can undergo a rearrangement to give the N-acyl urea 117, which is not 
reactive or sustains an intramolecular cyclization to give a 5(4H)-oxazolone. This is less 
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reactive than theO-acylisourea and can tautomerize with the corresponding loss of chiral-
ity.[103]  
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Scheme 28: Mechanism of peptide bond formation by carbodiimide activation 
 
Another problem is racemization of the activated ester 115 to 116 before attacking 115 
directly with the amino group of the second amino acid. Therefore it is better to have 
plenty of 1-Hydroxybenzotriazole (HOBt) which intercepts the activated ester 115 first so 
the new intermediate 118 does not racemize, mostly because the reaction is highly 
accelerated by the addition of HOBt. The second amino acid, protected on the carboxyl 
group, then attacks the HOBt 118 ester and gives the dipeptide 119 in a very fast reaction 
without racemization. All these factors make the addition of a benzotriazole derivative 
almost mandatory to maintain high yields and chiral configuration during the peptide bond 
formation by carbodiimide activation. 
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4.3.2 Coupling by uronium and phosphonium salts of benzotriazoles 
 
Other widely used coupling reagents include uronium and phosphonium salts such as 
HATU, HBTU,TBTU and PyBOP, PyAOP respectively. Amino acids react with onium 
salt in the presence of bases (Scheme 29) and form the hypothetic intermediate species of 
acyloxy-onium salts 120. 
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Scheme 29: Mechanism of peptide bond formation through onium salts activation 
 
Until now these intermediate species have not been detected or isolated, as they react 
immediately with the benzotriazole derivative 121 to give the hydroxybenzotriazole ester 
122. To accelerate this an extra equivalent 121 is added in some synthetic protocols. Ester 
122 reacts with the the amino component to lead to the corresponding amide 123.[103] 
Uronium salts having the counterion hexafluorophosphate are more soluble than 
tetrafluoroborates salts, which allow the preparation of more concentrated solutions. 
 
4.4 Yamaguchi esterification 
 
The coupling of carboxylic acids with alcohols to produce esters is a fundamental synthetic 
process. A variety of conditions have been developed to accommodate different synthetic 
scenarios.[104-106] In these procedures equimolar amounts of carboxylic acid and alcohol, 
II. THE FAMILY OF CRYPTOPHYCINS 
 39 
mild conditions, and the elimination of toxic byproducts were established. Of these, the 
Yamaguchi esterification is very effective and commonly used in the synthesis of mac-
rolactones. It has found great use in regioselective synthesis of highly functionalized es-
ters.[107] The Yamaguchi esterification involves the reaction of an acid with 2,4,6-
trichlorobenzoyl chloride to form the mixed 2,4,6-trichlorobenzoyl anhydride.[49] This iso-
lated mixed anhydride, upon reaction with an alcohol, in the presence of DMAP, produces 
the ester regioselectively (Scheme 30). 
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Scheme 30: Yamaguchi esterification 
 
In this mechanism all the reactions involved are reversible, except for the last ester 
formation step. The byproduct of this step is the aliphatic carboxylate, which reenters the 
cycle. Thus, until the regioselective completion of the reaction, there is always aliphatic 
carboxylate remaining, competing with the aromatic carboxylate and the alcohol. The 
mechanism is based on the assumption that the aliphatic carboxylates are better 
nucleophiles than the aromatic carboxylates and the alcohols. 
This proposed mechanism suggests that any aromatic acid chloride capable of producing 
preferentially and in situ the symmetric aliphatic anhydrides could be used in the 
regioselective synthesis of aliphatic esters. It is more important to consider the relationship 
between steric effects, electronic effects, and reactivity. The aliphatic anhydride produced 
in situ must be more electrophilic towards the alcohol than the aromatic carbonyl of the 
mixed aliphatic-aromatic anhydride for this procedure to succeed. 
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Scheme 31: Postulated mechanism of the Yamaguchi esterification 
 
4.5 Macrolactonization 
 
Macrolactones are quite common in nature. The lactone ring imposes conformational 
constraint and its general improves binding to a receptor. Due to the ring size, the synthesis 
of macrolactones requires special activation reagents combined with high dilution 
conditions. 
 
4.5.1 Corey and Nicolaou reactions 
 
The macrolactonization of thioesters corresponds to the biosynthetic pathway for the for-
mation of macrolides.[108-112] It is therefore not surprising that this strategy has also been 
one of the most popular chemical ways to obtain such macrolactones. The most famous 
reaction involving a thioester is the “double activation” method described in 1974 by 
Corey and Nicolaou.[113] This mechanism involves the initial formation of a 2-pyridine 
thioester of the ω-hydroxy acid via a Mukaiyama oxidation-reduction condensation with 
PySSPy and triphenylphosphine.[114] Internal proton transfer then affords an intermediate 
in which both the carbonyl and the hydroxyl group have been activated, leading to the elec-
trostatically driven macrolactonization (Scheme 32). This “double activation” has been 
II. THE FAMILY OF CRYPTOPHYCINS 
 41 
confirmed and a mechanism involving ketene formation was ruled out by deuterium label-
ing and kinetic studies.[115,116] 
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Scheme 32: Proposed mechanism of Corey-Nicolaou synthesis 
 
The “classical” Corey-Nicolaou method has been used in large a number of total syntheses 
and synthetic applications: e.g. zearalenone,[113] brefeldin,[117-119] tylonolide.[120,121] 
 
4.5.2 The Mukaiyama methods 
 
The use of 1-methyl-2-chloropyridinium iodide 124 (Figure 9) as an efficient reagent for 
the macrolactonization of ω-hydroxy acids was introduced by Mukaiyama in 1976.[122] The 
mechanism involves (Scheme 33) chloride substitution by the carboxylate ion to give a 
highly activated acyloxypyridinium species 125 which then undergoes macrolactonization. 
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Figure 9: Structure of Mukaiyama’s reagents 
 
Mukaiyama has described further developments of this reagent to suppress under the cycli-
zation conditions the decomposition of the pyridinium salt by attack of triethylamine either 
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on the 1-methyl group to form 2-chloropyridine or on the pyridinium ring to form pyridin-
ium salts. They synthesized a new pyridinium salt, 2-chloro-6-methyl-1,3-
diphenylpyridinium tetrafluoroborate 124a to avoid these side reaction.[114,123] Indeed, in 
the presence of benzyltriethylammonium chloride and a hindered non-nucleophilic base 
such as a 2,6-disubstituted pyridine, this reagent gave better yields in the macrolactoniza-
tion. 
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Scheme 33. Mechamism of Mukaiyama macrolactonization 
 
4.5.3 Mitsunobu reaction 
 
In 1976 Mitsunobu described a macrolactonization protocol to obtain medium and large 
macrolactones. This methodology is based on the activation of the seco-acid alcohol using 
diethyl azodicarboxylate (DEAD) and triphenylphosphine.[123-127] Initially diolides were 
usually obtained as the major products for the medium ring lactones,[128,129] and the 
Mitsunobu reaction has long been considered as a selective method to obtain diolides. A 
modification was introduced by Steglich in 1991 during the synthesis of combrestatin 
analogues.[130] Using the classical Mitsunobu protocol, the diolide was obtained as the 
major product (diolide 40%, macrolactone 25%), but with slow addition of the seco-acid to 
DEAD-triphenylphosphine, the macrolactone was the major product (macrolactone 59%, 
diolide trace yield) (Scheme 34). 
In the reaction mechanism, the key intermediate is an alkoxyphosphonium salt 126 
produced in situ, and the macrolactonization proceeds via an intramolecular SN2 reaction 
with inversion of the alcohol configuration. 
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Scheme 34: Reaction steps and mechanism of the Mitsunobu lactonization 
 
5. Goal of research 
 
As depsipeptides, the Cryptophycins are of particular interest in the context of the 
synthesis of natural product-like libraries. In principle, synthesis of this type of cyclic ring 
systems can be approached using various strategies,[131] such as the classical solution head-
to-tail cyclization, the solid phase cyclorelease strategy[132] or on-support cyclization using 
backbone or side chain attachment.[133] The molecule of Cryptophycin-3 offers vast scope 
to arrange different amino or hydroxy acids to test its biological activity. According to 
previous total syntheses, it can be acquired by many different retrosynthetic pathways. The 
most convenient one is the division of fragment A 12b and the tripeptide fragment 161, 
which can be the assembly of different amino acids or hydroxy acids (Scheme 35). In this 
point we need a strategy where fragments A and various types of tripeptide fragment can 
be produced efficiently and  in large scale. 
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Scheme 35. Retrosynthetic anylysis of Cryptophycin-3 (5) 
 
Several strategies for the total synthesis of Cryptophycins and its analouges were reported 
by different working groups, which all use the classical solution phase head-to-tail 
cyclisation. 
In the first synthesis by Tius et al.[24] there is a drawback for the synthesis of fragment A. 
According to them, for the large scale synthesis of compound 19 from 18  by bromination 
with NBS, a diastereomeric tetrahydrofuryl alcohol was formed as byproduct (Scheme 2). 
In the assembly of fragments they coupled first the expensive fragment A with fragment B, 
but this is not so clever for the synthesis of  such a macrocycle. 
In the first steps of the synthesis of fragment A Leahy-Gardiner established the 
stereochemistry of C7 and C8 by coupling two asymmetric compounds: (R)-mandeldehyde 
derivative 29 and boron enolate 30 (Scheme 6).[45] But the starting materials are expensive 
and the Evans aldol reaction is limited to a 2 g scale, in a large scale it gives a diastereo-
meric mixture of 31. 
Tius and Li used a hetero Diels-Alder reaction for the synthesis of A, where diene 43 was 
used as 9/1 mixture of geometrical isomer which is reflected in the ratio of Diels-Alder 
reaction products.[51] The exposure of crude Diels-Alder product 44 to trifluoroacetic acid  
gave 4/1 mixture of bicyclic products 45 and 46. Furthermore the protection reaction of 
syn C7-C8 diol in compound 47 is very sensitive, which easily gives a tetrrahydrofuran 
derivative with final compound up to 30% yield (Scheme 9). 
Therefore, the objective of our study is the development of simple and reliable synthetic 
strategy, where the fragment A can be made in an efficient way as well as the synthesis of 
tripeptide fragment allows the solid phase assembly to make a large number of such 
macrocycles. 
II. THE FAMILY OF CRYPTOPHYCINS 
 45 
6. Results and discussion 
 
6.1 Retrosynthetic analysis of Cryptophycin-3 (5) 
 
In our retrosynthetic analysis, Cryptophycin-3 (5), was obtained from the protected seco-
compound 127 which was partitioned into two halves: 5-hydroxy ester 12b (unit A) and 
tripeptide derivative, acid 126 (Scheme 36). The latter is composed of the depsipeptide 
fragment 128, and phenylalanine derivative 13c (unit B). Ester 128 could be synthesized 
by the coupling between β-amino acid 14c (unit C) and α-hydroxy ester 15c (unit D). 
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Scheme 36: Retrosynthetic disconnection of Cryptophycin-3 (5) 
 
6.2 Synthesis of 5-hydroxy ester 12b (unit A) 
 
The synthesis of fragment A has to address the attachment of the aryl ring and the estab-
lishment of the anti-stereorelationship at C5 and C6. Therefore we sought to develop a 
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route where the stereochemistry is based on aldol methodology, followed by anti selective 
hydroboration and flexible introduction of the aryl group by Wittig olefination. The re-
mainder of the carbon atoms of fragment A were added by Wittig-Horner homologation 
(Figure 10). 
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aldol reaction
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Figure 10: Overview of the synthesis of unit A 
 
6.2.1 Retrosynthetic analysis of 5-hydroxy ester 12b (unit A) 
 
The retrosynthetic analysis of 5-hydroxy ester 12b is shown in the Scheme 37. The α,β-
unsaturated erter 12b was acquired from the anti-alcohol 136 which was prepared from the  
disubstituted allyl ether 135 by hydroboration reaction. The terminal alkene 170 was 
produced from the aldol product of aldehyde 130 and chiral auxiliary 129. 
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Scheme 37: Retrosynthetic pathway to 5-hydroxy ester 
 
6.2.2 Aldol reaction with Evans methodology 
 
The key reaction in the synthesis of 5-hydroxy ester 12b was an asymmetric Evans aldol  
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reaction,[134-136] which provided the two stereocenters at C5 and C6. In our synthesis we 
exploited a modified Evans procedure which according to the literature also results in 
“Evans” syn-type products.[100,78] The N-propionyloxazolidinone 129 was treated with 
TiCl4 (1 eq.) and (−)-spartein (2.5 eq.) at –78°C and led to Z-enolate, which on further 
reaction with the protected aldehyde 130 produced the syn-aldol product 131. This reaction 
was carried out through the non-chelated transition state vii with an excellent 
diastereoselectivity (>99% de) (Scheme 38).  
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Scheme 38: Evans aldol reaction 
 
In this reaction we used 2.5 eq. (−)-sparteine instead of diisopropylethylamine or 
tetramethylethylenediamine (TMEDA) to generate the titanium enolate of N-propionyl-
oxazolidi-none 129, because it changed the rate of the reaction and 
diastereoselectivities.[100] The isolated yield with (−)-sparteine was improved substantially 
compared to TMEDA. Another important point is that TiCl4 and (−)-sparteine were used 
directly as received without further purification in contrast with n-Bu2BOTf (now it can 
also possible to buy), which was needed to be prepared in advance.[100] 
 
6.2.3 Further synthetic pathway to 5-hydroxy ester 12b 
 
After Evan’s aldol reaction, the syn-aldol product 131 was purified by flash chromatogra-
phy and the hydroxyl group was protected with tert-butyldimethylsilyl triflate (TBSOTf) in 
presence of lutidine leading to 132 (Scheme 39). This protection reaction was followed by 
reductive removal of the auxiliary with lithium borohydride producing syn-alcohol 133. 
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Thereafter a terminal double bond had to be introduced, which was accomplished in high 
yield method by forming tosylate and base induced elimination.[137,78] The tosylation of 
alcohol 133 was done by para-toluenesulfonyl chloride (p-TsCl) in pyridine and Subse-
quent heating of the tosylate 134 at reflux in glyme (1,2-dimethoxyethane) in presence of 
sodium iodide and DBU effected clean elimination to provide the disubstituted allyl ether 
135. The stereocenter destroyed in this proces was reintroduced through diastereoselective 
hydroboration,[138,139] by using 9-BBN (bicyclic 9-borabicyclo[3.3.1]nonane), which gave 
the anti product 136 with high diastereoselectivity (9:1) and high yield. 
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Scheme 39: Synthetic pathway to compound 136 
 
The stereochemistry of the hydroboration can be explained by the Houk model (Figure 
11).[139] According to this model, the anti diol is produced via a staggered transition state xi 
where the substituents R and OTBS occupy the anti and outside positions, respectively. 
Attack of the borane takes place anti to the R group which is the best electron doner among 
the three substituents. 
R
HTBSO H
H
H BR2
xi
Me
 
 
Figure 11: Probable T S of hydroboration reaction 
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Then the terminal hydroxyl group was oxidized to aldehyde 137 by Swern oxidation, 
which was then extended by reaction with diethylbenzyl phosphonate, (EtO)2P(O)CH2Ph 
under Wittig-Horner conditions to produce the styrene derivative 138 (Scheme 40).  
Selective cleavage of the primary silyl protecting group from 138 was done by 
pyridiniumtoluene-4-sulfonate (PPTS) leading  to alcohol 139. After that, one-pot Swern 
oxidation of 139 and Wittig treatment[140] with Ph3P=CHCO2tBu[141-143] provided the 
unsaturated ester 12d in good yield. Finally, the removal of the secondary silicon 
protecting group by using tetra-n-butylammonium fluoride (TBAF) furnished the key 
building block 12b. 
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Scheme 40: Synthetic pathway to the 5-hydroxy ester 12b 
 
According to the 1H-NMR spectrum (Figure 12), the hydroxy acid 12b was 
diastereomerically pure. The expanded region clearly showed the chemical shift value of 
methyl group (1.07 ppm) and the proton at  C-5 (3.58 ppm). 
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Figure 12: 1H-NMR spectrum of hydroxy acid 12b 
 
The preparation of oxazolidinone  141 was done by reduction of D-phenylalnine with 
borane dimethylsulfide to amino alcohol 140, followed by condensation with 
diethylcarbonate in presence of catalytic amount of potassium. Further deprotonation with 
n-butyllithium and subsequent acylation with propionyl chloride led to the N-
propionyloxazolidinone 129 in good overall yield for the three steps (Scheme 41).[134] 
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Scheme 41: Synthesis of acylated Evans auxiliary 129 
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6.2.4 Aldol reaction using the Seebach auxiliary 
 
For the synthesis of 5-hydroxy ester 12d we also attempted the aldol reaction using the 
Seebach auxiliary, 5,5-diphenyl-oxazolidinone 142 (Figure 13). This chiral auxiliary is 
easily accessible from valine and a useful alternative to the widely employed Evans 
auxiliary 141. We chose this auxiliary because it has a number of advantages:[134] 
i) The N-acyl derivative 143 of this auxiliary is more prone to crystallize than the 
corresponding derivative of other auxiliaries.  
ii) Recycling of this auxiliary after cleavage can be achieved by simple filtration, 
because of the high insolubility of auxiliary 142 in most organic solvents. 
iii) Acylation of the auxiliary 142 with n-BuLi can be performed at elevated 
temperature (0° as compared to –78 °C for Evans auxiliary 141), which is an 
energetical and apparative advantage, especially in large scale applications. 
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Figure 13: Structure of Seebach and Evans auxiliary 
 
For the synthesis of N-propionyl-oxazolidin-2-one 143 (Scheme 42) we first converted D–
valine to (R)-N-(t-Butyloxycarbonyl) valine (144) with Boc-anhydride which was then 
methylated by methyl iodide and potassium hydrogen carbonate to get the fully protected 
valine 145. This was added to freshly prepared phenyl magnesium bromide (prepared from 
phenyl bromide and magnesium) and led to tertiary alcohol 146. This addition reaction was 
followed by the cyclization with potassium tert-butoxide and created oxazolidinone 142 in 
good yield. Acylation of oxazolidinone 142 was done with propanoyl chloride and n-BuLi  
to provide the required N-propanoyl-oxazolidin-2-one 143.[144,134] 
 
II. THE FAMILY OF CRYPTOPHYCINS 
 52 
MeI, KHCO3
DMF
(Boc)2O,
NaOH
96%
THF
H2O
86%
KOtBu
THF
80%
n-BuLi, 0 °C
EtCOCl
94%
O NH
Ph
Ph
O
D-valine
144 145
146
142
143
NH2
HO
O
N
H
HO
O
Boc N
H
MeO
O
BOC
N
H
HO Boc
Ph Ph
2 steps
THF
THF
PhMgBr
 
 
Scheme 42: Synthesis of N-acyloxazolidin-2-one 143 
 
In the aldol reaction N-acyloxazolidin 143 reacted with protected aldehyde 130 (Scheme 
43) at –78 °C using n-BuB2OTf and i-Pr2NEt. This resulted in a mixture of aldol products 
with low diastereose-lectivity and low yield. Then we tried different  reagents, TiCl4 and 
(−)-sparteine, but in this case we also got a mixture of diastereomers with low de. 
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Scheme 43: Aldol reactions using Seebach auxiliary 
 
These stereochemical results of the aldol reactions could be explained by a chair-like tran-
sition-state model.[144] It was assumed that the Bu2B- and TiCl4-enolate derivatives gave 
syn-1 and syn-2  aldol products via intermediate ix and x (Scheme 44). The anti-1  aldol 
product moght have formed via intermediate xi, which can be explained by an attractive 
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interaction between the silicon protecting hydroxyl group in 130 and the two Ph groups in 
the oxazolidinone 143. 
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Scheme 44: T. S. of Seebach aldol reaction 
 
Therefore we decided to proceed our synthesis of unit A using Evans aldol methodology, 
inspite of many advantages of oxazolidinone 142. 
 
6.3. Synthesis of amino acid 13c (unit B) by enantioselective alkylation 
 
The phenylalanine derivative 13c is usually prepared from D-tyrosine through chlorination 
of the aromatic core. Since these conditions would probably not be compatible with the 
Fmoc protecting group, a new synthesis based on the highly enantioselective alkylation of 
the glycine derivative 148 was developed.[145-149] The alkylation reaction was done with 
glycine imine 148 with compound 149 in presence of the chiral cinchona derived catalyst 
147 (Figure 14) under phase-transfer conditions (Scheme 45). 
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Scheme 45: Retrosynthetic pathway to amino acid 13c 
 
Phase-transfer catalysis (PTC) is a useful method for practical synthesis, because of its 
operational simplicity and mild reaction conditions, which enables this method to be 
applied to industrial processes.[150-154] This asymmetric alkylation is based on the fact that 
the introduction of a bulky subunit at the nitrogen atom of cinchona alkaloids leads to an 
enhancement of the stereoselectivity. This enhancement of the stereoselectivity is a result 
of the scereening effect between each cinchona unit, which can make the substrate 
approach from preferentially one direction. Among the dimeric catalysts, cinchona-
alkaloid-derived catalysts, which have a naphthalene moiety as a bridging ligand turned 
out to provide good ee-values for the alkylation of glycine imine derivatives. High 
selectivities are also obtained if the tertiary nitrogen atom is alkylated with fluorinated 
benzyl[155] or anthracenylmethyl halides.[156] This electronic effect is attributed to the 
formation of tighter ion pairs. 
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Figure 14. Structure of chiral catalyst 147 
 
6.3.1 Synthesis of chiral catalyst 147 
 
For the synthesis of chiral catalyst 147[145] we used commercially available (+)-
cinchonidine 150 which was  reduced by Pd/C under hydrogen atmosphere to hydrocin-
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chonidine 151 (Scheme 46). Amide 151 then reacted with dibromonaphthalene 152 at 100 
°C to generate dimeric compound 153. In this reaction two molecules of 151 reacted with 
one molecule of dibromonaphthalene 152, which was prepared from dimethylnaphthalene 
by bromination with n-bromosuccinimide (NBS). After that, the hydroxyl group of 153 
was reacted with allyl bromide in presence of 50% potassium hydroxide to get the desired 
chiral catalyst 147. 
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Scheme 46: Synthesis of chiral catalyst 147 
 
6.3.2 Preparation of N-(Diphenylmethylene)glycine tert-butyl ester 148 
 
The synthesis of N-(Diphenylmethylene)glycine tert-butyl ester 148[157] was started by 
nickel catalyzed oxidation of amine 154. First commertially available 154 was 
dehydrogenated under catalytic conditions with nickel sulfate NiSO4 and aqueous basic 
solution of potassium thiosulfate (K2S2O8) to diphenylmethanimine 155 quantitatively. 
Then 155 reacted with tert-butyl-2-bromo-acetate in presence of diisopropylethylamine to 
get the desired glycine imine 148 (Scheme 47). 
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Scheme 47: Synthesis of glycine derivative 148 
 
6.3.3. Synthetic pathway to amino acid 13c (unit B) 
 
In the synthetic pathway to phenylalanine derivative 13c (Scheme 48), the hydroxyl group 
of phenol 156 was converted to methyl ether 157 with dimethyl sulfate for the making of 
the tyrosine aromatic core. The methyl group of 157 was then brominated with N-
bromosuccinimide (NBS) to form benzylic bromide 149. The enantioselective 
alkylation[145] of the glycine imine 148 with benzylic bromide 149 was done with the use 
of the chiral cinchona-derived phase-transfer catalyst 147 to produce benzylated imine 158 
in good yield. The reaction was carried out with 50% aqueous potassium hydroxide in 
toluene and chloroform (7:3). The ee was determined to be 96 % by HPLC using a chiral 
column (DAICEL Chiral OB-H, 250 × 2.6 mm; 98:02 heptane and isopropanol, flow 0.5 
mL min-1, tminor = 8.82 min, tmajor = 9.79 min). 
 
Hydrolysis of imine 158 was done by 15% citric acid to give free amine 159. The free 
amino group of 159 was then immediately protected with (fluorenylmethoxy)carbonyl 
chloride (Fmoc-Cl) (160) and provided fully protected amino acid 161. Treatment of  161 
with trifluoroacetic acid (TFA) furnished the desired amino acid 13c. 
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Scheme 48: Synthetic pathway to phenyl alanine derivative 13c 
 
6.4 Synthesis of β-amino acid 14c (unit C) 
 
The synthesis of β-amino acid 14c started from commercially available (−)-methyl D-
hydroxy isobutyrate 162 (Roche ester) as shown in Scheme 49. The hydroxyl group of  162 
was first tosylated with tosyl chloride and led to tosylate 163.[158-161] Substitution of the 
tosyl group with azide was done by using sodium azide in DMSO forming azide 164. 
Then, catalytic hydrogenation[162] of the azide function with Pd/C under hydrogen 
atmosphere provided the free amine 165.[163,164] The amino group was then immediately 
protected under Schotten-Baumann conditions using (fluorenylmethoxy)carbonyl chloride 
(Fmoc-Cl) in methanol and sodium carbonate and resulted in Fmoc protected ester 166. 
Hydrolysis of the ester function of 166 to derive the amino acid 14c was then achieved 
under acidic conditions.[165] 
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Scheme 49: Synthetic pathway to β-amino acid 14c 
 
6.5 Synthesis of α-hydroxy ester 15c (unit D) 
 
The α-hydroxy ester 15c was prepared from commercially available L-isoleucine 167 by 
diazotazation[166,167] as shown in Scheme 50. L-isoleucine was diazotized with sodium 
nitrite and sulfuric acid  giving α-hydroxy carboxylic acid 168 (isoleucic acid) with 
retention of configuration at the α-carbon due to the neighboring-group participation. The 
hydroxyl group of 168 was protected with acetyl chloride to give hydroxyl protected acid 
169. After that  the protection of the carboxylic group as t-butyl ester with t-butyl alcohol 
using dicyclohexylcarbodiimide (DCC) and 4-(N,N-dimethylamino)pyridine (DMAP) 
produced fully protected 170. Finally the acyl group was deprotected with sodium 
carbonate in methanol to give the required α-hydroxy ester 15c. 
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Scheme 50: Synthetic pathway to α-hydroxy ester 15c 
 
6.6 Assembly of tripeptide derivative acid 126 (D + C + B section) 
 
The assembly of tripeptide derivative 126 began with ester formation between the 
secondary hydroxyl group of 15c (unit D) and the carboxylic acid function of protected β-
amino acid 14c (unit C) (Scheme 51). Use of dicyclohexylcarbodiimide (DCC) and (N,N-
dimethylamino)pyridine (DMAP) in the esterification provided an excellent yield of the 
dipeptide analogue 171 (D + C section). The treatment of 171 with diethylamine in THF 
caused cleavage of the Fmoc protecting group, resulting in the primary amine 128. This 
compound turned out to be stable towards intramolecular amide formation. After that 
amide formation in presence of dicyclohexylcarbodiimide (DCC) and 1-
hydroxybenzotriazole (HOBT) coupled 128 with the Fmoc protected amino acid 13c (unit 
B) and provided the D + C + B section 172, in good yield. 
 
The next stage in the plan was forming an ester bond between the alcohol of unit A 12b 
and the carboxylic group of tripeptide derivative D + C + B section 172. Accordingly, 
treatment of 172 with trifluoroacetic acid liberated the C-terminal carboxyl group, giving 
the tripeptide acid 126. 
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Scheme 51: Assembly of tripeptide unit 126 
 
6.7 Synthesis of protected seco-compound 127 and macrocyclization 
 
For the synthesis of seco compound 127, coupling through ester bond formation between  
the secondary hydroxyl group of 12b and the carboxylic acid function of 126 was tried 
with different condensing reagents as shown in Table 2. 
 
Table 2: 1) by using DCC / DMAP, yield was very poor due to racemization; the excess 
DCC and the byproduct was also dificult to separate by column chromatography 
 2) by using  EDCl/ DMAP, yield was also poor  
 3) by Yamaguchi esterification, the reaction was completely finished with very 
good yield 
 
Entry Coupling reagent Reaction conditions Yield 
1 DCC / DMAP CH2Cl2, 0 °C 25% 
2 EDCl / DMAP CH2Cl2, rt 31% 
3 2,4,6-trichlorobenzoylchloride/DMAP DIEA, THF, rt 73% 
  
In the Yamaguchi esterification, the carboxyl group of the tripeptide derivative 126 was 
activated using theYamaguchi reagent, 2,4,6-trichlorobenzoyl chloride,[167] in presence of 
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DMAP and diisopropylethylamine (DIEA), and coupled with the hydroxyl group of 12b.  
This resulted in fully protected seco compound 127 (Scheme 52).  
 
The tert-butyl ester group was then removed with trifluoroacetic acid (TFA) and after 
evaporating the solvent and excess TFA, the Fmoc group was cleaved with diethylamine 
(DEA) in the same step to get the intemediate seco-compound 173. The macrocyclization 
of 173 was achieved using the coupling reagent 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium tetrafluoroborate (TBTU) in presence of 1-hydroxybenzo-triazole 
(HOBT) and diisopropylethylamine (DIEA) leding to the macrocycle 5 in good overall 
yield. 
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Scheme 52: Final steps of the synthesis of Cryptophycin-3 (5) 
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The 13C-NMR spectrum shows the pure compound of 5 in Figure 15. 
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Figure 15: 13C-NMR spectrum of compound 5 
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6.8 Synthesis of Cryptophycin analogue 11 
 
6.8.1 Retrosynthetic analysis 
 
The Cryptophycin analogue 11 was prepared in similar fashion, by the combination of unit 
A (12b) and the tripeptide derivative 174. This tripeptide derivative 174 is the combination 
of the dipeptide 128 and Fmoc protected phenylalanine 175 as shown in Scheme 53. 
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53: Retrosynthetic pathway to compound 11 
 
6.8.2 Synthesis of the tripeptide derivative 174 
 
For the synthesis of the tripeptide derivative 174, we replaced the Fmoc-protected amino 
acid 13b with commercially available Fmoc protected (R)-phenylalanine 175 (Scheme 54). 
Acid 175 was coupled with dipeptide 128 in a similar fashion using DCC and HOBt to 
gave 174.  
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Scheme 54: Synthetic pathway to the tripeptide derivative 174 
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6.8.3 Synthesis of seco-compound 177 and final cyclization 
 
The ester group of the tripeptide derivative 174 was cleaved with TFA providing acid 176 
which was immediately coupled without further purification. Acid 176 was coupled with 
the hydroxyl group of unit A 12b using the Yamaguchi reagent and produced ester 177 
(Scheme 55). For cyclization first the tert-butyl group was cleaved with TFA, followed by 
removal of Fmoc protecting group with diethylamine resulting in the seco-compound 177a. 
By using the same coupling reagent TBTU and HOBt in presence of diethylamine the final 
cyclization led to depsipeptide 11 in good yield. 
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Scheme 55: Final steps of synthesis of compound 11 
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Figure 16 shows the 13C-NMR spectrum of the compound of 11. 
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Figure 16: 13C-NMR-spectrum of compound 11 
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III. THE PROTEASOME INHIBITOR EPOXOMICIN 
 
1. Biological activity  
 
Proper function of cells is governed by well-coordinated regulatory mechanisms involving 
numerous interactions among millions of cellular proteins with high degree of specificity. 
Many important eukaryotic regulatory proteins that are involved in the regulation of 
various cellular processes are synthesized when required and degraded after performing the 
desired function in a signal dependent manner. So precise timing of synthesis and 
degradation is the key to the regulation of many important cellular processes such as cell 
cycle progression, antigen presentation and cytokine-stimulated signal transduction. 
Therefore, deregulation of some of these mechanisms may lead to improper functioning of 
the cell that might lead to adverse consequences in these cellular processes. 
 
Intracellular protein degradation in eukaryotic cells occurs predominantly through a highly 
regulated proteasomal pathway in which proteins targeted for destruction are ligated to the 
76 amino acid polypeptide ubiquitin. Poly-ubiquitinated proteins are recognized by the 19S 
regulatory domain of the 26S proteasome and through a series of ATP hydrolysis-
dependent processes, are deubiquitinated and threaded into the core proteolytic complex, 
the 20S proteasome, where they are finally proteolyzed into short peptides.[20] Eukaryotic 
proteasome, an approximately 700 kDa cylindrical-shaped multicatalytic protease complex 
composed of 28 subunits, is a dimeric assembly of two symmetrical discs, each consisting 
of 7 alpha-type subunits and 7 beta-type subunits. Alpha subunits form the outer rings and 
the beta subunits form the inner rings. Besides expressing β-subunits ubiquitously, higher 
vertebrates also possess three interferon inducible β-subunits (LMP7, LMP2, MECL1), 
which replace normal counterparts X, Y and Z respectively and alter the catalytic activities 
of the proteasome.[20]  
 
In order to understand the proteasome function and its role in cell biology researchers have 
employed ‘chemical genetics’ approaches using various proteasome inhibitors. These in-
hibitors include the natural products and small cell membrane-permeable peptides with 
aldehyde, vinyl sulfone, boronic acid and glyoxal functional groups. Specific peptide alde-
hydes of substrate analogues have been found to form reversible covalent adducts with the 
proteasome and inhibit certain proteolytic activities. However, these inhibitors also hinder 
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lysosomal and Ca2+ activated proteases, thus limiting their use in understanding their pre-
cise effects on cells. In spite of great interest in identifying specific novel targets as 
therapeutics for various diseases, many natural products, with unknown mode of actions, 
have been identified that have therapeutic potentials such as anti-tumor activity. 
Epoxomicin, a natural product isolated from an Actinomycetes species, is an α′,β′-epoxy-
ketone-tetrapeptide and has  potent in vivo anti-tumor activity against solid tumors. Crews 
et al. have found that Epoxomicin targets proteasomal pathways to exert its anti-tumor 
activity. Epoxomicin primarily inhibits chymotrypsin-like activity 80-fold faster than 
lactacystin, another proteasome inhibitor. It is a cell membrane permeable, selective and 
irreversible proteasome inhibitor. Crews et al. demonstrated that Epoxomicin covalently 
binds to the LMP7, X, Z and MECL1 catalytic β-subunits of the proteasome and 
selectively inhibits the proteasome. In contrast to peptide aldehyde inhibitors, Epoxomicin 
does not significantly inhibit nonproteasomal proteases such as trypsin, chymotrypsin, 
papain, calpain and cathepsin B. It has also been shown to inhibit NF-κB activation and 
can be used as a potential anti-inflammatory agent.[20, 168]. 
 
 
 
Figure 17. Stereoview of the electron density map of the Epoxomicin adduct at β5 
 
To address the unique specificity of Epoxomicin for the proteasome, a co-crystallized 
α′,β′-epoxyketone-containing natural product with the yeast S cerevisrae 20S proteasome 
(Figure 17) has been reported.[169] A comparison between that structure and a crystal stuc-
ture of 20S proteasome complexed with acetyl-Leu-norleucinal[170] showed that both the 
Epoxomicin and the peptide aldehyde bind similarly to the catalytic subunits, completing 
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an antiparallel β-sheet.[170] However, a striking difference is the covalent adduct formed by 
each inhibitor with the amino terminal threonine (Thr 1). Whereas the peptide aldehyde is 
attacked by the threonyl Oγ to form a hemiacetal, a well-defined electron density map of 
the β5/Pre2 subunit complexed with Epoxomicin reveals  the presence of a unique 6-atom 
morpholino ring.  
 
This morpholino derivative results from adduct formation between the α′,β′-epoxyketone 
of Epoxomicin and the amino terminal threonyl Oγ and N of the β5 subunit (Scheme 56). 
Formation of an irriversible morpholino adduct upon Epoxomicin addition is consistent 
with the observed kinetic profile of the Epoxomicin and 20S proteasome interaction.[20, 168] 
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Scheme 56: The proposed mechanism of morpholino derivative adduct formation 
 
The mechanism of the morpholino derivative formation is most likely a two-step process. 
First, activation of the threonyl Oγ by its N-terminal amino group directly[171] or via a 
neighboring water molecule, which is positioned between the nucleophilic oxygen of the 
side chain and the α-amino nitrogen, acting as a base (B). The second step is the formation 
of a hemiacetal by intramolecular cyclization, where Thr1 N opens the epoxide ring with 
consequent inversion of the C2 carbon. Activation of the epoxide may be facilitated by the 
hydrogen bond formation between the N5 hydrogen and the oxygen of the epoxide. 
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Since other proteases, which are common targets for many proteasome inhibitors, do not 
have an amino terminal nucleophilic residue as part of their active sites, Epoxomicin 
cannot form the same morpholino adduct with those proteases as it does with 20S 
proteasome, thus explaining why Epoxomicin does not inhibit those proteases.[169] The 
unique specificity of Epoxomicin towards proteasome inhibition allowed the Crews group 
to evaluate its therapeutic potential against various diseases involving proteasome function. 
 
2. Previous total syntheses of Epoxomicin 
 
The total synthesis of Epoxomicin (7) has been reported by Crews et al. in 1999[20] and 
Williams et al. in 2004.[172]  Here in this thesis we describe those two syntheses briefly. 
 
2.1. Total synthesis of Epoxomicin by Crews et al. 
 
In the total synthesis by Crews and his group α,β-epoxyketone Epoxomicin (7) and 
biotinylated Epoxomicin[20] were synthesized, but here we describe only the total synthesis 
of Epoxomicin (7). They made first the tripeptide molecule which was coupled with the 
epoxide moiety, prepared from an unsaturated ketone. 
 
For the synthesis ot the tripeptide fragment (Scheme 57), Fmoc-N-isoleucine 178 was 
coupled with protected hydroxy ester 179 in presence of HBTU and HOBT to give 
dipeptide 180. The hydroxyl group of the dipeptide was protected with  TBSCl and 
removal of the Fmoc group was done with piperidine. This was followed by coupling of 
the amine with Fmoc-N-methyl-isoleucine (181) with HBTU/HOBT and led to the fully 
protected fragment 182. Removal of the Fmoc group and subsequent acetylation followed 
by catalytic hydrogenolysis gave the target tripeptide fragment 183. 
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Scheme 57: Crews’ synthetic pathway to tripeptide fragment 183 
 
After synthesis of tripeptide fragment 183, it was coupled with α,β-epoxy leucine 184, in 
presence of HATU/HOAt (Scheme 58).[173] Finally, the TBS protecting group was removed 
with TBAF to provide the desired Epoxomicin (7). 
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Scheme 58: Crews’ final steps of the synthesis of Epoxomicin 
 
2.2 Total synthesis of Epoxomicin by Williams et al. 
 
Williams and his group developed an efficient route to Epoxomicin (7) and established the 
first use of the spirodiepoxide functional group in total synthesis.[172] In this synthesis they 
described, that the spirodiepoxide of type xiii could serve as a precursor of simplified 
structure xii, present in 7 (Scheme 59). In the presence of a suitable nucleophile, species 
xiii should undergo a regioselective SN2 reaction. Enantiomerically pure xiv would be 
derived from oxidation of optically pure, appropriately protected allene xv, which could 
arise from aldehyde, alkyne and organometallic precursors. 
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Scheme 59: Williams’ retrosynthetic pathway to Epoxomicin (7) 
 
The optimized synthesis of Epoxomicin is represented in Scheme 60. Isovaleraldehyde 185 
was subjected to asymmetric alkynylation[174] to form 186 (>95% ee). The alcohol was 
converted to mesylate and subsequently transformed into allene 187. Treatment of 187 
with DMDO[175] and exposure to sodium azide produced an azide, which in situ after 
reduction, protection and treatment with TFA led to stable amine salt 188. 
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Scheme 60: Synthesis of amino salt 188 
 
Now DCC promoted coupling between acid 189 and HCl.II-OMe 190 led to a dipeptide 
which on Boc removal, acetylation and saponification gave acid 191 (Scheme 61). Then 
this compound was coupled with threonine 192 and on hydrogenolysis resulted in 193, 
which was again coupled with amine salt 188 and furnished hydroxy ketone 194. Exposure 
of 194 to fluoride cleaved the TBS group and the resulting  primary alcohol was converted 
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to mesylate and then finally after cyclization and deprotection of the tert-butyl group pro-
duced Epoxomicin (7). 
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Scheme 61: Williams’ final steps of Epoxomicin synthesis 
 
3. Goal of research 
 
Structural studies with the co-crystallization of the 20S proteasome-Epoxomicin complex 
revealed that the unique specifity of the natural product toward proteasome is mainly due 
to the α,β-epoxyketone pharmacophore, which forms an unusual six-membered 
morpholino ring with the amino terminal catalytic threonine (Thr-1) of the 20S 
proteasome. [169] The observed selectivity of Epoxomicin for the proteasome is rationalized 
by the requirements for both N-terminal amino group and side chain nucleophile for adduct 
formation.  
 
In most eukaryotic organisms Ntn-Hydrolases, which maintain the control over protein 
quality are represented by the three active sub-units of the proteasome (β1, β2, and β5). In 
addition to the proteasome, plasmodium falciparum, which causes malaria tropica, contains 
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another Ntn-Hydrolase (PFL1465c) similar to prokaryotic proteasome progenitors. There-
fore four different activities can be targeted by selective inhibitors. A naturally occurring 
epoxide containing peptide (Epoxomicin) and synthetic derivatives block P. falciparum 
growth in the low nanomolar range. Changes of this peptide moiety of the drug can be used 
to target the inhibitor to individual proteasome subunits. B. Mordmüller et al. found that 
this property of epoxide-containing peptides can be used to target selectively plasmodial 
Ntn-Hydrolases[176], facilitating a new approach in the treatment of malaria tropica. 
In addition proteasome inhibition is currently being evaluated for a variety of therapeutic 
purposes enabled by e.g. antitumor activity.[177] 
 
However, apart from the aforementioned studies, relatively little has been reported 
regarding the synthesis of this α,β-epoxyketone inhibitor. Current efforts are focused on 
the synthesis of additional peptide epoxyketone proteasome inhibitors that display specifity 
for each of the three proteolytic activities of the proteasome.[20,178] For this reason the 
synthesis method will enable future in vivo studies using this reagent. 
 
4. Results and discussion 
 
4.1 Retrosynthetic analysis of Epoxomicin (7) 
 
Epoxomicin is a tetrapeptide molecule with the first amino acid ending with an acetyl 
protecting group and the last peptide containing an epoxide. In the retrosynthetic analysis 
the Epoxomicin molecule would be obtained from the amino group protected tripeptide, 
left hand fragment 183, which would be coupled with the α,β-epoxy leucine, right hand 
fragment 184 to yield the complete backbone of the target compound 7 (Scheme 62). The 
left hand fragment 183 is the combination of protected threonine 195, isoleucine 196 and 
hydroxy group protected N-methyl isoleucine 197. The epoxide containing right-hand 
fragment 184 could be prepared from the precursor α,β-unsaturated ketone 198. 
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Scheme 62: Retrosynthetic pathway to Epoxomicin (7). 
 
4.2 Synthesis of the left hand tripeptide fragment 183 
 
The synthesis of left hand tripeptide fragment 183 started from commercially available L-
threonine (Scheme 63). The carboxyl group was first protected by formation of ester with 
allyl alcohol in presence of p-toluenesulfonic acid (p-TsOH) followed by protection of the 
hydroxyl group with TBDPS-Cl giving ester 199. This amine was coupled with Fmoc 
protected isoleucine 178 and produced dipeptide 200. Here we used the coupling reagent 
O-benzotriazo-1-yl-N,N,N,N-tetramethyl-uronium hexafluoroborate (TBTU) and 1-
hydroxybenzotroazole (HOBt). After removal of the Fmoc protecting group with 
piperidine, the free amine 221 was again coupled with the commercially available Fmoc-
N-methyl-isoleucine 181 using the coupling reagent Bromo-tris-pyrrolidino-phosphonium 
hexafluorophosphate (PyBroP) with dimethylaminopyridine (DMAP) to get tripeptide 202. 
The Fmoc protecting group of 202 was then removed again with piperidine and led to 203. 
Subsequent acetylation with acetyl chloride and diisopropylethyl amine resulted in 
tripeptide 204. The allyl ester of compound 204 was then cleaved using phenyl silane 
(PhSiH3) and tetrakistriphenylphosphine palladium [Pd(PPh3)4] to get the desired 
compound, acid 183. 
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Scheme 63: Synthesis of the tripeptide fragment 183 
 
4.3 Synthesis of the right hand fragment 184 
 
4.3.1 Synthesis of α,β-unsaturated ketone 198 
 
For the synthesis of the right-hand fragment 184, first we synthesized α,β-unsaturated 
ketone 198 (Scheme 64). This synthesis was initiated from Boc-N-leucine 205, which was 
converted to the Boc-leucine Weinereb amide 206 by reaction with benzotriazol-1-yloxy-
tris[dimethylamino]phosphonium hexafluorophosphate (BOP) and O,N-dimethylhydroxyl-
amine hydrochloride (OMe-N-MeH2Cl). The addition of propen-2-yl lithium to 206 was 
done by using 2-bromopropene and tBuLi resulting in the formation of α,β-unsaturated 
ketone 198 in almost quantitative yield. 
 
III. THE PROTEASOME INHIBITOR EPOXOMICIN 
 76 
N
H O
N
OMeN
H O
OH
Et3N, BOP
MeNHOMe.HCl
N
H O
tBuLi,
2-Bromo-
   propene
Et2O, -78 °C
96%
BocBocBoc
CH2Cl2, rt
88%
205 206 198
 
 
Scheme 64: Synthesis of enone 198 
 
In this transformation the Weinereb amide 206 was attacked by an organolithium reagent 
(propen-2-yl lithum) and led to the formation of a tetrahedral intermediate (xvii) which is  
stabilized by chelation of the lithium atom by two oxygen atoms (Scheme 65). This 
intermediate is stable under the reaction conditions thus preventing double addition. Upon 
aqueous work up, the desired ketone 198 is obtained. 
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Scheme 65: Mechanism of the Weinreb amide reduction 
 
The α,β-unsaturated ketone 198 was confirmed from the 13C-spectrum data in Figure 18. It 
clearly showed the chemical shift value of α,β-unsaturated  carbonyl carbon (201.5 ppm), 
as well as the olefinic carbon atoms. 
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Figure 18: 13C-NMR spectrum of α,β-unsaturated ketone 198 
 
4.3.2 Synthesis of the epoxide using chiral dioxiranes 
 
Dioxiranes generated in situ from chiral ketones have been shown to be highly 
enantioselective for the asymmetric epoxidation of a variety of olefins.[179] It was reported 
that fructose-derived ketone 207 and its acetate analogue 208 (Figure 19) are effective 
epoxidation catalysts and give high ee’s for a variety of trans- and trisubstituted olefins.[180] 
Therefore, in our synthetic route we first synthesized the acetate 208 from 207 and used 
both of them for epoxidation of α,β-unsaturated ketone 198.  
O
O
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O
AcO
AcO
OO
O
208  
Figure 19: Structures of chiral ketone 
 
4.3.2.1 Preparation of ketone 208 
 
The fructose derivative ketone 207 was purchased from Aldrich and reacted with di-
chlorodicyano benzoquinone (DDQ), which deprotected selectively only adjacent hydroxyl 
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groups, to produce diol 209 (Scheme 66). The acetylation of both hydroxyl groups was 
done by using acetic anhydride (Ac2O) and DMAP. In this step, it was interesting to note 
that we got predominantly eliminated product 210, when the reaction was carried out at 0 
°C  but the desired ketone 208, when the reaction was done at –40 °C. We assumed that in 
situ the product 208 was converted to eliminated product 210 through its chair like con-
formation  xviii, because of the higher temperature (Figure 20). 
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Scheme 66: Preparation of chiral ketone 208 
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Figure 20: Probable structure of xviii 
 
 
4.3.2.2 Asymmetric epoxidation through ketone 207 and 208 
 
For the epoxidation reaction unsaturated ketone 198 was treated separately with chiral ke-
tone 207 and 208 in presence of tetrabutylammonium hydrogen sulfate (Bu4NHSO4) and 
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oxone in buffer solution (Scheme 67).[180] But unfortunately in both cases the reaction 
products were decomposed. 
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Scheme 67: Asymmetric epoxidation of 198  
 
4.3.3 Synthesis of the epoxide through  alkaline peroxide  
 
After unsatisfactory results of selective epoxide formation by chiral ketones, we proceeded 
our synthesis by epoxide formation with alkaline hydrogen peroxide (H2O2) (Scheme 68). 
The α,β-unsaturated ketone 198 was treated with hydrogen peroxide in presence of 
diisopropylethylamine (i-Pr2EtN) and benzonitrile (PhCN) to furnish a mixture of the 
epoxides 184 and 184a in a ratio of 3:1. The major epoxide 184, which produced the final 
product identical to Epoxomicin (7) was separated by column chromatography very easily 
and used in the next steps.  
 
BocHN BocHN
O
+
O OBocHN
O
PhCN, i-Pr2EtN
H2O2-H2O,
MeOH, 0°C
70% O
198 184 184a  
 
 
Scheme 68: Synthesis of epoxide 184 with hydrogen peroxide 
 
4.4. Coupling of fragments and final steps of synthesis of Epoxomicin (7) 
 
Before coupling of two fragments, the Boc protecting group of the right-hand fragment 184 
was removed with trifluoroacetic acid (TFA) to get the salt of amine 211 (Scheme 69). 
III. THE PROTEASOME INHIBITOR EPOXOMICIN 
 80 
After removing the solvent and excess TFA, the salt 211 was directly coupled with left-
hand fragment 183 using O-benzotriazo-1-yl-N,N,N,N-tetramethyluronium hexafluorobo-
rate (TBTU) and 1-hydroxybenzotroazole (HOBt) in presence of diisopropylethylamine (i-
Pr2EtN). In the resulting compound 212, the TBDPS protecting group was lastly removed 
with tetrabutylammonium fluoride (TBAF) to get our target molecule Epoxomicin (7) in 
very good overall yield.  
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Scheme 69: Final steps of synthesis of Epoxomicin (7) 
 
The optical rotation value of compound 7 [α]D24 = ─64.4 (c = 0.36, MeOH), lit[172] ─66.1(c 
= 0.50, MeOH), confirmed that the stereochemistry of epoxide is identical with the natural 
Epoxomicin. 
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IV. CONCLUSION 
 
This dissertation includes two parts, the first one is a convergent total synthesis of the 
natural product Cryptophycin-3 (5) and its analogue and the second part contains the 
synthesis of a proteasome inhibitor, α,β-epoxy ketone Epoxomicin (7). 
 
In the first part, the present synthetic route consists of the synthesis of the four building 
blocks (fragment A, B, C and D), the assembly of these building blocks and the final 
cyclization. The most interesting building block A 12b contains two stereocenters at C5 
and C6 with anti-stereorelationship, which were created by an Evans syn aldol reaction. 
The necessary inversion of the methyl–bearing stereocenter was done by hydroboration of 
a terminal 2,2-disubstituted double bond (Scheme 52). The aryl part and the remaining 
carbons of the molecule were introduced by Wittig-Horner olefination and a Wittig 
reaction, respectively. The building block B was prepared by a very efficient 
enantioselective alkylation between the glycine derivative 148 and benzyl bromide 149 in 
presence of chiral catalyst 147 with high stereoselectivity. The other two building blocks C 
and D were prepared by  very short and efficient synthetic pathways, which make the 
whole synthesis short. The assembly of three fragments (D, C, B) was very advantageous 
because of the Fmoc amino protecting group, which was deprotected very easily by 
diethylamine. The final coupling between tripeptide 126 and building block A was done by 
a high yield Yamaguchi esterification. The final cyclization was performed by using 
coupling reagent TBTU and HOBT which completed the total synthesis nicely and drives 
efficient enough to produce the whole molecule in large scale. The total synthesis of an 
analogue 11 was made in a similar fashion but with different tripeptide 174 instead of 127. 
 
Therefore, from the new synthetic point of view and according to our goal of total 
synthesis of Cryptophycins, the whole synthesis can be described as follows: 
1) The synthesis of fragment A is very efficient, also in large scale where the anti-stereo-
relationship at C5 and C6 is based on aldol methodology, followed by anti-selective 
hydroboration and flexible introduction of aryl group was done by Wittig olefination. 
2) The synthesis of α-amino acid B by an enantioselective alkylation is a totally new 
approach, especially for the use of the Fmoc protecting group. 
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3) The use of the Fmoc protecting group should in principle allow a solid-phase assembly 
of a suitable seco compound which also means a new approach for the synthesis of Cryp-
tophycins and  natural product like libraries. 
 
The second goal of the present thesis was the synthesis of the very promising epoxide 
reactive molecule Epoximicin (7). We made the whole molecule in such a way that the 
tripeptide left-hand fragment 183 was coupled with the epoxide containing right-hand 
fragment 211. By using a suitable coupling reagent (TBTU/HOBT) destruction of the 
epoxide could be prevented (Scheme 69). All the protecting groups were removed very 
easily in good yield. Efforts were made to form the epoxide stereoselectively using chiral 
dioxiranes. However, under these conditions the epoxide did not form. Finally, we 
synthesized the epoxide in a 3:1 ratio by using alkaline peroxide, which are separated 
easily by flash chromatography. The whole synthesis was done in only 13 steps in good 
overall yield. Our synthesis of Epoxomicin is improved concerning efficiency and 
described in more detail than the previous reports for Epoxomicin or related compounds. 
This way we established a facile method for the synthesis of multi-gram quantities. Key 
features of the synthesis of the tripeptide part include the use of an allyl protecting group 
for the right-handed carboxyl function, combined with Fmoc and tert-butylsilyl protectin 
groups for the amino and alcohol functions, respectively. 
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V. EXPERIMENTAL PART 
 
1. General Remarks 
 
1.1 Chemicals and Working Techniques 
 
The chemicals were purchased from the firms Acros, Aldrich, Fluka, Lancaster, Avocado 
and Merck. All reagents were obtained from commercial suppliers and used without 
further purification unless otherwise stated. All solvents were distilled and/or dried prior to 
use by standard methodology except for those, which were reagent grades. The applied 
petroleum ether fraction had a b.p. of 40–60 oC. Anhydrous solvents were obtained as 
follows: THF, diethyl ether and toluene by distillation from sodium and benzophenone, 
dichloromethane and chloroform by distillation from calcium hydride, acetone by 
distillation from phosphorous pentoxide. Absolute triethylamine and pyridine and 
diisopropylethylamine were distilled over calcium hydride prior to use. Unless otherwise 
mentioned, all reactions were carried out under a nitrogen atmosphere and the reaction 
flasks were pre-dried by heat gun under high vacuum. All air or water sensitive chemicals 
were stored under inert atmosphere. Compounds that are not described in the experimental 
part were synthesized according to the literature. 
 
1.2 NMR-spectroscopy 
 
All the spectra were measured on a Bruker Avance 400 spectrometer, which operated at 
400 MHz for 1H and 100 MHz for 13C nuclei, respectively. 1H- and 13C-NMR spectra were 
performed in deuterated solvent and chemical shifts were assigned by comparison with the 
residual proton and carbon resonance of the solvent and tetramethylsilane (TMS) as an 
internal reference (δ = 0). Data are reported as follows: chemical shift (multiplicity: s = 
singlet, d = doublet, t = triplet, ddd = doublet of doublet of doublet, dt = doublet of triplet, 
td = triplet of doublet, m = multiplet, br = broadened, J = coupling constant (Hz), 
integration, peak assignment in italic form). 
 
1.3 Mass Spectrometry 
 
Mass spectra were recorded on Finnigan Triple-Stage-Quadrupol Spectrometer (TSQ-70)  
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from Finnigan-Mat. High-resolution mass spectra were measured on a modified AMD In-
tectra MAT 711 A from the same company. The used mass spectrometric ionization meth-
ods were electron-impact (EI), fast-atom bombardment (FAB) or field desorption (FD). 
FT-ICR-mass spectrometry and HR-FT-ICR mass spectra were measured on an APEX 2 
spectrometer from Bruker Daltonic with electrospray ionization method (ESI). Some of the 
mass spectra were also measured on an Agilent 1100 series LC-MSD. Analytical HPLC-
MS: HP 1100 Series connected with an ESI MS detector Agilent G1946C, positive mode 
with fragmentor voltage of 40 eV, column: Nucleosil 100–5, C-18 HD, 5 µm, 70 × 3 mm 
Machery Nagel, eluent: NaCl solution (5 mM)/acetonitrile, gradient: 0/10/15/17/20 min 
with 20/80/80/99/99% acetonitrile, flow: 0.6 mL min–1. High resolution mass (HRMS) are 
reported as follows: (ESI): calculated mass for the related compound followed by found 
mass. 
 
1.4 Infrared Spectroscopy 
 
The FT-IR spectra were recorded on a Fourier Transformed Infrared Spectrometer model 
FT/IR-430 from the company JASCO. Solid samples were pulverized with potassium 
bromide and percent reflection (R%) was measured. The percent transmittance (T%) of 
liquid substances was measured in film between potassium bromide plates. Absorption 
band frequencies are reported in cm–1. 
 
1.5 Polarimetry 
 
Optical rotations were measured on a JASCO Polarimeter P-1020. They are reported as 
follows: [α]temperatureD (concentration, solvent). The unit of c is g/100 mL. Anhydrous 
CH2Cl2 or CHCl3 was used as a solvent. For the measurement the sodium D line = 589 nm 
was used. 
 
1.6 Melting Points 
 
Melting points were determined with a Büchi Melting point B-540 apparatus and were not 
corrected. 
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1.7 Chromatographic Methods 
 
Flash column chromatography was performed using flash silica gel (40–63 µm, 230–400 
mesh ASTM) from Macherey-Nagel. 
Gas chromatography was performed on a CHROMPACK CP 9000 using a flame ioniza-
tion detector, and carrier gas H2. For GC-MS coupled chromatography, a GC-system series 
6890 with an injector series 7683 and MS-detector series 5973 from Hewlett Packard was 
used, with EI method and carrier gas He. Analytical HPLC was performed on a Hewlett 
Packard HP 1100 system. 
Analytical thin layer chromatography (TLC) was performed on silica gel 60 precoated F254 
plates (Merck) or Polygram Sil G/UV254 (Macherey Nagel). The compounds were 
visualized by UV254 light and the chromatography plates were developed with an aqueous 
solution of molybdophosphorous acid or an aqueous solution of potassium permanganate 
by heating with the hot gun. For preparation of the molybdate solution 20 g ammonium 
molybdate [(NH4)6Mo7O24.4H2O] and 0.4 g Ce(SO4)2.4H2O were dissolved in 400 mL of 
10% H2SO4. The potassium permanganate solution was prepared from 2.5 g KMnO4 and 
12.5 g Na2CO3 in 250 mL H2O. 
 
2. Experimental procedures 
 
The experimental procedures are arranged in ascending order of the number of the 
compounds. 
 
2.1 Synthesis of Cryptophycin-3 
 
Cryptophycin-3 (5) 
HN
ON
H
O
OO
O OMe
Cl
O
A
BC
D
 
Trifluoroacetic acid (5 mL) was added slowly at 0 °C to a solution of the protected seco 
compound 127 (80 mg, 0.085 mmol) in CH2Cl2 (2 mL) and the mixture was stirred for 2 h 
at room temperature. The solvent was removed in vacuo and toluene (5 mL) was added. 
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After removal of the solvent, the residue was redissolved in THF (3 mL) and diethylamine 
(3 mL) was added dropwise at 0 °C. The reaction mixture was stirred again 2 h at room 
temperature followed by the removal of the solvents in vacuo. The crude seco acid 173 was 
dissolved in dry DMF (15 mL), then TBTU (30 mg, 0.081 mmol), HOBT (2 mg), DIEA 
(33 µl, 0.19 mmol) were successively added at room temperature. The reaction mixture 
was stirred for 2 h at room temperature, saturated NaHCO3 solution (5 mL) was added and 
stirring continued for 1 hour. The mixture was extracted with CH2Cl2 (15 mL) and the or-
ganic layer dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified by flash chromatography (50% EtOAc in petroleum ether) to give compound 5 (22 
mg, 42% from 127).  
 
Rf = 0.31 (50% EtOAc in petroleum ether); 
[α]D27 = + 24.68 (c = 0.40, CHCl3), {ref.[66]; [α]D22 = + 29.5 (c = 0.20, CHCl3)}; 
IR (neat): νmax = 3430, 3310, 2959, 1727, 1667, 1504, 1250, 1173 cm–1; 
1H NMR (400 MHz, CDCl3): unit A δ = 7.34–7.17 (m, 5H, Ph), 6.65 (ddd, J = 15.2, 9.8, 
5.5 Hz, 1H, CH2CHCH), 6.37 (d, J = 15.9 Hz, 1H, PhCH), 5.97 (dd, J = 15.8, 8.7 Hz, 1H, 
PhCHCH), 5.74 (d, J = 15.4 Hz, 1H, CHCO), 5.08–4.93 (m, 1H, CHOCH2), 2.60–2.45 (m, 
2H, CHMe/CHCH2), 2.41–2.28 (m, 1H, CHCH2), 1.10 (d, J = 6.8 Hz, 3H, Me); unit B δ= 
7.04 (dd, J = 8.3, 1.8 Hz, 1H, Cortho), 6.96–6.91 (m, 1H, C’ortho), 6.80 (d, J = 8.3 Hz, 1H, 
C’meta), 5.66 (d, J = 8.6 Hz, N–H), 4.87–4.72 (m, 1H, NHCH), 3.83 (s, 3H, OMe), 3.10 (dd, 
J = 14.4, 5.3 Hz, 1H, CH2Ph), 3.00 (dd, J = 14.4, 7.0 Hz, 1H, CH2Ph); unit C δ = 7.34–
7.17 (m, N–H), 3.51–3.41 (m, 1H, CH2NH), 3.32–3.22 (m, 1H, CH2NH), 2.71–2.62 (m, 
1H, COCH), 1.19 (d, J = 7.0 Hz, 3H, Me); unit D δ = 4.87–4.72 (m, 1H, COCH), 1.75–
1.49 (m, 2H, CHCH2/CHMe), 1.38–1.26 (m, 1H CHCH2), 0.74 (d, J = 6.3 Hz, 3H, Me ), 
0.69 (d, J = 6.3 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): unit A δ = 165.4 (CO), 141.4 (CH2CHCH), 136.6 (Cquart), 
131.8 (PhCH), 129.7 (PhCHCH), 128.6 (Cortho), 127.5 (Cmeta), 126.1 (Cpara), 125.1 
(CHCO), 76.9 (CHOCH2), 42.2 (CHMe) 36.4 (CHCH2), 17.3 (Me); unit B δ = 170.2 (CO), 
153.9 (Cpara), 131.0 (Cortho), 130.0 (C’ortho), 128.6 (Cquart), 122.3 (C‘meta), 112.1 (Cmeta), 56.1 
(NHCH), 53.5 (OMe), 35.0 (CH2Ph); unit C δ = 175.6 (CO), 41.1 (CH2NH), 38.2 (COCH), 
14.0 (Me); unit D δ = 170.9 (CO), 71.5 (COCH), 39.5 (CHCH2), 24.4 (CHMe), 22.7 (Me), 
21.1 (Me) ppm; 
HRMS (FT-ICR): calcd. for C35H43N2O7Cl [M + Na]+ 661.2651, found 661.2654. 
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tert-Butyl(2E,5S,6R,7E)-5-{[tert-Butyl(dimethyl)silyl]oxy}-6-methyl-8-phenylocta-2,7-
dienoate (12d) 
 
CO2tBu
OTBS  
 
A solution of dimethyl sulfoxide (0.086 mL, 1.2 mmol) in CH2Cl2 (5 mL) was added to a 
stirred solution of oxalyl chloride (0.050 mL, 0.6 mmol) in CH2Cl2 (8 mL) dropwise at       
–78 °C. A solution of alcohol 139 (0.160 g, 0.50 mmol) in CH2Cl2 (5 ml) was added 10 
min later. After being stirred for 30 min at –78 °C, the reaction mixture was treated with 
Et3N (0.346 mL, 2.50 mmol) and allowed to warm to 0 °C. At this point tert-
butyl(triphenyl-phosphoranylidene)acetate (0.546 g, 0.150 mmol) in CH2Cl2 (6 mL) was 
added and the mixture stirred at room temperature overnight. The reaction mixture was 
poured into half-saturated NH4Cl solution (50 mL) and the layers were separated. The 
organic layer was dried with MgSO4, filtered and concentrated in vacuo. Purification of the 
residue by flash chromatography (5% EtOAc in petroleum ether) gave the enoate 12d (180 
mg, 78%) as a colorless oil. 
 
Rf = 0.25 (5% EtOAc in petroleum ether); 
[α]D24 = +50.1 (c = 0.95, CH2Cl2); 
IR (neat): νmax = 3350, 2950, 2856, 1715, 1471, 1366, 1256 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.48–7.11 (m, 5H, Ph), 6.78 (dt, J = 15.0, 7.0 Hz, 1H, 
CH2CHCH), 6.31 (d, J = 15.9 Hz, 1H, PhCH), 6.11 (dd, J = 15.9, 8.0 Hz, 1H, PhCHCH), 
5.69 (d, J = 15.6 Hz, 1H, CHCHCO), 3.72–3.64 (m, 1H, CHCHOCH2), 2.46–2.34 (m, 1H, 
CHCH3), 2.31–2.19 (m, 2H, CHCH2), 1.41 (s, 9H, CMe3), 1.04 (d, J = 6.8 Hz, 3H, Me), 
0.85 (s, 9H, SiCMe3), 0.0 (s, 6H, SiCMe2) ppm; 
13C NMR (100 MHz, CDCl3): δ = 165.7 (CO), 144.8 (CH2CHCH), 137.6 (Cquart), 132.0 
(PhCH), 130.3 (PhCHCH), 128.4 (Cmeta), 127.0 (Cpara), 126.0 (Cortho), 125.0 (CHCHCO), 
80.0 (CMe3), 75.1 (CHCHOCH2), 42.8 (CHCH3), 37.2 (CHCH2), 28.1 (OCMe3), 25.8 
(SiCMe3), 18.0 (SiCMe3), 16.0 (Me), –4.3 (SiMe), –4.4 (SiMe) ppm; 
HRMS (FT-ICR): calcd. for C25H40O3Si [M + Na]+ 439.2639, found 439.2638. 
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tert-Butyl(2E,5S,6R,7E)-5-Hydroxy-6-methyl-8-phenylocta-2,7-dienoate (12b) 
 
CO2tBu
OH  
 
Tetra-n-butylammonium fluoride (1 M in THF, 0.87 mL, 0.87 mmol) was added at 0 °C to 
a solution of enoate 12d (110 mg, 0.26 mmol) in dry THF (4 mL) and the reaction mixture 
was stirred at room temperature for 3 h. The mixture was washed with brine, dried with 
MgSO4, filtered, and concentrated. The residue was purified by flash chromato-graphy 
(first 30% and then 50% EtOAc in petroleum ether) to give the hydroxy ester 12b (55 mg, 
73%) as a colorless oil. 
 
Rf = 0.29 (30% EtOAc in petroleum ether); 
[α]D25 = +40.0 (c = 1.42, CH2Cl2);  
IR (neat): νmax = 3444, 3025, 2976, 2931, 1712, 1652, 1494, 1361 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.70–7.22 (m, 5H, Ph), 6.89–6.81 (m, 1H, CH2CHCH), 
6.41 (d, J = 15.9 Hz, 1H, PhCH), 6.06 (dd, J = 15.9, 8.5 Hz, 1H, PhCHCH), 5.77 (d, J = 
15.6 Hz, 1H, CHCO), 3.61–3.56 (m, 1H, CHOCH2), 2.42–2.22 (m, 3H, CHMe/CHCH2), 
1.41 (s, 9H, C(Me)3), 1.07 (d, J = 6.8 Hz, 6H, (Me)2) ppm; 
13C NMR (100 MHz, CDCl3): δ = 165.7 (CO), 143.9 (CH2CHCH), 137.0 (Cquart), 131.9 
(PhCHCH), 130.9 (PhCHCH), 128.5 (Cortho), 127.4 (Cmeta), 126.1 (Cpara), 125.9 (CHCO), 
80.2 (CMe3), 73.8 (CHOCH2), 43.2 (CHMe), 37.1 (CHCH2), 28.1 (CMe3), 16.7 (Me) ppm; 
RMS (FT-ICR): calcd. for C19H26O3 [M + Na]+ 325.1774, found 325.1775. 
 
3-Chloro-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-O-methyl-D-tyrosine (13c) 
 
Fmoc
HN
O
Fmoc
Cl
OMeHO
O1
2 4'
5'
6
7
8
94
5
7'
8'
9'
O
3
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The tert-butyl ester 161 (300 mg, 0.59 mmol) was dissolved in CH2Cl2 (5 mL) and 
trifluoroacetic acid (5 mL) was added dropwise at 0 °C. After stirring at room temperature 
for 5 h, the reaction mixture was concentrated in vacuo. To the residue was added toluene 
(5 mL) and this mixture was concentrated again. The residue was purified by flash 
chromatography (5% MeOH in CH2Cl2) to yield the Fmoc-protected acid 13c (245 mg, 
93%) as a white solid product. 
 
Rf = 0.25 (5% MeOH in CH2Cl2); 
[α]D25 = –20.71 (c = 0.38, CH2Cl2); 
IR (neat): νmax = 3410, 3316, 3065, 2953, 2930, 1722, 1716, 1606, 1504, 1450, 1280, 
1259, 1065 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.76–7.18 (m, 9H, Fmoc, Cortho), 6.98 (d, J = 8.0 Hz, 1H, 
C’ortho), 6.80 (d, J = 8.0 Hz, 1H, C’meta), 5.27 (d, J = 7.0 Hz, NH), 4.67–4.56 (m, 1H, 
NHCH), 4.47–4.29 (m, 2H, Fmoc), 4.24–4.11 (m, 1H, Fmoc), 3.84 (s, 3H, OMe), 3.16–
2.96 (m, 2H, CH2Ph) ppm; 
13C NMR (100 MHz, CDCl3): δ = 175.0 (CO), 155.7 (CO, Fmoc), 154.1 (Cpara), 143.5 
(4/4’, Fmoc), 141.2 (5/5’, Fmoc), 131.0 (Cortho), 128.6 (C’ortho), 127.7 (Cquart), 127.0 (7/7’, 
Fmoc), 125.3 (8/8’, Fmoc), 125.0 (9/9’, Fmoc), 122.3 (Cmeta), 119.8 (6/6’,Fmoc), 112.1 
(C’meta), 67.0 (2, Fmoc), 56.0 (NHCH), 54.5 (OMe), 47.0 (3, Fmoc), 36.6 (CH2Ph) ppm; 
HRMS (FT-ICR): calcd. for C25H22ClNO5 [M + Na]+ 474.1079, found 474.1077. 
 
(2R)-3-{[(9H-Fluoren-9-ylmethoxy)carbonyl]amino}-2-methylpropanoic acid (14c) 
 
NHFmoc
O
HO
O
O
2 3 4'
5'
6
7
8
9
4 5
6'
7'
8'
9'
 
 
A solution of the ester 166 (500 mg, 1.4 mmol) in acetic acid (50 mL) was treated with 
concentrated HCl (5 mL) followed by heating of the mixture at 100 °C for 15 h. After 
cooling it was poured into water (500 mL) and the colorless precipitate collected by 
filtration. The product was purified by flash chromatography (5% MeOH in CH2Cl2) to 
provide 320 mg (67%) of the acid 14c as a colorless solid substance. 
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Rf = 0.38 (5% MeOH in CH2Cl2 + 2 drops of AcOH); 
[α]D25 = –10.85 (c = 0.27, CH2Cl2); 
IR (neat): νmax = 3344, 2360, 1715, 1520, 1450, 1247 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.71–7.19 (m, 8H, Fmoc), 5.16 (s, br, OH), 4.46–4.14 
(m, 3H, Fmoc), 3.39–3.23 (m, 2H, CH2NH), 2.72–2.69 (m, 1H, COCH), 1.16 (d, J = 7.1 
Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 177.4 (CO), 156.7 (CO, Fmoc), 146.2 (4/4’, Fmoc), 
143.8 (5/5’, Fmoc), 127.6 (7/7’, Fmoc), 127.0 (8/8’, Fmoc), 125.0 (9/9’, Fmoc), 119.9 
(6/6’, Fmoc), 66.7 (2, Fmoc), 47.9 (3, Fmoc), 43.5 (CHCH2NH), 39.7 (COCHCH2), 15.0 
(Me) ppm; 
HRMS (FT-ICR): calcd. for C19H19NO4 [M + Na]+ 348.1206, found 348.1204. 
 
tert-Butyl(2S)-2-Hydroxy-4-methylpentanoate (15c) 
 
OtBuO
OH
 
 
To the solution of Na2CO3 (2.76 g, 26.1 mmol) in methanol (12 mL) and water (20 mL) 
acetate 170 (2 g, 8.7 mmol) was added. The resulting solution was stirred vigorously at 
room temperature for 12 h. Methanol was removed under vacuum, and the resulting 
aqueous solution was extracted with CH2Cl2 twice. The organic layer was then dried over 
anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by 
flash chromatography (15% EtOAc in petroleum ether) to produce 15c (1.30 g, 79%) as a 
pale yellow oil. 
 
Rf = 0.27 (15% EtOAc in petroleum ether); 
[α]D25 = –8.16 (c = 1.47, CH2Cl2); 
1H NMR (400 MHz, CDCl3): δ = 3.96 (q, J = 6.4 Hz, 1H, CHOH), 2.93 (s, 1H, OH), 1.87–
1.75 (m, 1H, CHMe), 1.45–1.35 (m, 11H, CHCH2/C(Me)3), 0.85 (d, J = 6.8 Hz, 6H, Me) 
ppm; 
13C NMR (100 MHz, CDCl3): δ = 175.0 (CO), 81.8 (CMe3), 69.1 (CHOH), 43.4 (CHCH2), 
27.8 (CMe3), 24.3 (CHMe), 23.1 (Me), 21.4 (Me) ppm; 
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(2S)-2-{[(2R)-3-({3-Chloro-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-O-methyl-D-
tyrosyl}amino)-2-methylpropanoyl]oxy}-4-methylpentanoic acid (126) 
 
HN
ON
H
O
OHO
O OMe
Cl
Fmoc
1
6 BC
D
O
O1
2 3 4'
5'
6
7
8
9
4 5
6'
7'
8'
9'
Fmoc  
The tert-butylester 172 (100 mg, 0.14 mmol) was dissolved in CH2Cl2 (5 mL) followed by 
the addition of trifluoroacetic acid (5 mL) at 0 °C. The reaction mixture was stirred for 3 h 
at room temperature. Then toluene (5 mL) was added and the mixture concentrated in 
vacuo. This procedure was repeated twice to give the crude acid which was purified by 
flash chromatography (5% MeOH in CH2Cl2 + 2 drops of AcOH) resulting in acid 126 (82 
mg, 79%) as a white solid product. 
 
Rf = 0.21 (5% MeOH in CH2Cl2 + 2 drops of AcOH); 
[α]D24 = –34.87 (c = 0.44, CH2Cl2); 
IR (neat): νmax = 3416, 3310, 2850, 2051, 1700, 1630, 1502, 1180 cm–1; 
1H NMR (400 MHz, CD3OD): unit B δ = 7.67–6.58 (m, 11H, Ph), 4.24–4.00 (m, 4H, 
NHCH/Fmoc), 3.58 (s, 3H, OMe), 2.72–2.43 (m, 2H, CH2Ph), unit C δ = 3.45–3.30 (m, 
2H, CH2NH), 3.08–2.89 (m, H, COCH), unit D δ = 4.86 (dd, J = 9.8, 4.5, Hz, 1H, COCH), 
1.73–1.52 (m, 2H, CHCH2) 1.25–1.18 (m, 1H, CHMe), 1.04 (d, J = 6.8 Hz, 3H, Me), 0.82 
(d, J = 6.3 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CD3OD): unit B δ = 169.6 (CO), 156.4 (CO, Fmoc), 153.7 (Cpara), 
142.5 (4, Fmoc), 140.7 (5, Fmoc), 131.3 (Cortho), 128.7 (C’ortho), 128.1 (Cquart), 127.9 (7/7, 
Fmoc), 127.5 (8/8’, Fmoc), 126.8 (9/9’, Fmoc), 126.2 (C’meta), 120.0 (6/6’, Fmoc), 114.8 
(Cmeta), 63.1 (2, Fmoc), 57.4 (NHCH), 55.5 (OMe), 44.7 (3, Fmoc), 36.1 (CH2Ph), unit C δ 
= 172.2 (CO), 43.8 (CH2NH), 41.1 (COCH), 21.9 (Me), unit D δ =174.0 (CO), 74.5 
(COCH), 38.2 (CHCH2), 23.7 (CHMe), 16.8 (Me), 15.0 (Me) ppm; 
HRMS (FT-ICR): calcd. for C35H39ClN2O8 [M + Na]+ 674.1350, found 674.1343. 
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tert-Butyl(2E,5S,6R,7E)-5-[((2S)-2-{[(2R)-3-({3-chloro-N-[(9H-fluoren-9-
ylmethoxy)carbonyl]-O-methyl-D-tyrosyl}amino)-2-methylpropanoyl]oxy}-4-
methylpentanoyl)oxy]-6-methyl-8-phenylocta-2,7-dienoate (127) 
 
O
O1
2 3 4'
5'
6
7
8
9
4 5
6'
7'
8'
9'
Fmoc
HN
ON
H
O
OO
O
CO2tBu
Fmoc
6
A
B
C
D
Cl
OMe
 
 
To a solution of the tripeptide derivative amino acid 126 (90 mg, 0.153 mmol) in THF (3 
mL) DIEA (35 µL, 0.201 mmol), 2,4,6-trichlorobenzoyl chloride (27 µL, 0.173 mmol) and 
DMAP (2 mg) were added at room temperature. After 30 min the alcohol 12b (25 mg, 
0.082 mmol), dissolved in THF (1 mL) was added slowly in a dropwise fashion. After 
being stirred for an additional 2 h, saturated aqueous NaHCO3 solution (5 mL) was added. 
The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 × 20 mL). 
The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The residue was purified by flash chromatography (30% EtOAc in petroleum ether) to give 
the seco compound 127 (94 mg, 73%) as a colorless oil. 
 
Rf = 0.23 (30% EtOAc in petroleum ether); 
[α]D24 = 1.19 (c = 0.28, CH2Cl2); 
IR (neat): νmax = 3566, 2925, 2900, 1750, 1730, 1653, 1506, 1456, 1258 cm–1; 
1H NMR (400 MHz, CDCl3): unit A δ = 7.57–7.16 (m, 5H, Ph), 6.82–6.73 (m, 1H, 
CH2CHCH), 6.14 (d, J = 8.6 Hz, 1H, PhCH), 6.00 (dd, J = 15.9, 8.5 Hz, 1H, PhCHCH), 
5.81 (d, J = 15.9 Hz, 1H, CHCO), 5.12–4.88 (m, 1H CHOCH2), 2.82–2.30 (m, 3H, CHMe 
/CHCH2), 1.44 (s, 9H, CMe3), 1.10 (d, J = 7.1 Hz, Me); unit B δ = 7.74 (d, J = 7.3 Hz, 2H, 
Ph-Fmoc), 7.57–7.16 (m, 6H, Ph-Fmoc), 7.11 (dd, J = 8.5, 2.0 Hz, 1H, Cortho), 7.08–7.02 
(m, 1H C’ortho), 6.82–6.73 (m, 1H C’meta), 5.12–4.88 (m, N–H), 4.57–4.29 (m, 1H, NHCH), 
4.21–3.97 (m, 2H, Fmoc), 3.78 (s, 3H, OMe), 3.74–3.61 (m, 1H, Fmoc), 3.01–2.85 (m, 2H, 
CH2Ph); unit C δ = 7.57–7.16 (m, N–H), 3.29–3.06 (m, 2H, CH2NH), 2.82–2.30 (m, 1H, 
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COCH), 1.15 (d, J = 7.1 Hz, 3H, Me); unit D δ = 4.57–4.29 (m, 1H, COCH), 1.80–1.52 
(m, 3H, CH2CH/CHMe), 0.80 (d, J = 6.3 Hz, 3H, Me), 0.74 (d, J = 6.3 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): unit A δ = 164.5 (CO), 143.7 (CH2CHCH), 137.5 (Cquart), 
137.2 (PhCH), 135.6 (PhCHCH), 133.0 (Cortho), 130.7 (Cmeta), 127.6 (Cpara) 126.1 (CHCO), 
80.1 (C(Me)3), 73.7 (CHOCH2), 40.4 (CHMe), 33.6 (CHCH2), 28.0 (CMe3), 16.7 (Me); 
unit B δ = 171.0 (CO), 158.4 (CO, Fmoc), 157.5 (Cpara), 144.0 (4, Fmoc), 141.1 (5, Fmoc), 
131.7 (Cortho), 130.2 (C’ortho), 129.7 (Cquart), 128.3 (7/7’, Fmoc), 127.9 (8/8’, Fmoc), 126.1 
(9/9’, Fmoc), 125.0 (C’meta), 119.8 (6/6’, Fmoc), 113.8 (Cmeta), 60.3 (2, Fmoc), 55.0 
(NHCH), 53.5 (OMe), 52.5 (3, Fmoc), 37.1 (CH2Ph); unit C δ = 173.8 (CO), 47.0 
(CH2NH), 43.1 (2, COCH), 14.1 (Me); unit D δ = 171.8 (CO), 70.6 (COCH), 39.3 
(CH2CH), 24.6 (CHMe), 22.9 (Me), 21.4 (Me) ppm; 
HRMS (FT-ICR): calcd. for C54H63ClN2O10 [M + Na]+ 957.4063, found 957.4061. 
 
tert-Butyl(2S)-2-{[(2R)-3-Amino-2-methylpropanoyl]oxy}-4-methylpentanoate (128) 
 
NH2
O
OtBuO
O
C
D
 
 
A solution of ester 171 (300 mg, 0.60 mmol) in THF (85 mL) was treated with 
diethylamine (5 mL) at 0 °C. The reaction mixture was stirred for 15 min at 0 °C and 12 h 
at room temperature. After evaporation of the solvent in vacuo, the residue was purified by 
flash chromatography (2% MeOH in CH2Cl2) to give the amine 128 (110 mg, 67%) as a 
colorless liquid. The amine 128 was immediately used for the next step. 
 
Rf = 0.19 (2% MeOH in CH2Cl2); 
IR (neat): νmax = 3286, 2959, 2872, 2285, 1738, 1651, 1556, 1369, 1141 cm-1; 
1H NMR (400 MHz, CDCl3): unit C δ = 2.98–2.90 (m, 1H, CH2NH2) 2.82–2.75 (m, 1H, 
CH2NH2), 2.62–2.53 (m, 1H, COCH), 1.18 (d, J = 7.0 Hz, Me); unit D δ = 4.89 (dd, J = 
9.3, 4.5 Hz, 1H, COCH), 1.80–1.69 (m, 2H, CHCH2), 1.66–1.54 (m, 1H, CHMe), 1.43 (s, 
9H, (Me)3), 0.94 (d, J = 6.3 Hz, 3H, Me), 0.90 (d, J = 6.3 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): unit C δ =175.0 (CO), 45.5 (CH2NH2), 39.6 (COCH), 14.6 
(Me); unit D δ = 169.8 (CO), 81.9 (C(Me)3), 71.2 (COCH), 43.4 (CHCH2), 27.9 (C(Me)3),  
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24.7 (CHMe), 23.0 (Me), 21.5 (Me) ppm; 
HRMS (FT-ICR): calcd. for C14H27NO4 [M + H]+ 274.2013, found 274. 2014. 
 
(4R)-4-Benzyl-3-propionyl-1,3-oxazolidin-2-one (129) 
 
O N
OO
Ph
 
 
To a cooled solution of Evans chiral auxiliary 141 (10 g, 56 mmol) in THF (150 mL) at –
78 oC was added dropwise n-BuLi (22.6 mL, 56.5 mmol, 2.5 M in hexane). After 15 min 
propionyl chloride (5.4 mL, 58.9 mmol) was added dropwise at –78 oC. The reaction 
mixture was stirred at the same temperature for 1 h, warmed to room temperature within 5 
h and stirred again at room temperature for 90 min. The reaction mixture was quenched 
with saturated aqueous NH4Cl (50 mL) and diluted with water (50 mL). The layers were 
separated and the organic layer was concentrated at vacuo. The crude product was 
dissolved in 5:1 hexane and EtOAc containing 1% MeOH. This solution was washed with 
saturated aqueous NH4Cl solution (50 mL) and water (50 mL). The organic layer was dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography (30% EtOAc/petroleum ether) yielding N-propionyl-oxazolidinone 129 
(11.7 g, 89%) as a colorless oil. 
 
Rf = 0.42 (50% EtOAc/petroleum ether); 
1H NMR (400 MHz, CDCl3): δ = 7.37–7.24 (m, 5H, Ph), 4.66 (ddd, J = 3.3, 7.1, 13.1 Hz, 
1H, CH2CHNCH2), 4.26–4.13 (m, 2H, CHCH2O), 3.29 (dd, J =13.4, 3.3 Hz, 1H, 
PhCH2CH), 2.03–2.85 (m, 2H, COCH2 Me), 2.79 (dd, J = 13.4, 9.6 Hz, 1H, PhCH2CH), 
1.19 (t, J =7.3 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 174.0 (CO), 153 (CO, oxazolidinone), 135.3 (Cquart), 
129.3 (Cmeta), 128.9 (Cortho), 127.9 (Cpara), 66.1 (CHCH2O), 55.1 (CH2CHCH2), 37.9 
(PhCH2CH ), 29.1 (COCH2 Me), 8.2 (CH2 Me) ppm. 
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3-{[tert-Butyl(dimethyl)silyl]oxy}propanal (130) 
 
H
O OTBS  
 
Sodium hydride (1.92 g, 80 mmol) was added to THF (200 mL) after being washed with 
hexane. The propanediol (6 g, 78 mmol) was added to this mixture at room temperature 
followed by stirring for 45 min, resulting in a large amount of an opaque white precipitate. 
Then, tert-butyldimethylsilyl chloride (11.8 g, 78 mmol) was added and vigorous stirring 
was continued for 45 min. The mixture was poured into ether (1 L), washed with 10% 
aqueous K2CO3 solution (2 x 200 mL) and brine (2 x 200 mL), dried with MgSO4, filtered 
and concentrated in vacuo. The crude residue was purified by flash chromatography to get 
the monoprotected alcohol (13.9 g, 92% yield), which was used for the next step.  
To this solution of monoprotected alcohol (2 g, 10.5 mmol) and dried trimethylamine (13.8 
g, 10.1 mmol) in dried DMSO (20 mL) a solution of pyridine sulfur trioxide complex (5 g, 
31 mmol) in DMSO (15 mL) was added. After 10 min of stirring the mixture was dropped 
in ice and diluted HCl was added to adjust the pH to about 7. The solution was extracted 
with ether (2 x 100 mL) and the organic layer was dried with MgSO4, filtered and 
concentrated in vacuo. The crude residue was purified by flash chromatography (10% 
EtOAc in petroleum ether) and produced the protected aldehyde 130 (1.64 g, 82%) as a 
colorless oil. 
 
IR (neat): νmax = 2954, 1397, 1241 cm–1; 
1H NMR (400 MHz, CDCl3): δ =9.73–9.66 (s, 1H, CHO), 3.93–3.90 (m, 2H, CH2), 2.55–
2.51 (m, 2H, CH2), 0.82 (s, 9H, SiCMe3), 0.01 (s, 6H, SiMe2)ppm; 
13C NMR (100 MHz, CDCl3): δ = 202.7 (CO), 48.0 (CH2), 47.2 (CH2), 26.5 (SiCMe3), 
18.6 (SiCMe3), –4.7 (SiMe2); 
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(4R)-4-Benzyl-3-[(2R,3S)-5-{[(tert-butyl)dimethylsilyl]oxy}-3-hydroxy-2-
methylpentanoyl]-1,3-oxazolidin-2-one (131) 
 
O N
OO OTBSOH
Ph
 
 
Titanium(IV) chloride (0.49 mL, 4.50 mmol) was added dropwise to a cooled (0 °C) 
solution of the oxazolidinone 129 (1.0 g, 4.29 mmol) in CH2Cl2 (50 mL). The mixture was 
stirred for 5 min. Subsequently (–)-sparteine (2.51 g, 10.72 mmol) was added to the yellow 
slurry. The dark red enolate solution was stirred at 0 °C for 20 min, after which aldehyde 
130 (0.89 gm, 4.72 mmol) dissolved in CH2Cl2 (10 mL) was added dropwise. The reaction 
mixture was stirred at 0 °C for 1 h and then quenched with half-saturated NH4Cl (10 mL). 
After separation of the layers the organic layer was dried (Na2SO4), filtered and 
concentrated in vacuo. Purification of the residue by flash chomatography (20% EtOAc in 
petroleum ether) afforded 131 (1.58 g, 87%) as a colorless oil. 
 
Rf = 0.26 (15% EtOAc in petroleum ether); 
[α]D24 = –42.0 (c = 0.98, CHCl3); 
IR (neat): νmax = 3504, 2954, 2857, 1782, 1737, 1697, 1241 cm–1;  
1H NMR (400 MHz, CDCl3): δ = 7.30–7.05 (m, 5H, Ph), 4.65–4.55 (m, 1H, 
oxazolidinoneCH), 4.17–4.01 (m, 3H, oxazolidinoneCH2/CHCHOCH2), 3.82–3.66 (m, 3H, 
COCHMe /CH2CH2O), 3.51 (d, J = 1.8 Hz, OH), 3.18 (dd, J = 8.3, 13.1 Hz, 1H, PhCH2), 
2.70 (dd, J = 9.4, 13.4 Hz, 1H, PhCH2), 1.75–1.51 (m, 2H, CHCH2), 1.21 (d, J =7.1 Hz, 
Me), 0.82 (s, 9H, SiCMe3), 0.17 (s, 6H, SiMe2) ppm; 
13C NMR (100 MHz, CDCl3): δ = 176.3 (CO), 153.1 (CO, oxazolidinone), 135.1 (Cquart), 
129.4 (Cmeta), 128.9 (Cortho), 127.3 (Cpara), 71.2 (CHCHOCH2), 66.0 (oxazolidinoneCH), 
61.9 (CH2CH2O), 55.3 (oxazolidinoneCH2), 42.8 (COCHMe), 37.7 (PhCH2CH), 35.8 (2H, 
CHCH2), 25.8 (SiCMe3), 18.1 (SiCMe3), 11.2 (Me), –5.6 (Si(Me)2) ppm. 
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(4R)-4-Benzyl-3-[(2R,3S)-3,5-bis{[(tert-butyl)dimethylsilyl]oxy}-2-methylpentanoyl]-
1,3-oxazolidin-2-one (132) 
 
O N
OO
Ph
OTBS
OTBS  
 
tert-Butyldimethylsilyltriflate (0.47 g, 2.0 mmol) was added to a solution of compound 131 
(0.60 g, 1.4 mmol) and lutidine (0.46 g, 3.9 mmol) in CH2Cl2 (10 mL) and the solution was 
stirred overnight. Water (5 mL) was added, the mixture stirred for 20 min and the organic 
layer separated. The organic layer was washed with saturated NaHCO3 solution and brine, 
dried (Na2SO4), filtered and concentrated in vacuo. Purification of the residue by flash 
chromatography (10% EtOAc in petroleum ether) afforded 0.70g (92%) of 132 as a 
colourless gummy product. 
 
Rf = 0.21 (10% EtOAc in petroleum ether); 
[α]D24 = –56.5 (c = 0.98, CHCl3); 
IR (neat): νmax = 2954, 2857, 1784, 1703, 1383, 1252, 1209 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.36–7.15 (m, 5H, Ph), 4.63–4.55 (m, 1H, 
oxazolidinoneCH), 4.19–4.06 (m, 3H, oxazolidinoneCH2/CHOH), 3.93–3.84 (m, 1H, 
CHMe), 3.75–3.61 (m, 2H, CH2CH2O), 3.28 (dd, J = 3.0, 13.4 Hz, 1H, PHCH2), 2.72 (dd, 
J = 9.6, 13.4 Hz, 1H, PHCH2), 1.85–1.74 (m, 1H, CHCH2CH2), 1.21 (d, J = 6.8 Hz, 3H, 
Me), 0.87 (s, 18H, 2SiCMe3), 0.17 (s, 12H, SiMe2) ppm; 
13C NMR (100 MHz, CDCl3): δ = 175.1 (CO), 152.9 (CO, oxazolidinone), 135.3 (Cquart), 
129.4 (Cmeta), 128.9 (Cortho), 127.3 (Cpara), 70.4 (CHOH), 65.9 (oxazolidinoneCH2), 59.4 
(CH2CH2O), 55.7 (oxazolidinoneCH), 43.1 (CHMe), 38.2 (PHCH2), 37.6 (CHCH2CH2), 
25.9 (SiCMe3), 18.1 (SiCMe3), 12.3 (Me), –4.8 (SiMe2) ppm. 
 
(2S,3S)-3,5-Bis{[tert-Butyl(dimethyl)silyl]oxy}-2-methylpentan-1-ol (133) 
 
HO OTBS
OTBS  
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A solution of 2M LiBH4 in THF (0.63 mL, 1.26 mmol) was added dropwise to a solution 
of aldol product 132 (450 mg, 0.8 mmol) in Et2O (8 mL) and H2O (25 µL) at 0 °C. The 
reaction mixture was stirred for 1 h at 0 °C and then 2 h at room temperature. Then the 
reaction was quenched by addition of saturated NH4Cl (5 mL) and the mixture was stirred 
for 1 hr. After that the organic layer was separated and the aqueous layer extracted with 
CH2Cl2 (2 x 20 mL). The combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography (with 10% 
EtOAc in petroleum ether) to get pure alcohol 133 (230 mg, 75%) as a colorless oil. 
 
Rf = 18.0 (10% EtOAc in petroleum ether); 
[α]D25 = –19.0 (c = 0.72, CHCl3); 
IR (neat): νmax = 3394, 2955, 2930, 2858, 1470, 1254, 1065 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 3.95–3.88 (m, 1H, CH2OH), 3.72–3.56 (m, 3H, CH2OH/ 
CH2OTBS), 3.52 (dd, J = 10.9, 5.1 Hz, 1H, CHOTBS), 2.87 (s, br, 1H, OH), 2.02–1.91 (m, 
1H, CHMe), 1.68 (q, J = 6.3 Hz, 2H, CH2CH2), 0.86 (s, 18H, SiCMe3), 0.78 (d, J = 7.1 Hz, 
3H, Me), 0.08 (s, 3H, SiMe), 0.06 (s, 3H, SiMe), 0.02 (s, 6H, SiMe3) ppm; 
13C NMR (100 MHz, CDCl3): δ = 72.6 (CHOTBS), 65.8 (CH2OH) 59.7 (CH2OTBS) 39.7 
(CHCH3), 35.0 (CH2CH2), 25.8 (SiCMe3), 18.1 (SiCMe3), 17.9 (SiCMe3), 12.4 (CH3), –4.4 
(SiMe), –4.7 (SiMe), –5.7 (SiMe2) ppm; 
HRMS (FT-ICR): calcd. for C18H42O3Si2Na [M + Na]+ 385.2564, found 385.2558. 
 
(2S,3S)-3,5-Bis{[tert-butyl(dimethyl)silyl]oxy}-2-methylpentyl-4-
methylbenzenesulfonate (134) 
 
TsO OTBS
OTBS  
 
p-Toluenesulfonyl chloride (420 mg, 2.20 mmol) was added at 0 °C to a stirred solution of 
alcohol 133 (400 mg, 1.10 mmol) in pyridine (3 mL). After being stirred for 2 hr, the reac-
tion mixture was quenched by addition of water (10 mL), diluted with Et2O (50 mL) and 
washed with 1 N HCl, saturated NaHCO3 solution and brine. The organic layer was dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography (with 5% EtOAc in petroleum ether) to give pure tosylate 134 (543 mg, 
95%) as a slightly yellow oil. 
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Rf = 0.33 (10% EtOAc in petroleum ether); 
[α]D25 = –15.7 (c = 1.28, CHCl3); 
IR (neat): νmax = 3394, 2955, 2930, 2858, 1470, 1254, 1065 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.76 (d, J = 8.3 Hz, 2H, Ph), 7.31 (d, J = 7.8 Hz, 2H, 
Ph), 4.02 (dd, J = 9.1, 5.8 Hz, 1H, CHOTBS), 3.86–3.75 (m, 2H, CH2OTBS), 3.60–3.45 
(m, 2H, CH2OTs), 2.42 (s, 3H, Me), 1.97–1.83 (m, 1H, CH2CH2), 1.65–1.53 (m, 1H, 
CH2CH2), 1.50–1.41 (m, H, CHMe), 0.85 (s, 9H, SiCMe3), 0.77 (s, 9H, SiCMe3), 0.00 (s, 
6H, SiMe2), 0.01 (s, 3H, Me), –0.07 (s, 6H, SiMe2) ppm; 
13C NMR (100 MHz, CDCl3): δ = 144.5 (Ph), 133.0 (Ph), 129.0 (Ph), 127.9 (Ph), 72.6 
(CHOTBS), 69.1 (CH2OTs), 59.5 (CH2OTBS) 37.9 (CHCH3), 36.3 (CH2CH2), 25.8 
(SiCMe3), 25.7 (SiCMe3), 21.5 (Me), 18.1 (SiCMe3), 17.9 (SiCMe3), 11.1 (CH3), –4.5 
(SiMe), –4.8 (SiMe), –5.7 (SiMe2) ppm; 
HRMS (FT-ICR): calcd. for C25H48O5SSi2Na [M + Na]+ 539.2653, found 539.2662. 
 
(3S)-3,5-Bis{[tert-butyl(dimethyl)silyl]oxy}-2-methylpent-1-ene (135) 
 
OTBS
OTBS  
 
A mixture of tosylate 134 (400 mg, 0.81 mmol), NaI (365 mg, 2.44 mmol), DBU (371 mg, 
2.44 mmol) in glyme (10 mL) was heated at reflux with stirring for 3 h. After the reaction 
mixture had cooled to room temperature, Et2O (50 mL) and H2O (50 mL) were added and 
the layers were separated. The combined organic layers were washed with saturated 
NaHCO3 solution (30 mL), 1 N HCl (30 mL) and brine (50 mL). Then it was dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography (with 5% EtOAc in petroleum ether) to give pure alkene 135 (266 mg, 
95% yield) as a slightly yellow oil. 
 
Rf = 0.31 (5% EtOAc in petroleum ether); 
[α]D25 = –14.0 (c = 0.88, CHCl3); 
IR (neat): νmax = 2954, 2930, 2857, 1471, 1254, 1092 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 4.85 (s, 1H, CH2=CMe), 4.75 (s, 1H, CH2=CMe), 4.20 
(dd, J = 7.3, 5.3 Hz, 1H, CHOTBS), 3.68–3.55 (m, 2H, CH2OTBS), 1.57–1.17 (m, 5H, 
CH2CH2/CMe), 0.88 (s, 18H, 2SiCMe3), 0.03 (s, 12H, 2SiMe2) ppm; 
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13C NMR (100 MHz, CDCl3): δ = 147.7 (CH2=CMe), 110.4 (CH2=CMe), 73.3 
(CHOTBS), 59.7 (CH2OTBS), 39.5 (CH2CH2), 25.8 (SiCMe3), 18.2 (SiCMe3), 17.0 
(SiCMe3), –4.8 (Me), –5.2 (SiMe2), –5.3 (SiMe2) ppm. 
 
(2R,3S)-3,5-Bis-{[tert-butyl(dimethyl)silyl]oxy}-2-methylpentan-1-ol (136) 
 
HO OTBS
OTBS  
 
A solution of 9-BBN in THF (0.5 M, 4.3 mL, 2.17 mmol) was added dropwise at 0 °C to a 
solution of alkene 135 (250 mg, 0.72 mmol) in THF (2 mL). After that the reaction mixture 
was stirred at ambient temperature for 3 h and was treated with EtOH (1.35 mL), aqueous 
NaOH (3 N, 0.9 mL) and 30% aqueous H2O2 (0.9 mL) and stirred at rt for additional 2 h. 
The mixture was saturated with solid K2CO3 and extracted with Et2O (20 mL). The 
combined organic layers were washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography (with 10% 
EtOAc in petroleum ether) and resulted in pure alcohol 136 (218 mg, 83% yield) as a 
colorless oil. 
 
Rf = 0.24 (5% EtOAc in petroleum ether); 
[α]D25 = –4.0 (c = 0.89, CHCl3); 
IR (neat): νmax = 3394, 2955, 2930, 2858, 1470, 1254, 1065 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 3.86 (dd, J = 10.9, 6.1 Hz, 1H, CH2OH), 3.73 (dd, J = 
10.9, 4.3 Hz, 1H, CH2OH), 3.62 (t, J = 6.6 Hz, 2H, CH2OTBS), 3.49 (dd, J = 10.9, 5.3 Hz, 
1H, CHOTBS), 2.68 (s, br, 1H, OH), 1.90–1.79 (m, 0.5H, CHMe), 1.78–1.69 (m, 2H, 
CH2CH2), 1.56–1.45 (m, 0.5H, CHMe), 0.98 (d, J = 7.1 Hz, 3H, CH3), 0.86 (s, 9H, 
SiCMe3), 0.85 (s, 9H, SiCMe3), 0.05 (s, 6H, SiMe2), 0.00 (s, 6H, SiMe2) ppm; 
13C NMR (100 MHz, CDCl3): δ = 74.1 (CHOTBS), 65.1 (CH2OH), 59.6 (CH2OTBS) 38.5 
(CHCH3), 37.5 (CH2CH2), 25.8 (SiCMe3), 18.2 (SiCMe3), 17.9 (SiCMe3), 14.3 (CH3), –4.4 
(SiMe2), –5.3 (SiMe2) ppm; 
HRMS (FT-ICR): calcd. for C18H42O3Si2Na [M + Na]+ 385.25647, found 385.25613. 
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(2R,3S)-3,5-Bis-{[tert-butyl(dimethyl)silyl]oxy}-2-methylpentananal(137) 
 
O OTBS
OTBS  
 
Dimethyl sulfoxide (0.22 mL, 3.12 mmol) dissolved in CH2Cl2 (5 mL) was added dropwise 
at –78 °C to a solution of oxalyl chloride (0.139 mL, 1.6 mmol)  in CH2Cl2 (10 mL). After 
5 min, alcohol 136 (0.5 g, 1.3 mmol) in CH2Cl2 (10 mL) was added dropwise to the 
reaction mixture, and stirring was continued at –78° C for 1 h. Triethylamine (0.91 mL, 6.5 
mmol) was then added dropwise, and the reaction mixture was warmed to room 
temperature over 3 h. For the workup the mixture was treated with water (15 mL) and the 
layers were separated. The aquous layer was extracted with CH2Cl2 (2 x 15 mL). The 
combined organic layers were washed with brine (30 mL), dried with MgSO4, filtered and 
concentrated in vacuo to give crude aldehyde 137, which was used for the next step 
without further purification. 
 
[(1E,3R,4S)-4,6-Di-{[tert-butyl(dimethyl)silyl]oxy}-3-methylhex-1-enyl]benzene (138) 
 
OTBS
OTBS
 
 
A solution of diethyl benzylphosphonate (0.77 mL, 3.71 mmol) in THF (15 mL) was 
treated at –78 °C with n-BuLi (2.5 M in hexane, 0.83 mL, 2.07 mmol). Stirring was 
continued at –78 °C for 1 h before a solution of aldehyde 137 (from the previous step), 
dissolved in THF (7 mL) was added dropwise. After being stirred at –78 °C for 1 h, the 
reaction mixture was allowed to warm gradually to room temperature within 6 h. Aqueous 
NH4Cl solution (25 mL) was added and the mixture extracted with Et2O (3 × 40 mL). The 
combined organic layers were washed with water (30 mL) and brine (30 mL), dried over 
MgSO4, filtered and concentrated. The residue was purified by flash chromato-graphy (5% 
EtOAc in petroleum ether) to give the styrene 138 (345 mg, 58%, 2 steps) as a colorless 
oil. 
 
Rf = 0.55 (5% EtOAc in petroleum ether); 
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[α]D25 = +17.8 (c = 1.00, CH2Cl2); 
IR (neat): νmax = 2955, 2928, 1471, 1463, 1256, 1067 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.39–7.10 (m, 5H, Ph), 6.37 (d, J = 15.9 Hz, 1H, 
PHCH), 6.18 (dd, J = 15.6, 7.8 Hz, 1H, PhCHCH), 3.88–3.79 (m, 1H, CHCHOCH2), 3.74–
3.59 (m, 2H, CH2OH), 2.54–2.43 (m, 1H, CHCH3), 1.65 (q, J = 6.5 Hz, 2H, CH2CH2OH), 
1.11 (d, J = 7.0 Hz, 3H, CH3), 0.95 (s, 9H, SiCMe3), 0.85 (s, 9H, SiCMe3), 0.11 (s,6H, 
SiMe2), 0.00 (s, 6H, SiMe2) ppm; 
13C NMR (100 MHz, CDCl3): δ = 137.8 (Cquart), 132.8 (PhCHCH), 129.7 (PHCH), 128.4 
(Cmeta), 126.8 (Cpara), 126.0 (Cortho), 72.6 (CHCHOCH2), 60.1 (CH2OH), 42.7 (CHCH3), 
36.7 (CH2CH2OH), 25.9 (SiCMe3), 18.1 (SiCMe3), 15.5 (CH3), –4.5 (SiMe2), –5.3 (SiMe2) 
ppm; 
HRMS (FT-ICR): calcd. for C25H46O2Si2 [M + Na]+ 457.7920, found 457.7925. 
 
(3S,4R,5E)-3-{[tert-Butyl(dimethyl)silyl]oxy}-4-methyl-6-phenylhex-5-en-1-ol (139) 
 
OHTBSO  
 
A solution of disilyl ether 138 (0.36 g, 0.85 mmol) and pyridinium para-toluenesulfonate 
(70 mg, 0.27 mmol) in MeOH (20 mL) was stirred for 4 h at 50 °C. Thereafter most of the 
MeOH was removed under reduced pressure and the mixture partitioned between water 
and Et2O. The aqueous layer was extracted with Et2O and the combined organic layers 
were washed with saturated NaHCO3 solution and brine, dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash chromatography (15% EtOAc in 
petroleum ether) to give the primary alcohol 139 (225 mg, 85%) as a colorless oil.  
 
Rf = 0.25 (15% EtOAc in petroleum ether); 
[α]D25 = +44.4 (c = 0.75, CH2Cl2); 
IR (neat): νmax = 3352, 2955, 2930, 1465, 1378, 1255, 1093 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.26–7.06 (m, 5H, Ph), 6.27 (d, J = 16.1 Hz, 1H, 
PHCH), 6.02 (dd, J = 15.9, 7.5 Hz, 1H, PhCHCH), 3.81–3.73 (m, 1H, CHOCH2), 3.68–
3.57 (m, 2H, CH2OH), 2.50–2.37 (m, 1H, CHMe), 1.84 (s, br, OH), 1.61 (q, J = 5.8 Hz, 
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2H, CH2CH2OH), 0.99 (d, J = 6.8 Hz, 3H, Me), 0.80 (s, 9H, Si–CMe3), 0.00 (2 s, 6H, 
SiMe2) ppm; 
13C NMR (100 MHz, CDCl3): δ = 137.5 (Cquart), 132.5 (PhCHCH), 130.0 (PHCH). 128.4 
(Cmeta), 127.0 (Cpara), 125.9 (Cortho), 74.5 (CHCHOCH2), 60.4 (CH2OH), 42.6 (CHCH3), 
34.9 (CH2CH2OH), 25.8 (SiCMe3), 18.0 (SiCMe3), 14.7 (Me), –4.3 (SiMe), –4.5 (SiMe) 
ppm; 
HRMS (FT-ICR): calcd. for C19H32O2Si [M + Na]+ 343.5310, found 343.5314. 
 
(R)-Phenylalanol (140) 
NH2
OH  
 
D-Phenyl alanine (20 g, 121.0 mmol) was dissolved in absolute THF (60 mL) followed by 
the dropwise dropwise addition of boron trifluoride etherate (15.7 mL). After complete 
addition, the reaction mixture was heated at reflux for 2 h and the resulting solution 
became colorless and homogeneous. Thereafter to the vigorously refluxed reaction mixture 
borone-dimethyl sulfide complex (12.4 mL, 131.6 mmol) was added carefully and 
dropwise over a 30 min period. During the course of addition there was continuous 
evolution of dimethyl sulfide and hydrogen, and the solution turned from orange to light 
brown. The reaction mixture was stirred for additional 6 h under reflux condition and then 
allowed to cool to ambient temperature. The excess borane was quenched by the slow 
addition of a 1:1 mixture of THF and water (20 mL), followed by the addition of 5M 
aqueous solution of sodium hydroxide (90 ml). The resulting two-phase mixture was 
heated to reflux for additional 12 h, cooled to room temperature and filtered through a 
glass funnel. The residual solid product was washed with small portions of THF and the 
filtrate was concentrated under reduced pressure to remove the bulk of the THF. The 
resulting slurry was then extracted with CH2Cl2 and the combined organic layers were 
dried over anhydrous MgSO4, filtered and concentrated in vacuo. The solid residue was 
crystallized from boiling EtOAc to give aminoalcohol 140 (16.5 g, 90%) as white needles 
(m.p.: 91–92 °C, in literature: 88–91 °C[134]). 
 
1H NMR (400 MHz, CDCl3): δ = 7.33–7.16 (m, 5H, Ph), 3.63 (dd, J = 10.8, 7.2 Hz, 1H, 
CHCH2OH), 3.37 (dd, J = 10.8, 7.2 Hz, 1H, CHCH2OH), 3.05–3.15 (m, 1H, 
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CH2CHNCH2), 2.78 (dd, J = 13.4, 5.2 Hz, 1H, PhCH2CH), 2.46 (dd, J = 13.3, 5.2 Hz, 1H, 
PhCH2CH), 2.47-2.56 (m, 3H, NH2, OH, ) ppm; 
13C NMR (100 MHz, CDCl3): δ = 138.6 (Cquart), 129.1 (Ph), 128.5 (Ph), 126.4 (Ph), 66.2 
(CHCH2OH), 54.1 (CH2CHCH2), 40.8 (PhCH2CH) ppm. 
 
(4R)-4-Benzyl-1,3-oxazolidin-2-one (141) 
 
O
HN
O
 
 
A mixture of (R)-phenylalanol 140 (15.0 g, 92 mmol), anhydrous K2CO3 (1.37 g, 99.2 
mmol) and diethyl carbonate (25 mL, 203.6 mmol) was placed into a round bottom flask 
and lowered into a preheated (150 °C) oil bath with distillation flask. The distillation 
receiver was cooled in an ice bath and the ethanol (ca. 2 mL) was collected. After the 
distillation, the reaction mixture was allowed to cool to room temperature, diluted with 
CH2Cl2 (400 mL) and washed with water (100 mL). The resulting organic phase was dried 
over anhydrous MgSO4, filtered and concentrated. The white solid product was crystallized 
with EtOAc and hexane to produce oxazolidinone 129 (16 g, 91%) as white crystals (m.p.: 
87–88.3 °C, in literature: 84.5–86.5 °C[134]). 
 
1H NMR (400 MHz, CDCl3): δ = 7.37–7.09 (m, 5H, Ph), 5.51 (br, s, NH), 4.35–4.45 (m, 
1H, CH2CHNCH2), 4.02–4.16 (m, 2H, CHCH2O), 2.85 (d, J =6.8 Hz, 2H, PhCH2CH) ppm; 
13C NMR (100 MHz, CDCl3): δ = 159.2 (CO), 135.9 (Cquart), 128.9 (Ph), 128.8 (Ph), 127.2 
(Ph), 69.6 (CHCH2O), 53.7 (CH2CHCH2), 41.4 (PhCH2CH) ppm. 
 
2,7-Bis-[O(9)-allylhydrocinchonidinium-N-methyl]naphthalene-dibromide (147) 
 
N
O
N
N
O
N
H
H
H
H
2 Br-
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To a suspension of dimer 153 (1.8 g, 1.99 mmol) in CH2Cl2 (10 mL) allyl bromide (1.03 
mL, 11.9 mmol) and 50% aqueous KOH (2.23 mL, 19.9 mmol) were added. The resulting 
mixture was stirred vigorously at room temperature for 4 h, in which all solid products 
were dissolved. The mixture was diluted with water (20 mL) and extracted with 
dichloromethane (2 x 50 mL). The combined organic extracts were dried over MgSO4, 
filtered and concentrated in vacuo. The crude solid product was recrystallized from 
dichloromethane-ether to afford 2.95 g (95% yield) of desired product 147 as a light 
yellow solid product. 
 
1H NMR (400 MHz, CD3OD): δ = 8.92 (d, J = 4.5 Hz, 2H), 8.52 (s, 2H), 8.32 (d, J = 8.3 
Hz, 2H), 8.12 (d, J = 8.3 Hz, 2H), 8.05 (d, J = 8.3 Hz, 2H), 7.96 (d, J = 4.5 Hz, 2H), 7.91 
(d, J = 8.3 Hz, 2H), 7.81–7.69 (m, 4H), 6.64 (s, 2H), 5.33 (d, J = 12.3 Hz, 2H), 5.18 (d, J = 
12.1 Hz, 2H), 4.83–4.51 (m, 2H), 4.34–4.21 (m, 2H), 4.06 (d, J = 9.6 Hz, 2H), 3.68 (s, 
2H), 3.28 (d, J = 15.4 Hz, 2H), 3.07 (d, J = 9.8 Hz, 2H), 2.94 (m, 2H), 2.80 (m, 2H), 2.40 
(m, 2H), 1.90 (m, 2H), 1.80–1.72 (m, 4H), 1.62–1.57 (m, 2H), 1.33–1.0 (m, 6H), 0.88 (t, J 
= 7.2Hz, 6H) ppm; 
13C NMR (100 MHz, CD3OD): δ = 150.1, 148.6, 147.4, 136.1, 135.6, 134.2, 132.7, 131.1, 
130.2, 129.9, 129.2, 127.5, 126.1, 124.5, 121.3, 69.2, 66.9, 64.3, 58.1, 49.6, 49.4, 49.2, 
49.0, 48.7, 48.5, 48.6, 36.9, 25.9, 25.3, 22.1, 11.6 ppm; 
 
tert-Butyl-N-(diphenylmethylene)glycinate (148) 
 
Ph Ph
N
O
OtBu  
 
A solution of tert-butyl-2-bromo acetate (7.0 g, 35.9 mmol) in acetonitrile (40 mL) was 
treated with benzophenonimine 155 (6.5 g, 35.8 mmol) and diisopropylethylamine (6.2 
mL, 4.6 g, 35.6 mmol) followed by refluxing of the mixture for 12 h. After cooling to room 
temperature most of the acetonitrile was removed in vacuo. The remainder was partitioned 
between water (40 mL) and diethyl ether (60 mL) and the phases were separated. The 
organic layer was dried with MgSO4, filtered and concentrated in vacuo until the mixture 
became turbid. Cooling in an icebath provided a first fraction of 4.1 g. Concentration of all 
the filtrates resulted in another crop; total yield 10.2 g of 148 (96% yield), as a slightly 
yellow solid product. 
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1H NMR (400 MHz, CDCl3): δ = 7.71–7.20 (m, 10H, Ph), 4.17 (s, 2H, NCH2), 1.44 (s, 9H, 
CMe3) ppm; 
13C NMR (100 MHz, CDCl3): δ = 171.3 (CO), 169.6 (C=N), 139.2 (Ph), 136.0 (Ph), 132.2 
(Ph), 130.2 (Ph), 129.9 (Ph), 128.6 (Ph), 128.4 (Ph), 128.3 (Ph), 128.1 (Ph), 127.9 (Ph), 
127.5 (Ph), 80.8 (CMe3), 56.2 (NCH2), 27.9 (CMe3) ppm; 
 
4-(Bromomethyl)-2-chloro-1-methoxybenzene (149) 
 
MeO
Cl
Br
 
 
A mixture of 2-chloro-1-methoxy-4-methylbenzene 157 (4.0 g, 25.5 mmol), NBS (5.0 g, 
28.1 mmol) and AIBN (190 mg, 1.15 mmol) in dry CCl4 (160 mL) was refluxed overnight. 
After being cooled to room temperature the mixture was washed with NaOH solution (1.5 
N, 75 mL) and water (75 mL). The organic layer was dried over MgSO4, filtered and con-
centrated in vacuo. The residue was purified by flash chromatography (3:1 petroleum ether 
and diethyl ether) to provide the benzyl bromide 149 (4.1 g, 68% yield) as a colorless oil. 
 
Rf = 0.52; 
IR (neat): νmax = 2946, 1698, 1603, 1503, 1261, 1065 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.40 (d, J = 2.0 Hz, 1H, Ph), 7.22 (dd, J = 8.4, 2.1 Hz, 
1H, Ph), 6.85 (d, J = 8.5 Hz, 1H, Ph), 4.43 (s, 2H, CH2Br), 3.86 (s, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 154.7(Cpara), 130.6 (Cortho), 128.4 (C’ortho), 125.6 (Cquart), 
122.2 (C’meta), 112.5 (Cmeta), 56.6 (OMe), 32.5 (Me) ppm; 
HRMS (FT-ICR): calcd. for C8H8BrClO [M + Na]+ 258.5050, found 258.5034. 
 
(+)-Hydrocinchonidine (151) 
 
N
OH
N H
H
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A mixture of (+)-cinchonidine 150 (5.0 g, 16.98 mmol) and 10% Pd/C (1 g) in methanol 
(130 mL) was stirred under hydrogen atmosphere at room temperature for 10 h. The 
reaction mixture was filtered through a pad of Celite and the filtrate was concentrated in 
vacuo. The residue was suspended in hexane (200 mL) and stirred at room temperature for 
1 h and then filtered. The solid products were collected to afford 4.6 g 151 (92% yield) of 
the desired product as a white solid product. 
 
1H NMR (400 MHz, CDCl3): δ = 8.73 (d, J = 4.5 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.81 
(d, J = 8.0 Hz, 1H), 7.50 (m, 2H), 7.2 (t, J =7.2 Hz, 1H), 5.56 (d, J = 3.9, 1H), 3.53–3.30 
(m, 1H), 2.94 (m, 2H), 2.76–2.69 (m, 2H), 1.84–1.79 (m, 3H), 1.37–1.28 (m, 3H), 1.13–
0.99 (m, 2H), 0.72 (t, J = 6.9Hz, 6H) ppm; 
13C NMR (100 MHz, CDCl3): δ = 150.1, 148.1, 130.3, 128.9, 126.6, 125.5, 122.9, 118.3, 
60.1, 51.0, 50.8, 50.07, 37.9, 26.0. 24.9, 11.9 ppm. 
 
2,7-Bis(bromomethyl)naphthalene (152) 
 
BrBr
 
 
A mixture of 2,7-dimethylnaphthalene (2.0 g, 12.80 mmol), N-bromosuccinimide (5.0 g, 
28.16 mmol) and 2,2’-azobisisobutyronitrile (190 mg, 1.15 mmol) in CCl4 (160 mL) was 
stirred at reflux for 10 min after which the mixture was cooled to 0 °C. The precipitated 
succinimide was filtered off and the filtrate evaporated under reduced pressure. The 
residue was recrystallized from chloroform to give 3.5 g (88% yield) of the desired product 
152 as a white solid product. 
 
1H NMR (400 MHz, CDCl3): δ = 7.82–7.75 (m, 4H, Ph), 7.50 (dd, J = 8.3, 1.5 Hz, 2H, 
Ph), 4.64 (s, 4H, CH2Br) ppm; 
13C NMR (100 MHz, CDCl3): δ = 135.8, 132.9, 132.6, 129.5, 127.8, 127.4, 33.6 ppm. 
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2,7-Bis(hydrocinchonidinium-N-methyl)naphthalene-dibromide (153) 
 
N
OH
N
N
HO
H
H
H
H
2 Br-
N  
 
A mixture of (+)-hydrocinconidine 151 (2.0 g, 6.75 mmol) with 2,7-bis(bromomethyl)-
naphthalene (152) (1.04 g, 3.31 mmol) in a mixture of ethanol (5mL), DMF (6 mL) and 
chloroform (2 mL) was stirred at 100 °C for 6 h. After cooling the reaction mixture to 
room temperature, the resulting suspension was diluted with methanol (20 mL) and ether 
(60 mL) and stirred for 1 h. The solid product was filtered and washed with ether. The 
crude product 153 (2.5 g, 83%) was used for the next step without further purification. 
 
1,1-Diphenylmethanimine (155) 
 
NH
 
 
An aqueous solution of 1 mol% of NiSO4 (13.6 mL, 0.54 mmol) was added to a stirring 
mixture of benzhydrylamine 154 (20 g, 109 mmol) in 250 mL CH2Cl2 and an aqueous 
solution of (1.5 L ) of K2S2O8 / NaOH (74.2 g, 0.28 mol / 22 g, 0.80 mol). The resulted 
mixture was stirred vigorously at room temperature for 6 h. Then the mixture was passed 
through a short Celite column to remove the black precipitates of nickel peroxide. The 
filtrate was extracted with CH2Cl2 (2 x 200 mL). The combined organic extracts were dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography to give pure imine 155 (18.5 g, 93%). 
 
1H NMR (400 MHz, CDCl3): δ = 9.54 (s, NH), 7.79 (d, J = 7.0 Hz, 2H, Cortho), 7.56 (d, J = 
7.0 Hz, 2H, C’ortho), 7.56–7.37 (m, 6H, Ph) ppm; 
13C NMR (100 MHz, CDCl3): δ = 178.0 (CN), 139.1 (Cquart), 132.1 (Cortho), 130.0 (C’ortho), 
129.8 (Cortho), 128.2 (Cmeta), 128.1 (C’meta) ppm. 
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2-Chloro-1-methoxy-4-methylbenzene (157) 
 
OMe
Cl
 
 
A suspension of 2-chloro-4-methylphenol 156 (5.0 g, 35 mmol) in 2.5 N NaOH (15 mL) 
was cooled to 10 °C and dimethylsulfate (3.2 mL, 38 mmol) was added slowly. Then the 
reaction mixture was heated overnight under reflux condition, cooled and extracted with 
ether (3 x 25 mL). The combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography to give the 
amisol derivative 157 (4.4 g, 80%) as a dark yellow liquid. 
 
1H NMR (400 MHz, CD3OD): δ = 7.17 (s, 1H, Cortho), 7.00 (d, J = 8.3 Hz, 1H, Cmeta), 6.80 
(d, J = 8.3 Hz, 1H, C’ortho), 3.85 (s, 3H, OMe), 2.26 (s, 3H, Me) ppm; 
13C NMR (100 MHz, CD3OD): δ = 154.5 (Cpara), 137.8 (Cquart), 129.6 (Cortho), 121.7 
(C’ortho), 119 (C’meta), 112.8 (Cmeta), 55.8 (OMe), 21.2 (Me) ppm. 
 
tert-Butyl-3-chloro-N-(diphenylmethylene)-O-methyl-D-tyrosinate (158) 
 
N CO2tBuPh
Ph
OMe
Cl
 
 
To a stirred mixture of N-(diphenylmethylene)glycine tert-butyl ester 148 (500 mg, 1.7 
mmol) and chiral catalyst  147 (17.0 mg, 0.017 mmol) in toluene/chloroform (7:3, 10 mL) 
was added the benzyl bromide 149 (500 mg, 2.1 mmol). The reaction mixture was cooled 
to 0 °C and treated with 50% aqueous KOH (2.5 mL). The mixture stirred at room tem-
perature for approximately 20 h (TLC control). The suspension was diluted with ether (100 
mL), washed with water (2 × 50 ml) and the phases were separated. The organic layer was 
dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography (2:1 petroleum ether / diethyl ether) to give the alkylation product 158 
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(0.65 g, 87%) as a colorless oil. The ee was determined to be 96% by HPLC using a chiral 
column (DAICEL Chiral OB-H, 250 × 2.6 mm; 98:02 heptane and isopropanol, flow 0.5 
mL min–1, tminor = 8.82 min, tmajor = 9.79 min). 
 
Rf = 0.29 (2:1 petroleum ether / diethyl ether); 
[α]D23 = 155.41 (c = 0.62, CH2Cl2); 
IR (neat): νmax = 2975, 2928, 1731, 1622, 1502, 1445, 1256, 1150 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.48 (d, J = 7.0 Hz, 2H, CHortho, CH’ortho), 7.30–7.16 (m, 
6 H, Ph, ), 6.94–6.83 (m, 2H, Ph, CHmeta), 6.70–6.58 (m, 3H, Ph), 4.00 (dd, J = 8.9, 4.4 Hz, 
1H, CHNH), 3.72 (s, 3H, OMe), 3.08–2.93 (m, 2H, CHCH2), 1.35 (s, 9H, CMe3) ppm; 
13C NMR (100 MHz, CDCl3): δ = 171.0 (CO), 153.8 (Cpara), 139.8 (Cortho), 136.7 (C’ortho), 
131.7 (Cquart), 130.6 (Ph), 129.5 (Ph), 129.1 (Ph), 128.8 (Ph), 128.6 (Ph), 128.3 (Ph), 128.0 
(Ph), 122.2 (Cmeta), 112.0 (C’meta), 81.6 (CMe3), 68.0 (CHNH), 56.5 (OMe), 38.8 
(CHCH2), 28.4 (CMe3) ppm; 
HRMS (FT-ICR): calcd. for C27H28ClNO3 [M + Na]+ 472.5035, found 472.5030. 
 
tert-Butyl-3-chloro-O-methyl-D-tyrosinate (159) 
 
H2N CO2tBu
OMe
Cl
 
 
A solution of the alkylated imine 158 (500 mg, 1.1 mmol) in THF (10 mL) and 15% 
aqueous citric acid (5 mL) was stirred at room temperature for 14 h. Then the mixture was 
diluted with Et2O (10 mL) and extracted with 1 M HCl (3 × 10 mL). The combined 
aqueous layers were washed with Et2O (10 mL), basified with solid K2CO3 and then 
extracted with EtOAc (3 × 15 mL). The organic extracts were dried over MgSO4, filtered 
and concentrated in vacuo resulting in the crude amino acid 159 which was used in the 
next step without further purification. 
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tert-Butyl-3-chloro-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-O-methyl-D-tyrosinate 
(161) 
 
FmocHN CO2tBu
OMe
Cl
 
 
The crude amino ester 159 (400 mg, 1.4 mmol) was dissolved in THF (10 mL) and 10% 
aqueous Na2CO3 (10 mL) was added, followed by FmocCl (160) (0.4 g, 1.5 mmol). The 
reaction mixture was stirred 14 h at room temperature. The aqueous layer was extracted 
with EtOAc (3 × 10 mL), dried over MgSO4, filtered and concentrated in vacuo. The 
residue was purified by flash chromatography (10% EtOAc in petroleum ether) to give 161 
(510 mg, 72%) as a colorless oil.  
 
Rf = 0.30 (10% EtOAc in petroleum ether); 
[α]D25 = –25.07 (c = 1.22, CH2Cl2); 
IR (neat): νmax = 3421, 3335, 3064, 2978, 2933, 1732, 1606, 1503, 1450, 1368, 1280 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.76 (d, J = 7.3 Hz, 2H, Fmoc), 7.61–7.17 (m, 7H, Ph, 
Fmoc), 6.98 (d, J = 8.0 Hz, 1H, Ph), 6.81 (d, J = 8.3 Hz, 1H, Ph), 5.30 (d, J = 7.8 Hz, 1H, 
NH), 4.53–4.41 (m, 2H, Fmoc), 4.36–4.28 (m, 1H, CHNH), 4.21 (t, J = 6.9 Hz, 1H, Fmoc), 
3.86 (s, 3H, OCH3), 3.05–2.96 (m, 2H, CHCH2), 1.43 (s, 9H, CMe3) ppm; 
13C NMR (100 MHz, CDCl3): δ = 170.3 (CO), 155.4 (CO, Fmoc), 154.0 (Cpara), 143.7 
(Fmoc), 141.2 (Fmoc), 131.2 (Cortho), 128.7 (C’quart), 127.7 (C’ortho), 127.0 (Fmoc), 125.0 
(Fmoc), 122.1 (Cmeta), 119.9 (Fmoc), 111.9 (C’meta), 82.7 (CMe3), 66.9 (Fmoc), 56.1 
(OMe), 55.0 (CHNH), 47.1 (Fmoc), 37.1 (CHCH2), 27.9 (CMe3) ppm; 
HRMS (FT-ICR): calcd. for C25H22ClNO5 [M + Na]+ 474.1078, found 474.1077. 
 
Methyl-(2R)-2-methyl-3-{[(4-methylphenyl)sulfonyl]oxy}propanoate (163) 
 
TsO OMe
O  
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D-(–)-Methyl-β-hydroxy-iso-butyrate 162 (2.0 g, 16.9 mmol), TsCl (5.0 g, 26.2 mmol) and 
Et3N (4.48 mL, 44.2 mmol) were stirred in CH2CL2 (40 mL) for 3h. Water (100 mL) and 
diethyl ether (100 mL) were added and the mixture stirred for further 5 min. The aqueous 
layer was separated and washed with ether. The organic layers were washed with 1 N HCl 
(100 mL), NaCO3 solution (100 mL) and brine (100 mL) respectively and dried over 
MgSO4. The solvent was removed and the crude residue was purified (10% then 20% 
EtOAc in petroleum ether) to produce 163 (3.6 g, 78%) as a colorless oil. 
 
Rf = 0.20 (20% EtOAc in petroleum ether); 
1H NMR (400 MHz, CDCl3): δ = 7.72 (d, J = 8.3 Hz, 2H, Ph), 7.31 (d, J = 8.3 Hz, 2H, 
Ph), 4.18–4.12 (m, 1H, CH2OTs), 4.03–3.99 (m, 1H, CH2OTs), 3.58 (s, 3H, OMe), 2.80–
2.75 (m, 1H, CHMe), 2.40 (s, 3H, MePh), 1.12 (d, J =7.3 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 170.9 (CO), 144.8 (Cquart), 132.5 (Cortho), 129.7 (Cmeta), 
127.8 (Cpara), 70.6 (CH2OTs), 51.9 (OMe), 39.0 (CHCH3), 21.4 (MePh), 13.4 (Me) ppm. 
 
Methyl (2R)-3-azido-2-methylpropanoate (164) 
 
N3 OMe
O  
 
A mixture of tosylate 163 (2.0 g, 7.3 mmol) and sodium azide (1.0 g, 15.3 mmol) in 
DMSO (30 mL) was heated at 80 °C for 2–3 h.After being cooled to room temperature, 30 
mL of water were added and the mixture was extracted with CH2Cl2 (3 × 30 mL). The 
combined extracts were dried with MgSO4, filtered and concentrated in vacuo. The crude 
product was purified by flash chromatography (20% EtOAc in petroleum ether) resulting 
in azide 164 (0.9 g, 85%) as a colorless oil. 
 
Rf = 0.47 (20% EtOAc in petroleum ether); 
[α]D22 = –14.32 (c = 0.99, CH2Cl2); 
IR (neat): νmax = 2982, 2103, 1732, 1463, 1381, 1199 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 3.68 (s, 3H, OMe), 3.56–3.46 (m, 1H, CH2N3), 3.35 (dd, 
J = 12.1, 5.8 Hz, 1H, CH2N3), 2.73–2.60 (m, 1H, CHMe), 1.28 (d, J = 7.0 Hz, 3H, Me) 
ppm; 
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13C NMR (100 MHz, CDCl3): δ = 174.7 (CO), 54.1 (OMe), 52.9 (CH2N3), 40.0 (CHMe), 
15.1 (Me) ppm;  
HRMS (FT-ICR): calcd. for C5H9N3O2 [M + Na]+ 166.0587, found 166.0585. 
 
Methyl-(2R)-3-amino-2-methylpropanoate (165) 
 
H2N OMe
O  
 
A mixture of azide 164 (0.28 g, 2.0 mmol) and 10% Pd–C (140 mg) in MeOH (2 mL) was 
stirred under hydrogen atmosphere at room temperature for 15 h. The reaction mixture was 
filtered through a pad of celite. Concentration of the filtrate gave the crude amine 165 
which was immediately protected without further purification. 
 
Methyl-(2R)-3-{[(9H-Fluoren-9-ylmethoxy)carbonyl]amino}-2-methylpropanoate 
(166) 
 
HN OMe
O
Fmoc
 
 
The crude amino ester 165 (300 mg, 2.5 mmol) was dissolved in THF (10 mL), 10% 
aqueous Na2CO3 (10 mL) was added, followed by FmocCl (1.0 g, 3.8 mmol). The reaction 
mixture was stirred at room temperature for 14 h. The aqueous layer was extracted with 
EtOAc (2 × 30 mL) and the combined organic extracts were dried with MgSO4, filtered 
and concentrated. The residue was purified by flash chromatography (20% EtOAc in 
petroleum ether) providing the protected amine 166 (0.61 g, 90%) as a colorless solid 
product. 
 
Rf = 0.25 (20% EtOAc in petroleum ether); 
[α]D22 = –13.2 (c = 0.962, CH2Cl2); 
IR (neat): νmax = 3310, 2250, 1760, 1520, 1350, 1250 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.77–7.28 (m, 8H, Fmoc), 5.43–5.33 (m, 1H, NH), 4.40  
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(d, J = 6.3 Hz, 2H, Fmoc), 4.22 (t, J = 6.8 Hz, 1H, Fmoc), 3.71 (s, 3H, OMe), 3.46–3.29 
(m, 2H, CH2NH), 2.79–2.68 (m, 1H, CHMe), 1.20 (d, J = 7.3 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 176.1 (CO), 156.8 (Fmoc), 144.3 (Fmoc), 141.7 
(Fmoc), 128.0 (Fmoc), 127.4 (Fmoc), 125.4 (Fmoc), 120.3 (Fmoc), 67.0 (Fmoc), 52.2 
(OMe), 47.6 (Fmoc), 43.7 (CH2NH), 40.2 (CHMe), 15.1 (Me) ppm; 
HRMS (FT-ICR): calcd. for C20H21NO4 [M + Na]+ 362.3850, found 362.3855. 
 
(2S)-2-Hydroxy-4-methylpentanoic acid (168) 
 
OH
OHO
 
 
L-Leucine 167 (5.0 g, 38 mmol) was dissolved in diluted 0.5 M H2SO4 (150 mL) at 0 °C. 
Sodium nitrite (15.7 g, 228 mmol) was added. The mixture was allowed to stir at 0 °C for 6 
h. The reaction mixture was extracted with diethyl ether. The combined organic layers 
were dried over MgSO4 and concentrated in vacuo. The residue was azeotroped with 
toluene twice to yield a yellow syrup. After removal of residual toluene under high 
vacuum, the residue was washed again with hexane and filtered to give 168 (3.27 g, 65%) 
as a colorless solid product. 
 
1H NMR (400 MHz, CDCl3): δ = 4.28 (dd, J = 8.4, 4.9 Hz, 1H, CHOH), 1.94–1.87 (m, 
1H, CH(Me)2), 1.45–1.35 (m, 2H, CHCH2,) 0.96 (d, J = 6.8 Hz, 6H, Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 175.0 (CO), 68.8 (CHOH), 43.2 (CHCH2), 24.4 
(CHMe), 23.1 (Me), 21.4 (Me) ppm. 
(2R)-2-(Acetyloxy)-4-methylpentanoic acid (169) 
OAc
OHO
 
 
To compound 168 (1.2 g, 9 mmol) acetyl chloride (10 mL) was added at 0 °C. The reaction 
mixture was then refluxed at 60 °C for 4 hr. Excess acetyl chloride was removed under 
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vacuum. Diethyl ether was added and the solution was washed with water. The organic 
layer was dried and concentrated under vacuum to give acid 169 as a crude oil, which was 
used in the next step without further purification. 
 
tert-butyl-(2S)-2-(acetyloxy)-4-methylpentanoate (170) 
 
OAc
OtBuO
 
 
Acid 169 and tert-butyl alcohol (1.31 g, 18.9 mmol) were dissolved in CH2Cl2 (30 mL) and 
DMAP (361mg, 2.97 mmol) was added. Then DCC (2.45 g, 11.9 mmol) in CH2Cl2 (10 
mL) was added at 0 °C. The reaction mixture was stirred at room temperature for 12 h. 
After the urea was filtered the organic layer was washed with water, dried over MgSO4 and 
evaporated in vacuo. The crude residue was purified by flash column chromatography 
(15% EtOAc in petroleum ether) to give ester 170 as a light yellow oil (1.45 g, 70%, 2 
steps). 
 
Rf = 0.35 (15% EtOAc in petroleum ether); 
1H NMR (400 MHz, CDCl3): δ = 4.75 (d, J = 9.3 Hz, 1H, CHOAc), 1.98 (s, 3H, COMe), 
1.65–1.60 (m, 2H, CHCH2), 1.49–1.45 (m, 1H, CHMe), 1.33 (s, 9H, CMe3), 0.82 (d, J = 
6.8 Hz, 6H, CH3) ppm; 
13C NMR (100 MHz, CDCl3): δ = 170.2 (CO), 169.6 (CO, Ac), 81.5 (CMe3), 71.2 
(CHOAc), 39.5 (CHCH2), 27.6 (CMe3), 24.4 (CHMe), 22.7 (Me), 21.3 (Me), 20.3 (COMe) 
ppm. 
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tert-Butyl(2S)-2-[((2R)-3-{[(9H-Fluoren-9-ylmethoxy)carbonyl]amino}-2-
methylpropanoyl)oxy]-4-methylpentanoate (171) 
 
NHFmoc
O
tBuOO
O
C
D
O
O
2 3 4'
5'
6
7
8
9
4 5
6'
7'
8'
9'
 
 
To a solution of hydroxy ester 15c (180 mg, 0.95 mmol), the amino acid 14c (373 mg, 1.14 
mmol) and DMAP (50 mg, 0.40 mmol) in CH2Cl2 (3 mL) at 0 °C was added dropwise a 
solution of DCC (293 mg, 1.42 mmol) in CH2Cl2 (3 mL). The clear solution was stirred 30 
min at 0 °C and then 5 h at room temperature. The white precipitate was filtered off and 
the filtrate concentrated. The residue was dissolved in Et2O and washed with 0.5 N HCl 
(10 mL), saturated NaHCO3 solution (10 mL) and brine (10 mL). The ether layer was dried 
over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography (10% of EtOAc in petroleum ether) to give the ester 171 (378 mg, 80%) 
as a colorless oil. 
 
Rf = 0.25 (10% of EtOAc in petroleum ether); 
[α]D24 = –32.41 (c = 0.44, CH2Cl2); 
IR (neat): νmax = 3366, 2958, 1732, 1522, 1450, 1369, 1249, 1159 cm–1; 
1H NMR (400 MHz, CDCl3): unit C δ = 7.77–7.22 (m, 8H, Fmoc), 6.03–5.92 (m, N–H), 
4.38–4.26 (m, 2H, Fmoc), 4.18 (t, J = 7.3 Hz, 1H, Fmoc), 3.59–3.50 (m, 1H, CH2NH), 
3.35–3.25 (m, 1H, CH2NH), 2.83–2.73 (m, 1H, COCH ), 1.21 (d, J = 7.0 Hz, 3H, Me); unit 
D δ = 4.92 (dd, J = 9.3, 4.5 Hz, 1H, COCH), 1.83–1.57 (m, 3H, CH2Me/CHMe), 1.47 (s, 
9H, CMe3), 0.94 (d, J = 6.3 Hz, 3H, Me), 0.91 (d, J = 6.3 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): unit C δ = 174.3 (CO), 156.5 (CO, Fmoc), 144.0 (4,4’, 
Fmoc), 141.2 (5,5’, Fmoc), 127.5 (7,7’, Fmoc), 126.9 (8,8’, Fmoc), 125.2 (9,9’, Fmoc), 
119.8 (6,6’, Fmoc), 66.7 (2, Fmoc), 47.1 (3, Fmoc), 43.6 (CH2NH), 40.8 (COCH), 14.5 
(Me), unit D δ = 170.3 (CO), 82.5 (CMe3), 71.3 (COCH), 39.5 (CHCH2), 27.9 (CMe3), 
24.7 (CH2CH Me), 23.0 (Me), 21.5 (Me) ppm; 
HRMS (FT-ICR): calcd. for C29H37NO6 [M + Na]+ 518.2513, found 518.2511. 
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tert-Butyl(2S)-2-{[(2R)-3-({3-chloro-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-O-methyl-
D-tyrosyl}amino)-2-methylpropanoyl]oxy}-4-methylpentanoate (172) 
 
O1
2 3 4'
5'
6
7
8
9
5
6'
7'
8'
9'
Fmoc
HN
ON
H
O
tBuOO
O
Fmoc
B
C
D
Cl
OMe
4
O
 
 
The amine 128 (150 mg, 0.54 mmol), the amino acid 13c (243 mg, 0.54 mmol) and HOBT 
(73 mg, 0.54 mmol) were dissolved in dry THF (3 mL), followed by the addition of DCC 
(166 mg, 0.81 mmol), dissolved in THF (2 mL) at 0 °C. The mixture was stirred for 7 h at 
room temperature before it was filtered and concentrated. The residue was diluted with 
Et2O and washed with water. The organic layer was dried over MgSO4, filtered and 
concentrated. The residue was purified by flash chromatography (30% EtOAc in petroleum 
ether) to give the tripeptide analogue 172 (325 mg, 84%) as a colorless oil. 
 
Rf = 0.32 (30% EtOAc in petroleum ether); 
[α]D24 = –21.93 (c = 1.25, CH2Cl2); 
IR (neat): νmax = 3317, 2950, 2152, 1738, 1670, 1504, 1257 cm–1; 
1H NMR (400 MHz, CDCl3): unit B δ = 7.74 (d, J = 7.5 Hz, 2H, Fmoc), 7.56–7.15 (m, 7H, 
Fmoc, Cortho), 7.03 (d, J = 8.0 Hz, 1H, C’ortho), 6.79 (d, J = 8.3 Hz, 1H, C’meta), 5.61 (d, J = 
8.3 Hz, NH), 4.51–4.38 (m, 1H, NHCH), 4.22–4.07 (m, 2H, Fmoc), 3.81 (s, 3H, OMe), 
3.78–3.70 (m, 1H, Fmoc), 3.20–3.08 (m, 2H, CH2Ph), unit C δ = 5.00–4.95 (m, NH), 3.04 
(dd, J = 13.9, 6.1, 1H, CH2NH), 2.95 (dd, J= 13.9, 6.8 Hz, 1H, CH2NH), 2.82–2.70 (m, 
1H, COCH), 1.17 (d, J = 6.8 Hz, Me), unit D δ = 4.51–4.38 (m, 1H, COCH), 1.78–1.53 
(m, 3H, CH2CH/CHMe), 1.43 (s, 9H, CMe3), 0.93 (d, J = 6.3 Hz, 3H, Me), 0.90 (d, J = 6.3 
Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): unit B δ =170.0 (CO), 155.6 (CO, Fmoc), 153.8 (Cpara), 
143.7 (4/4’, Fmoc), 141.2 (5/5’, Fmoc), 131.0 (C’ortho), 129.5 (Cortho), 127.6 (Cquart), 127.2 
(7/7’, Fmoc), 125.6 (8/8’, Fmoc), 125.0 (9/9’, Fmoc), 122.1 (C’meta), 119.9 (6/6’, Fmoc), 
112.1 (Cmeta), 67.0 (2, Fmoc), 60.3 (NHCH), 56.0 (OMe), 41.8 (3, Fmoc), 38.0 (CH2Ph), 
unit C δ = 173.6 (CO), 47.0 (CH2NH), 40.6 (COCH), 14.7 (Me), unit D δ =171.0 (CO), 
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83.1 (CMe3), 71.0 (COCH), 39.4 (CHCH2), 27.9 (CMe3), 124.8 (CHMe), 22.9 (Me), 21.1 
(Me) ppm; 
HRMS (FT-ICR): calcd. for C39H47ClN2O8 [M + Na]+ 729.2913, found 729.2912. 
 
2.2 Synthesis of a Cryptophycin analogue 11 
 
Cryptophycin (11) 
 
O O
H
N
O
N OO
O
H
A
B
C
D
 
 
To a solution of seco compound 177 (100 mg, 0.11 mmol) in CH2Cl2 (3 mL) 
trifluoroacetic acid (5 mL) was added slowly at 0 °C and the mixture stirred for 2 h at room 
temperature. The solvent was removed in vacuo and toluene (5 mL) was added. The 
residue was dissolved in THF (3 mL) and diethylamine (3 mL) was added dropwise at 0 
°C. The reaction mixture was stirred for 2 h at room temperature, followed by removal of 
the solvents in vacuo. This crude product 177a was dissolved in dry DMF (15 mL) and the 
mixture was treated successively with TBTU (60 mg, 0.16 mmol), HOBT (2 mg), and 
DIEA (66 µl, 0.38 mmol) at room temperature. The reaction mixture was stirred for 2 h 
before saturated NaHCO3 solution (10 mL) was added and stirring continued for 1 h. After 
extraction with CH2Cl2 (3 × 15 mL) the combined organic layers were dried over MgSO4, 
filtered and concentrated. The residue was purified by flash chromatography (50% EtOAc 
in petroleum ether) to provide macrocycle 11 (47 mg, 74%) as a slightly yellow oil. 
 
Rf = 0.29 (50% EtOAc in petroleum ether); 
[α]D24 = 7.04 (c = 0.32, CH2Cl2); 
IR (neat): νmax = 3271, 2960, 1744, 1714, 1675, 1540, 1457, 1341, 1175 cm–1; 
1H NMR (400 MHz, CDCl3): unit A δ = 7.34–7.13 (m, 5H, Ph), 6.66 (ddd, J = 15.1, 10.0, 
4.9 Hz, 1H, CH2CHCH), 6.36 (d, J = 15.9 Hz, 1H, PhCH), 5.97 (dd, J = 15.9, 8.8 Hz, 1H, 
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PhCHCH), 5.70 (d, J = 15.6 Hz, 1H, CHCO), 5.05–4.94 (m, 1H, CHOCH2), 2.57–2.44 (m, 
2H, CHMe/CHCH2), 2.39–2.26 (m, 1H, CHCH2), 1.09 (d, J = 6.8 Hz, 3H, Me); unit B δ = 
7.34–7.13 (m, 5H, Ph), 5.62 (d, J = 8.3 Hz, 1H, N–H), 4.86–4.74 (m, 1H, NHCH), 3.18 
(dd, J = 14.1, 5.3 Hz, 1H, CH2Ph), 3.08 (dd, J = 14.4, 7.3 Hz, 1H, CH2Ph); unit C δ = 
7.06–6.99 (m, 1H, N–H), 3.26–3.22 (m, 2H, CH2NH), 2.70–2.60 (m, 1H, COCH), 1.20 (d, 
J = 8.0 Hz, 3H, Me); unit D δ= 4.86–4.74 (m, 1H, COCH), 1.67–1.54 (m, 2H, CHCH2), 
1.43–1.36 (m, 1H, CHMe), 0.71 (d, J = 6.3 Hz, 3H, Me), 0.68 (d, J = 6.3 Hz, 3H, Me) 
ppm; 
13C NMR (100 MHz, CDCl3): unit A δ =165.3 (CO), 141.6 (CH2CHCH), 136.7 (Cquart), 
131.8 (PhCH), 129.2 (PhCHCH), 128.6 (Cortho), 127.5 (Cmeta), 126.1 (Cpara), 125.0 
(CHCO), 72.4 (CHOCH2), 42.3 (CHMe), 38.1 (CHCH2), 17.3 (Me); unit B δ = 170.8 
(CO), 130.1 (Cquart), 128.6 (Cortho), 126.9 (Cmeta), 126.1 (Cpara), 53.7 (NHCH), 35.6 
(CH2Ph); unit C δ = 175.9 (CO), 40.8 (CH2NH), 39.5 (COCH), 14.2 (Me); unit D δ = 
171.1 (CO), 71.1 (COCH), 36.4 (CHCH2), 24.4 (CHMe), 22.7 (Me), 21.2 (Me) ppm; 
HRMS (FT-ICR): calcd. for C34H42N2O6 [M + Na]+ 597.2935, found 597.2934. 
 
tert-Butyl(2S)-2-{[(2R)-3-({N-[(9H-fluoren-9-ylmethoxy)carbonyl]-D-
phenylalanyl}amino)-2-methylpropanoyl]oxy}-4-methylpentanoate (174) 
 
O
OtBuO
O
N
H
O
HN
B
C
D
Fmoc
 
 
A mixture of the amine 128 (150 mg, 0.54 mmol), the Fmoc-protected D-phenylalanine 
175 (212 mg, 0.54 mmol) and HOBT (50 mg, 0.37 mmol) in dry THF (3 mL) was treated 
with DCC (166 mg, 0.81 mmol) dissolved in THF (2 mL) at 0 °C. The reaction mixture 
was stirred for 7 h at room temperature, filtered and concentrated. The residue was diluted 
with Et2O and the resulting mixture washed with water. The organic layer was dried over 
MgSO4, filtered and concentrated. The residue was purified by flash chromatography (30% 
EtOAc in petroleum ether) to give the tripeptide analogue 174 (280 mg, 81%) as a 
colorless oil. 
 
Rf = 0.33 (30% EtOAc in petroleum ether); 
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[α]D24 = –23.63 (c = 1.25, CH2Cl2); 
IR (neat): νmax = 3064, 2957, 2341, 1732, 1665, 1539, 1450, 1246, 1106 cm–1; 
1H NMR (400 MHz, CDCl3): unit B δ = 7.65 (d, J = 7.3 Hz, 2H, Fmoc), 7.51–6.95 (m, 
11H, Ph/Fmoc), 5.49 (d, J = 8.0 Hz, 1H, NH), 4.45–4.27 (m, 1H, NHCH), 4.16–3.98 (m, 
2H, Fmoc), 3.69–3.55 (m, 1H, Fmoc), 3.09–3.00 (m, 2H, CH2Ph); unit C δ = 4.91–4.84 
(m, 1H, NH), 2.95 (dd, J = 13.7, 7.2 Hz, 1H, CH2NH), 2.85–2.75 (m, 1H, CH2NH), 2.70–
2.61 (m, 1H, COCH), 1.06 (d, J = 7.0 Hz, 3H, Me); unit D δ = 4.45–4.27 (m, 1H), 1.69–
1.40 (m, 3H, CH2CH/CHMe), 1.34 (s, 9H, CMe3), 0.84 (d, J = 6.3 Hz, 3H, Me), 0.81 (d, J 
= 6.3 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): unit B δ = 170.7 (CO), 155.6 (CO, Fmoc), 143.7 (4/4’, 
Fmoc), 141.2 (5/5’, Fmoc), 136.4 (Cquart), 129.5 (Cortho), 129.2 (Cpara), 128.5 (Cmeta), 127.6 
(7/7’, Fmoc), 127.0 (8/8’, Fmoc), 125.0 (9/9’, Fmoc), 119.9 (6/6’, Fmoc), 66.9 (2, Fmoc), 
56.1 (NHCH), 41.8 (3, Fmoc), 39.1 (CH2Ph); unit C δ = 173.7 (CO), 47.0 (CH2NH), 40.5 
(COCH), 14.7 (Me); unit D δ = 171.0 (CO), 82.9 (CMe3), 71.0 (COCH), 39.5 (CHCH2), 
27.9 (CMe3), 24.7 (CHMe), 23.0 (Me), 21.5 (Me) ppm; 
HRMS (FT-ICR): calcd. for C38H46N2O7 [M + Na]+ 665.3197, found 665.3202. 
 
tert-Butyl(2E,5S,6R,7E)-5-[((2S)-2-{[(2R)-3-({N-[(9H-fluoren-9-ylmethoxy)carbonyl]-
D-phenylalanyl}amino)-2-methylpropanoyl]oxy}-4-methylpentanoyl)oxy]-6-methyl-8-
phenylocta-2,7-dienoate (177) 
 
HN
ON
H
O
OO
O
CO2tBu
Fmoc
A
B
C
D
 
 
To a solution of the fully protected amino acid 174 (230 mg, 0.35 mmol) in CH2Cl2 (7 mL) 
trifluoroacetic acid (7 mL) was added at 0 °C followed by stirring of the reaction mixture 
for 3 h at room temperature. Then toluene (5 mL) was added and the mixture concentrated. 
This was repeated twice and the crude acid 176 was subjected to the next reaction without 
further purification. 
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To a solution of the N-protected crude acid 176 (200 mg, 0.34 mmol) in THF (3 mL) DIEA 
(45 µL, 0.40 mmol), 2,4,6-trichlorobenzoyl chloride (91 µL, 0.374 mmol) and DMAP (2 
mg) were added. After stirring for 30 min the alcohol 12b (51 mg, 0.17 mmol), dissolved 
in THF (1 mL) was added slowly in a dropwise fashion. After 2 h saturated aqueous 
NaHCO3 solution (5 ml) was added and the layers were separated. The aqueous layer was 
extracted with CH2Cl2 (10 mL). The combined organic layer was dried over MgSO4, 
filtered and concentrated. The crude product was purified by flash chromatography (30% 
EtOAc in petroleum ether) to give the protected seco compound 177 (231 mg, 75%) as a 
colorless oil. 
 
Rf = 0.21 (30% EtOAc in petroleum ether); 
[α]D25 = 1.88 (c = 0.84, CH2Cl2); 
IR (neat): νmax = 3318, 3063, 2959, 1735, 1600, 1545, 1450, 1254, 1152, 1081 cm–1; 
1H NMR (400 MHz, CDCl3): unit A δ = 7.47–7.02 (m, 5H, Ph), 6.97–6.90 (m, 1H, 
CH2CHCH), 6.23 (d, J = 15.6 Hz, 1H, PhCH), 6.03 (dd, J = 15.9, 8.4 Hz, 1H, PhCHCH), 
5.81 (d, J = 8.4 Hz, 1H, CHCO), 5.76–5.69 (m, 1H, CHOCH2), 3.13–2.93 (m, 2H, 
CHCH2), 2.70–2.23 (m, 1H, CHMe), 1.41 (s, 9H, CMe3), 1.06 (d, J = 7.0 Hz, 3H, Me); 
unit B δ = 7.65 (d, J = 7.6 Hz, 2H, Fmoc), 7.47–7.02 (m, 11H, Ph/Fmoc), 5.04–4.79 (m, 
1H, NH), 4.52–4.26 (m, 2H, Fmoc), 4.13–3.85 (m, 2H, NHCH/Fmoc), 2.70–2.23 (m, 2H, 
CH2Ph); unit C δ = 6.83–6.74 (m, 1H, NH), 3.69–3.57 (m, 1H, CH2NH), 3.30–3.20 (m, 
1H, CH2NH), 2.70–2.23 (m, 1H, COCH), 1.15 (d, J = 8.0 Hz, 3H, Me); unit D δ = 5.04–
4.79 (m, 1H, NH), 1.76–1.43 (m, 3H, CH2CH/CHMe), 0.72 (d, J = 6.3 Hz, 3H, Me), 0.67 
(d, J = 6.3 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): unit A δ = 165.9 (CO), 142.0 (CH2CHCH), 137.2 (Cquart), 
136.6 (PhCH), 133.7 (PhCHCH), 131.7 (Cortho), 129.3 (Cmeta), 127.0 (Cpara), 126.0 
(CHCO), 80.5 (CMe3), 70.6 (CHOCH2), 42.0 (CHMe), 34.8 (CHCH2), 28.1 (CMe3), 16.8 
(Me); unit B δ = 171.0 (CO), 156.0 (CO, Fmoc), 144.0 (4, Fmoc), 141.1 (5, Fmoc), 131.7 
(Cortho), 129.8 (Cquart), 128.5 (7/7’, Fmoc), 127.5 (8/8’, Fmoc), 126.6 (9/9’, Fmoc), 125.0 
(Cmeta) 119.8 (6/6’, Fmoc), 67.0 (2, Fmoc), 56.5 (NHCH), 52.5 (3, Fmoc), 39.4 (CH2Ph); 
unit C δ = 173.5 (CO), 47.1 (CH2NH), 40.6 (COCH), 14.5 (Me); unit D δ = 171.2 (CO), 
40.4 (COCH), 38.5 (CH2CH), 24.6 (CHMe), 22.8 (Me), 21.2 (Me) ppm; 
HRMS (FT-ICR): calcd. for C53H62N2O9 [M + Na]+ 893.4347, found 893.4344. 
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2.3 Synthesis of Epoxomicin 
 
Epoxomicin (7) 
 
N
O
N
H
O
O
H
N
OH
N
H
O
O
O
 
 
To the solution of TBDPS-ether 212 (70 mg, 0.088 mmol) in dry THF (2 mL) TBAF (100 
µl, 1 M solution in THF) was added at 0 °C and the mixture stirred for 1 h (0 °C to room 
temperature). The solvent was evaporated at room temperature and the residue was 
purified by flash chromatography (70% EtOAc in hexene) to generate 7 (34 mg, 75%) as a 
colorless solid product. 
 
Rf = 0.34 (70% EtOAc in hexane); 
[α]D24 = –62.4 (c = 0.36, MeOH), {ref.[170 [α]D24 = –66.1 (c = 0.50, MeOH)},  
IR (neat): νmax = 3270, 3079, 1675, 1540, cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.46 (d, J = 7.5 Hz, 1H, NH), 7.30 (d, J = 8.0 Hz, 1H, 
NH), 6.96 (d, J = 7.5 Hz, 1H, NH), 4.69 (d, J = 11.3 Hz, 1H, CHOH), 4.54–4.50 (m, 1H, 
NCH), 4.48 (dd, J = 7.7, 2.9 Hz, 1H, NHCHCH2), 4.29–4.17 (m, 2H, NHCH), 3.29 (d, J = 
5.0 Hz, 1H, CH2epoxide), 2.97 (s, 3H, NMe) 2.86 (d, J = 5.0, 1H, CH2epoxide), 2.10 (s, 
3H, COMe), 2.07–2.00 (m, 2H, 2NCHCH), 1.98–1.88 (m, 1H, CHMe2), 1.75–1.57 (m, 2H, 
CHCH2), 1.51 (s, 3H, Meepoxide), 1.37–1.18 (m, 4H, 2CHCH2), 1.08 (s, 3H, MeCHOH), 
0.91–0,70 (m, 18H, 6Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 207.0 (CO), 170.8 (CO), 170.4 (CO), 169.9 (COMe), 
169.4 (CO), 65.2 (CHOH), 61.3 (Cepoxide), 59.1 (NHCH), 57.9 (NCH), 56.5 (NHCH), 
51.1 (CH2epoxide), 49.2 (NHCH), 38.1 (CH2CHMe2), 35.0 (NHCHCH), 30.8 (NHCHCH), 
30.7 (NMe), 23.8 (CMe2), 23.4 (CH2Me), 23.3 (CH2Me), 22.0 (CH2Me), 20.8 (COMe), 
19.8 (MeCHOH), 16.4 (CMe2), 15.5 (Me), 14.2 (Me), 14.2 (Meepoxide), 9.7 (MeCH2), 9.2 
(MeCH2) ppm; 
HRMS (FT-ICR): calcd. for C28H50N4O7 [M + Na]+ 577.7090, found 577.7088. 
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N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-O-[tert-butyl(diphenyl)silyl]-L-threonine 
(183) 
 
N
H O
H
N
O
OH
OTBDPS
O
N
O
 
 
PhSiH3 (0.14 mL, 1.15 mmol) was added dropwise at 0 °C to a of solution of allyl ester 
204 (390 mg, 0.57 mmol) and [Pd(Ph3P)4] (20 mg) in THF (3 mL). The resulting solution 
was stirred and maintained at 0 °C for 45 min. After that the reaction was quenched with 
H2O (0.1 mL) and concentrated. The crude residue was purified by flash chromatography 
(hexane and Et2O first 8:1, then 3:1, 1:1, 1:3 followed by pure Et2O and pure EtOAc) to 
give the tripeptide derivative 183 (325 mg, 88% yield) as a colorless oil. 
 
Rf = 0.17 (50% EtOAc in petroleum ether); 
[α]D24 = –70.4 (c = 1.3, CH2Cl2); 
IR (neat): νmax = 3300, 3054, 2962, 1743, 1639, 1519 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.64–7.60 (m, 4H, Ph), 7.45–7.34 (m, 6H, Ph), 6.69–
6.64 (m, 2H, 2NH), 4.67–4.38 (m, 4H, 2NHCH/CHOTBDPS/CHNMe), 2.94 (s, 3H, 
NMe), 2.11 (s, 3H, COMe), 1.56–1.20 (m, 6H, 2CHMe/2CH2Me), 1.00 (s, 9H, CMe3), 
0.98–0.82 (m, 15H, 5Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 172.3 (CO), 172.0 (CO), 171.2 (CO), 166.7 (CO), 135.8 
(CquartPh), 132.0 (Ph) 129.8 (Ph), 128.5 (Ph), 127.7 (Ph), 119.1 (Ph), 69.6 (CHOTBDPS), 
62.2 (NMeCH), 61.2 (NHCH), 60.3 (NHCH), 32.6 (CHMe), 31.4 (CHMe), 28.9 (COMe), 
27.8 (NMe), 26.9 (SiCMe3), 24.6 (CH2Me), 24.5 (CH2Me), 21.9 (Me), 19.3 (SiCMe3), 15.5 
(Me), 14.1 (Me), 11.2 (Me), 10.3 (Me) ppm. 
 
tert-Butyl (1S)-3-methyl-1-{[(2R)-2-methyloxiran-2-yl]carbonyl}butylcarbamate (184) 
 
BocHN
O
O  
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To a solution of unsaturated ketone 198 (500 mg, 1.9 mmol) in MeOH (5 mL) benzonitril 
(235 mg, 2.28 mmol) and iPr2NEt (328 mg, 2.28 mmol) were added at 0 °C. Then 30% 
H2O2 (1.21 g, 19 mmol) was added and the reaction mixture was stirred for 40 h at 0 to 4 
°C. After that the reaction mixture was diluted with ether (100 mL) and H2O (25 mL). The 
aqueous layer was separated and extracted with CH2Cl2 (100 mL). The combined organic 
layers were washed with brine (100 mL), dried with MgSO4, filtered and concentrated. The 
crude residue was purified and separated from 184a by flash chromatography (10% then 
5% EtOAc in petroleum ether) to provide pure epoxide 184 (6.5 g, 56%) as a colorless oil. 
 
Rf = 0.21 (10% EtOAc in petroleum ether); 
[α]D24 = 134.0 (c = 0.23, CH2Cl2); 
IR (neat): νmax = 3374, 2965, 1708, 1508, 1369 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 4.85 (d, J = 8.3 Hz, 1H, NH), 4.30 (t, J = 9.6 Hz, 
NHCH), 3.25 (d, J = 5.0 Hz, 1H, CH2–epoxide), 2.85 (d, J = 5.0 Hz, 1H, CH2–epoxide), 
1.74–1.64 (m, 1H, CHMe2), 1.48 (s, 3H, Me–epoxide), 1.37 (m, 9H, CMe3), 1.18–1.11 (m, 
2H, CHCH2), 0.93 (d, J = 6.5 Hz, 3H, Me), 0.89 (d, J = 6.5 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 209.5 (COCH=CH2), 155.5 (CO), 79.6 (CMe3), 58.9 
(Cquart, epoxide), 52,2 (CH2, epoxide), 51.3 (NHCH), 40.3 (CH2), 28.2 (CMe3), 25.0 
(CHMe2), 23.3 (Me), 21.2 (Me), 16.7 (MeCH=CH2) ppm. 
 
tert-Butyl(1S)-1-isobutyl-2,3-dioxobutylcarbamate (198) 
 
N
H O
Boc
 
 
2-Bromopropene (0.87 g, 7.3 mmol) was taken in THF (5 mL) and t-BuLi (1.5 M, 9.73 
mL, 14.6 mmol) was added at –78 °C. The reaction mixture was stirred for 1 h and 
Weinreb amide 206 (500 mg, 1.82 mmol) in THF (1 mL) was added. After stirring 3 h at –
78 °C, the reaction was quenched with NH4Cl solution (10 mL) and extracted with ether (2 
x 50 mL). The combined organic layers were dried with MgSO4, filtered and concentrated 
in vacuo. The crude residue was purified by flash chromatography (20% EtOAc in 
petroleum ether) to give pure enone 198 (435 mg, 93%) as a dark red colored oil. 
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Rf = 0.43 (20% EtOAc in petroleum ether); 
[α]D24 = 52.3 (c = 0.30, CH2Cl2); 
IR (neat): νmax = 3351, 2969, 2094, 1708, 1660, 1508 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 6.03 (s, 1H, CH=CH2), 5.83 (s, 1H, CH=CH2), 5.59 (d, J 
= 8.5 Hz, 1H, NH), 5.02 (t, J = 9.6 Hz, NHCH), 1.85 (s, 3H, CH2=CHMe), 1.73–1.64 (m, 
1H, CHMe2), 1.38 (m, 9H, CMe3), 1.35–1.21 (m, 2H, CHCH2), 0.95 (d, J = 6.5 Hz, 3H, 
Me), 0.85 (d, J = 6.5 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 201.5 (COCH=CH2), 155.4 (CO), 142.2 (CH=CH2), 
125.9 (CH=CH2), 79.4 (CMe3), 52.4 (NHCH), 43.0 (CH2), 28.2 (CMe3), 24.8 (CHMe2), 
23.3 (Me), 21.6 (Me), 17.7 (MeCH=CH2) ppm. 
 
Allyl-O-[tert-butyl(diphenyl)silyl]-L-threoninate (199) 
 
O
OAllyl
OTBS
H2N
 
 
A mixture of allyl alcohol (29 mL, 420 mmol), L-threonine (5.0 g, 42 mmol), p-TsOH (9.6 
g, 50 mmol) and C6H6 (150 mL) was refluxed for 45 h using a Dean-Stark trap and then 
concentrated. TBDPS-Cl (17.31 g, 63 mmol) was added to a 0 °C mixture of the crude 
residue, imidazole (15 g, 210 mmol) and CH2Cl2 (100 mL). The mixture was allowed to 
come to room temperature overnight and concentrated. The residue was dissolved in 
EtOAc (300 mL), washed with 1 M NaOH (3 x 50 mL) and brine (2 x 50 mL), dried with 
NaSO4, filtered and concentrated. The residue was purified by flash chromatography (30% 
then 50% EtOAc in petroleum ether) to give pure amine 199 (6.5 g, 56%) as a light yellow 
oil. 
 
Rf = 0.20 (50% EtOAc in petroleum ether); 
IR (neat): νmax = 3300, 2935, 1430, 1369, 1160 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.70–7.60 (m, 4H, Ph), 7.44–7.34 (m, 6H, Ph), 5.87–
5.76 (m, 1H, CH=CH2), 5.27–5.20 (m, 2H, CH=CH2), 4.59 (dd, J = 13.0, 5.9 Hz, 1H, CH2, 
allyl), 4.39 (dd, J = 13.0, 5.9 Hz, 1H, CH2, allyl), 4.37–4.33 (m, 1H, CHOTBDPS), 3.39 
(d, J = 2.5 Hz, 1H, NH2CH), 1.73 (m, 2H, NH2), 1.12 (d, J = 6.3 Hz, 3H, Me), 1.00 (s, 9H, 
CMe3) ppm;  
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13C NMR (100 MHz, CDCl3): δ = 174.2 (CO), 135.8 (Cquart–Ph), 134.0 (CH=CH2), 133.2 
(Ph), 131.8 (Ph), 129.6 (Ph), 127.5 (Ph), 118.7 (Ph), 70.8 (NHCH), 65.7 (CHOTBDPS), 
60.5 (CH2, allyl), 26.7 (SiCMe3), 20.5 (Me), 19.2 (SiCMe3) ppm. 
 
Allyl (2S,3R)-3-{[tert-butyl(diphenyl)silyl]oxy}-2-[((2S,3S)-2-{[(9H-fluoren-9-
ylmethoxy)carbonyl]amino}-3-methylpentanoyl)amino]butanoate (200) 
 
N
H O
H
N
O
OAllyl
OTBDPS
Fmoc
 
 
Compound 199 (400 mg, 1 mmol), Fmoc protected amino acid 178 (356 mg, 1 mmol), 
TBTU (375 mg, 1 mmol) and HOBT (136 mg, 1 mmol) were taken in CH2Cl2 (5 mL). The 
reaction mixture was allowed to warm to room temperature overnight and concentrated. 
The crude residue was then taken up in EtOAc (20 mL), dried with MgSO4 and 
concentrated. The crude product was purified by flash chromatography (30% EtOAc in 
petroleum ether) to furnish dipeptide 200 (315 mg, 85%) as a colorless thick oil. 
 
Rf = 0.37 (30% EtOAc in petroleum ether); 
[α]D24 = –2.9 (c = 1.0, CH2Cl2); 
IR (neat): νmax = 3430, 3313, 2958, 1731, 1673, 1519, 1376, 1241 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.71 (d, J = 7.5 Hz, 2H, Fmoc), 7.60–7.52 (m, 6H, 
Fmoc), 7.38–7.20 (m, 10H, Ph), 6.48 (d, J = 8.8 Hz, NH), 5.80–5.70 (m, 1H, CH=CH2), 
5.50 (d, J = 8.3 Hz, 1H, NH), 5.25–5.16 (m, 2H, CH=CH2), 4.56–4.46 (m, 3H, CH2, 
allyl/CHOTBDPS), 4.41–4.35 (m, 4H, 2NHCH/Fmoc), 4.18 (t, J = 6.9 Hz, 1H, Fmoc), 
1.92–1.87 (m, 1H, CHMe), 1.66–1.55 (m, 1H, CH2Me), 1.33–1.21 (m, 1H, CH2Me), 1.00–
0.90 (m, 18H, CMe3/ 3Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 171.2 (CO), 169.0 (CO), 156.0 (CO, Fmoc), 143.9 
(Fmoc), 141.2 (Fmoc), 135.8 (Cquart–Ph), 133.4 (CH=CH2), 132.5 (Ph), 131.3 (Ph), 129.9 
(Ph), 129.8 (Fmoc), 127.5 (Ph), 127.0 (Fmoc), 125.0 (Fmoc), 119.9 (Fmoc), 118.9 (Ph), 
69.9 (CHOTBDPS), 67.0 (NHCH), 66.2 (NHCH), 59.4. (Fmoc), 57,8 (CH2allyl), 47.1 
(Fmoc), 37.9 (CHMe), 26.7 (SiCMe3), 25.1 (CH2Me), 20.9 (Me), 19.1 (SiCMe3), 15.0 
(Me), 11.6 (Me) ppm. 
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Allyl-L-isoleucyl-O-[tert-butyl(diphenyl)silyl]-L-threoninate (201) 
 
H2N
O
H
N
O
OAllyl
OTBDPS  
 
Piperidine (0.078 mL, 0.80 mmol) was added to a 0 °C solution of the Fmoc-tripeptide 200 
(300 mg, 0.40 mmol) and CH3CN (5 mL). The resulting mixture was allowed to warm to 
room temperature over 3 h and then concentrated. The crude was purified by 
chromatography (hexane / Et2O first 8:1, then 3:1, 1:1 and 1:3 followed by pure Et2O and 
pure EtOAc) to give dipeptide amine 201 (178 mg, 85%) as a colorless oil. 
 
Rf = 0.19 (50% EtOAc in petroleum ether); 
IR (neat): νmax = 3374, 3066, 2958, 1743, 1673, 1504, 1376, 1311, 1103 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 8.18 (d, J = 9.6 Hz, 1H, NH), 7.62–7.52 (m, 5H, 
NH/Ph), 7.44–7.34 (m, 6H, Ph), 5.85–5.75 (m, 1H, CH=CH2), 5.25 (dd, J = 17.1, 1.2 Hz, 
1H, CH=CH2), 5.20 (dd, J = 10.4, 1.0 Hz, 1H, CH=CH2), 4.60–4.51 (m, 3H, CH2allyl/ 
CHOTBDPS), 4.41 (dd, J = 13.1, 5.8 Hz, 1H, NHCH), 3.44 (d, J = 3.9 Hz, 1H, CHNH2), 
2.06–1.98 (m, 1H, CHMe), 1.54–1.44 (m, 1H, CH2Me), 1.27–1.16 (m, 1H, CH2Me), 1.04–
0.91 (m, 18H, CMe3/3Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 174.7 (CO), 170.4 (CO), 143.9 (Fmoc), 135.7 (CquartPh), 
133.8 (CH=CH2), 132.8 (Ph), 131.5 (Ph), 129.8 (Ph), 127.6 (Ph),118.7 (Ph), 70.2 
(CHOTBDPS), 65.9 (NHCH), 60.0 (NH2CH), 57,5 (CH2allyl), 37.9 (CHMe), 26.7 
(SiCMe3), 23.9 (CH2Me), 21.0 (Me), 19.1 (SiCMe3), 10.0 (Me), 11.9 (Me) ppm. 
 
Allyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-isoleucyl-L-isoleucyl-O-
[tert-butyl(diphenyl)silyl]-L-threoninate (202) 
 
N
H O
H
N
O
OAllyl
OTBDPS
O
N
Fmoc
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Amide 201 (400 mg, 0.78 mmol), Fmoc protected acid 181 (288 mg, 0.78 mmol) and 
DMAP (100 mg, 0.78 mmol) were taken in CH2Cl2 (5 mL). PyBrop (363 mg, 0.78 mmol) 
was added and the reaction mixture was stirred for 20 h at room temperature. The resulting 
mixture was concentrated and the residue was purified by flash chromatography (10% then 
30% EtOAc in petroleum ether) to give the fully protected tripeptide 202 (612 mg, 91%) as 
a light yellow oil. 
 
Rf = 0.33 (30% EtOAc in petroleum ether); 
[α]D24 = –55 (c = 0.41, CH2Cl2); 
IR (neat): νmax = 3324, 2961, 1673, 1515, 1307, 1241, 1160 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.76 (d, J = 7.3 Hz, 2H, Fmoc), 7.64 (d, J = 7.3 Hz, 2H, 
Fmoc), 7.61–7.56 (m, 4H, Fmoc), 7.45–7.29 (m, 10H, Ph), 6.61 (d, J = 9.1 Hz, 2H, 2NH), 
5.85–5.74 (m, 1H, CH=CH2), 5.21 (d, J = 9.6 Hz, 1H, CH=CH2), 5.20 (d, J = 9.6 Hz, 1H, 
CH=CH2), 4.59–4.37 (m, 7H, CH2allyl/CHOTBDPS/CHNMe/Fmoc), 4.26 (d, J = 8.0 Hz, 
2H, 2NHCH), 2.91 (s, 3H, NMe), 2.20–2.00 (m, 1H, CHMe), 1.98–1.94 (m, 1H, CHMe), 
1.54–1.39 (m, 2H, CH2Me), 1.27–1.18 (m, 2H, CH2Me), 1.01 (s, 9H, CMe3), 0.98–0.80 
(m, 15H, 5Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 171.0 (CO), 169.9 (CO), 169.8 (CO), 157.3 (CO, 
Fmoc), 143.8 (Fmoc), 141.3 (Fmoc), 135.8 (CquartPh), 133.5 (CH=CH2), 132.5 (Ph), 131.3 
(Ph), 129.9 (Ph), 129.9 (Fmoc), 127.6 (Ph), 127.5 (Fmoc), 124.8 (Fmoc), 120.0 (Fmoc), 
119.1 (Ph), 69.9 (CHOTBDPS), 67.9 (NHCH), 66.2 (NHCH), 63.4 (NMeCH), 57.7 
(Fmoc), 57.4 (CH2allyl), 47.1 (Fmoc), 36.9 (CHMe), 31.5 (CHMe), 29.8 (NMe), 26.8 
(SiCMe3), 24.7 (CH2Me), 24.4 (CH2Me), 20.9 (Me), 19.1 (SiCMe3), 15.6 (Me), 15.0 (Me), 
11.6 (Me), 10.4 (Me) ppm. 
 
Allyl-N-methyl-L-isoleucyl-L-isoleucyl-O-[tert-butyl(diphenyl)silyl]-L-threoninate 
(203) 
 
N
H O
H
N
O
OAllyl
OTBDPS
O
HN
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Piperidine (0.09 mL, 0.92 mmol) was added to a 0 °C solution of the Fmoc-tripeptide 202 
(400 mg, 0.46 mmol) and CH3CN (5 mL). The resulting mixture was allowed to warm to 
room temperature over 3 h and then concentrated. The crude was purified by chromato-
graphy (hexane / Et2O first 8:1, then 3:1, 1:1, and 1:3 followed by pure Et2O and pure 
EtOAc) to produce the tripeptide derivative amine 203 (285 mg, 96%) as a colorless oil. 
 
Rf = 0.18 (50% EtOAc in petroleum ether); 
IR (neat): νmax = 3320, 3058, 2962, 2873, 2680, 1747, 1658, 1515, 1307, 1160 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.76 (d, J = 8.5 Hz, 1H, NH), 7.64–7.59 (m, 4H, Ph), 
7.44–7.34 (m, 6H, Ph), 6.61 (d, J = 8.8 Hz, 1H, NH), 5.83–5.73 (m, 1H, CH=CH2), 5.25 
(d, J = 9.0 Hz, 1H, CH=CH2), 5.20 (d, J = 9.0 Hz, 1H, CH=CH2), 4.58–4.37 (m, 6H, 
CH2allyl/CHOTBDPS/CHNMe/2CHNH), 3.11 (s, NHMe), 2.47 (s, 3H, NMe), 1.98–1.92 
(m, 2H, 2CHMe), 1.68–1.53 (m, 2H, CH2Me), 1.38–1.21 (m, 2H, CH2Me), 1.00 (s, 9H, 
CMe3), 0.98–0.80 (m, 15H, 5Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 171.0 (CO), 169.9 (CO), 169.8 (CO), 135.8 (CquartPh), 
133.5 (CH=CH2), 132.5 (Ph), 131.4 (Ph), 129.8 (Ph), 127.5 (Ph), 119.1 (Ph), 69.9 
(CHOTBDPS), 69.4 (NHCH), 66.2 (NHCH), 63.4 (NMeCH), 57.8 (CH2allyl), 37.2 
(CHMe), 35.1 (CHMe), 29.8 (NMe), 26.8 (SiCMe3), 25.4 (CH2Me), 24.2 (CH2Me), 20.7 
(Me), 19.1 (SiCMe3), 15.5 (Me), 15.3 (Me), 11.6 (Me), 11.4 (Me), ppm; 
 
Allyl-N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-O-[tert-butyl(diphenyl)silyl]-L-
threoninate (204) 
 
N
H O
H
N
O
OAllyl
OTBDPS
O
N
O
 
 
Compound 203 (200 mg, 0.31 mmol) was taken in CH2Cl2 (2 mL) and diisopropylethyl 
amine (0.072 mL, 0.63 mmol) was added. Then Ac2O (0.075 mg, 0.63 mmol) was added 
dropwise at 0 °C and the reaction mixture was stirred at room temperature for 4 h. After 
evaporation of the solvent in vacuo the residue was purified by flash chromatography (30% 
EtOAc in petroleum ether) to provide acetamide 204 (201 mg, 94%) as a slightly yellow 
oil. 
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Rf = 0.24 (30% EtOAc in petroleum ether); 
[α]D24 = –73.4 (c = 1.4, CH2Cl2); 
IR (neat): νmax = 3436, 3301, 3058, 2962, 2545, 1743, 1639, 1515, 1307, 1160 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.60 (dd, J = 19.3, 7.2 Hz, 4H, Ph), 7.42–7.31 (m, 6H, 
Ph), 6.74 (d, J = 8.3 Hz, 1H, NH), 6.65 (d, J = 9.1 Hz, 1H, NH), 5.82–5.71 (m, 1H, 
CH=CH2), 5.20 (d, J = 9.3 Hz, 1H, CH=CH2), 5.18 (d, J = 9.6 Hz, 1H, CH=CH2), 4.67–
4.45 (m, 4H, CH2allyl/CHOTBDPS/CHNMe), 4.36 (d, J = 8.0 Hz, 2H, 2NHCH), 2.94 (s, 
3H, NMe), 2.09 (s, 3H, COMe), 2.00–1.97 (m, 2H, 2CHMe), 1.52–1.43 (m, 1H, CH2Me), 
1.35–1.28 (m, 1H, CH2Me), 1.25–1.12 (m, 2H, CH2Me), 0.99 (s, 9H, CMe3), 0.91–0.82 
(m, 15H, 5Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 171.0 (CO), 171.0 (CO), 170.0 (CO), 169.8 (CO), 135.8 
(Cquart–Ph), 133.5 (CH=CH2), 132.5 (Ph), 131.3 (Ph), 129.6 (Ph), 127.5 (Ph), 118.9 (Ph), 
69.9 (CHOTBDPS), 66.0 (NMeCH), 60.7 (NHCH), 60.2 (NHCH), 57.6 (CH2allyl), 36.4 
(CHMe), 31.4 (CHMe), 31.3 (COMe), 29.8 (NMe), 26.7 (SiCMe3), 24.5 (CH2Me), 24.4 
(CH2Me), 20.6 (Me), 19.1 (SiCMe3), 15.5 (Me), 15.2 (Me), 11.2 (Me), 10.3 (Me) ppm; 
 
N2-(tert-Butoxycarbonyl)-N1-methoxy-N1-methyl-L-leucinamide (206) 
 
N
H O
N
OMe
Boc
 
 
Triethylamine (0.43 g, 4.3 mmol) was added to a stirred solution of Boc-amino acid 205 
(1.0 g, 4.3 mmol) in CH2Cl2 (10mL). Then BOP (1.9 g, 4.3 mmol) was added, followed 
after a few minutes by O,N-dimethylhydroxylamine hydrochloride (0.45 g, 4.4 mmol) and 
Et3N (1 mL). The reaction was monitored by TLC and pH paper (due to the pH smaller 
than 7 neutralization by adding a few drops of Et3N enabled a complete reaction). The 
mixture was then diluted with CH2Cl2 (100 mL) and washed successively with 3 N HCl (3 
x 20 mL) and saturated NaCl solution (3 x 20 mL). The resulting organic layer was dried 
with MgSO4, filtered and concentrated in vacuo. The crude residue was purified by flash 
chromatography (30% EtOAc in petroleum ether) to give pure amide 206 (105 mg, 88%) 
as a colorless oil.[181] 
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Rf = 0.28 (30% EtOAc in petroleum ether); 
IR (neat): νmax = 3325, 2935, 1710, 1660, 1500 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 5.03 (d, J = 9.1 Hz, 1H, NH), 4.68 (d, J = 3.2 Hz, 1H, 
NHCH), 3.75 (s, 3H, OMe), 3.16 (s, 3H, NMe), 1.73–1.63 (m, 1H, CHMe2), 1.38–1.35 (m, 
11H, CH2/CMe3), 0.93 (d, J = 6.5 Hz, 3H, Me), 0.89 (d, J = 6.5 Hz, 3H, Me) ppm; 
13C NMR (100 MHz, CDCl3): δ = 173.8 (CONMe), 155.5 (CO), 79.1 (CMe3), 61.5 
(OMe), 48.9 (NHCH), 42.0 (CH2), 32.0 (NMe), 28.2 (CMe3), 24.6 (CHMe2), 23.2 (Me), 
21.5 (Me) ppm. 
 
(2S)-2-amino-4-methyl-1-(2-methyloxiran-2-yl)pentan-1-one trifluoroacetate (211) 
 
TFA.H2N
O
O
 
 
Compound 184 (100 mg, 0.36 mmol) was taken in CH2Cl2 (3 mL) and TFA was added 
dropwise at 0 °C. The reaction mixture was stirred 1.5 h (TLC controlled) and 
concentrated. The crude residue was azeotroped twice with toluene and the solvent 
evaporated. This residue of  211 was used in the next step without further purification. 
 
N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-O-[tert butyl(diphenyl)silyl]-N1-((1S)-3-
methyl-1-{[(2R)-2-methyloxiran-2-yl]carbonyl}butyl)-L-threoninamide (212) 
 
N
O
N
H
O
O
H
N
OTBPS
N
H
O
O
O
 
 
Compound 183 (233 mg, 0.36 mmol), salt of amine 211 (100 mg, 0.36 mmol), TBTU (135 
mg, 0.36 mmol) and HOBT (50 mg, 0.36 mmol) were taken in CH2Cl2 and DMF (3:2, 
5mL). Diisopropylethylamine was added dropwise at 0 °C and the reaction mixture was 
stirred at room temperature for 20 h. After dilution with CH2Cl2 (15 mL) it was washed 
successively with H2O (10 mL), NaHCO3 solution (10mL) and brine (10mL). Then the 
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organic layer was dried with MgSO4, filtered and concentrated in vacuo. The crude residue 
was purified (30% EtOAc in petroleum ether) and produced compound 212 (153 mg, 51%) 
as a colorless oil. 
 
Rf = 0.34 (30% EtOAc in petroleum ether); 
[α]D24 = –39.0 (c = 0.41, CH2Cl2); 
IR (neat): νmax = 3294, 3080, 1636, 1540 cm–1; 
1H NMR (400 MHz, CDCl3): δ = 7.76–7.71 (m, 4H, Ph), 7.43–7.35 (m, 6H, Ph), 7.25 (d, J 
= 6.3 Hz, 1H, NH), 6.80 (d, J = 6.3 Hz, 1H, NH), 6.53 (d, J = 6.8 Hz, 1H, NH), 4.58–4.50 
(m, 3H, 3NHCH), 4.34–4.28 (m, 1H, NMeCH), 4.19–4.15 (m, 1H, CHOTBDPS), 3.39 (d, 
J = 5.0 Hz, 1H, CH2epoxide), 2.95–2.90 (m, 1H, CH2epoxide), 2.89 (s, 3H, NMe), 2.07 (s, 
3H, COMe), 1.97–1.87 (m, 1H, CHMe2), 1.71–1.65 (m, 2H, 2CHMe), 1.53 (s, 3H, 
Meepoxide), 1.36–1.18 (m, 6H, CHCH2), 1.10 (s, 9H, CMe3), 0.91–0,70 (m, 21 H, 7Me) 
ppm; 
13C NMR (100 MHz, CDCl3): δ = 208.3 (CO), 172.1 (CO), 170.4 (CO), 169.6 (COMe), 
135.8 (CquartPh), 133.3 (Ph), 132.1 (Ph), 130.1 (Ph), 127.7 (Ph), 119 (Ph), 69.1 
(CHOTBDPS), 59.3 (Cquartepoxide), 57.9 (NMeCH), 56.9 (NHCH), 52.4 (NHCH), 50.6 
(NHCH), 44.4 (CH2epoxide), 39.5 (CH2CHMe2), 36.2 (CHMe), 33.8 (CHMe), 31.3 
(CHMe2), 27.0 (CMe3), 25.1 (CHMe2), 24.3 (CH2Me), 23.2 (CH2Me), 22.0 (COMe), 21.1 
(MeCHOTBDPS), 19.2 (CMe3), 16.7 (Meepoxide), 15.7 (Me), 15.4 (Me), 11.2 (Me), 10.3 
(Me) ppm. 
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VI. APPENDIX 
 
1. NMR-Spectra for important compounds 
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1H- and 13C-NMR spectra of compound 5 
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1H- and 13C-NMR spectra of compound 12b 
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1H- and 13C-NMR spectra of compound 12c 
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1H- and 13C-NMR spectra of compound 13c 
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1H- and 13C-NMR spectra of compound 14c 
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1H- and 13C-NMR spectra of compound 15c 
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1H- and 13C-NMR spectra of compound 126 
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1H- and 13C-NMR spectra of compound 127 
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1H- and 13C-NMR spectra of compound 128 
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1H- and 13C-NMR spectra of compound 131 
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1H- and 13C-NMR spectra of compound 135 
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1H- and 13C-NMR spectra of compound 136 
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1H- and 13C-NMR spectra of compound 138 
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1H- and 13C-NMR spectra of compound 139 
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1H- and 13C-NMR spectra of compound 147 
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1H- and 13C-NMR spectra of compound 148 
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1H- and 13C-NMR spectra of compound 149 
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1H- and 13C-NMR spectra of compound 158 
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1H- and 13C-NMR spectra of compound 161 
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1H- and 13C-NMR spectra of compound 164 
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1H- and 13C-NMR spectra of compound 166 
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1H- and 13C-NMR spectra of compound 168 
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1H- and 13C-NMR spectra of compound 170 
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1H- and 13C-NMR spectra of compound 171 
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1H- and 13C-NMR spectra of compound 172 
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1H- and 13C-NMR spectra of compound 11 
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1H- and 13C-NMR spectra of compound 174 
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1H- and 13C-NMR spectra of compound 177 
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1H- and 13C-NMR spectra of compound 7 
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1H- and 13C-NMR spectra of compound 183 
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1H- and 13C-NMR spectra of compound 184 
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1H- and 13C-NMR spectra of compound 198 
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1H- and 13C-NMR spectra of compound 199 
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1H- and 13C-NMR spectra of compound 200 
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1H- and 13C-NMR spectra of compound 201 
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1H- and 13C-NMR spectra of compound 202 
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1H- and 13C-NMR spectra of compound 203 
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1H- and 13C-NMR spectra of compound 204 
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1H- and 13C-NMR spectra of compound 206 
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1H- and 13C-NMR spectra of compound 212 
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